

# CITATION REPORT

List of articles citing

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

DOI: PM/7968073

Lancet, The, 1994, 344, 1383-9.

**Source:** <https://exaly.com/paper-pdf/129817203/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2340	Selective release of newly synthesised and newly captured GABA from synaptosomes by potassium depolarisation. <b>1975</b> , 258, 254-6		37
2339	Cardiologists rebuked. <i>Lancet, The</i> , <b>1994</b> , 344, 1557	40	5
2338	Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. <b>1995</b> , 29, 743-59		122
2337	Prevention of macrovascular disease: absolute proof or absolute risk?. <b>1995</b> , 12, 561-2		
2336	Cholesterol and psyche. <b>1995</b> , 7, 122-6		1
2335	Drugs affecting lipid metabolism. <b>1995</b> , 19, 407-410		
2334	Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. <b>1995</b> , 79, 973-98		16
2333	Coronary risk factors and their modification: Lipids, smoking, hypertension, estrogen, and the elderly. <b>1995</b> , 20, 539-610		8
2332	Clustering of cardiovascular risk factors: targeting high-risk individuals. <b>1995</b> , 76, 8A-20A		97
2331	Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database. <b>1995</b> , 76, 71A-75A		6
2330	Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. <b>1995</b> , 76, 97A-101A		22
2329	Secondary Prevention of Coronary Heart Disease in Practice. <b>1995</b> , 81, 398		1
2328	Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. <b>1995</b> , 38, 129-54		150
2327	Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. <b>1995</b> , 37, 243-71		53
2326	Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. <b>1995</b> , 76, 474-9		94
2325	Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. <b>1995</b> , 76, 485-91		61
2324	Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. The Clinical Quality Improvement Network (CQIN) Investigators. <b>1995</b> , 76, 570-3		46

2323	Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). <b>1995, 76, 899-905</b>	44
2322	Cholesterol reduction and its impact on coronary artery disease and total mortality. <b>1995, 76, 10C-17C</b>	42
2321	Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. <b>1995, 76, 60C-63C</b>	38
2320	Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). <b>1995, 76, 64C-68C</b>	115
2319	Range of serum cholesterol values in the population developing coronary artery disease. <b>1995, 76, 69C-77C</b>	219
2318	What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?. <b>1995, 76, 93C-97C</b>	8
2317	Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. <b>1995, 76, 98C-106C</b>	91
2316	Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). <b>1995, 76, 107C-112C</b>	30
2315	Extending the benefit of lipid-regulating therapy to primary prevention. <b>1995, 76, 118C-121C</b>	3
2314	Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. <b>1995, 76, 122C-126C</b>	40
2313	Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. <b>1995, 75, 621-3</b>	34
2312	Reporting of coronary risk factors. <b>1995, 75, 716-7</b>	4
2311	Why cardiologists must be interested in lipids. <b>1995, 75, 1067-8</b>	7
2310	Coronary risk factors in women six months after coronary artery bypass grafting. <b>1995, 75, 1092-5</b>	16
2309	Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). <b>1995, 75, 1189-95</b>	129
2308	Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. <b>1995, 75, 1196-201</b>	192
2307	Cholesterol-raising effects of coffee: clues to regulation of cholesterol metabolism. <b>1995, 238, 475-7</b>	3
2306	Treatment for survivors of acute myocardial infarction: what have we learned from large intervention trials?. <b>1995, 9 Suppl 3, 495-502</b>	1

2305	Coadministration of calcium antagonists and ACE inhibitors--is a skeptic convinced?: a personal view. <b>1995</b> , 9 Suppl 3, 525-8		1
2304	Heretical report on the efficacy of blood pressure treatment in a population setting. <b>1995</b> , 9, 373-4		
2303	Synthesis and biological activity of J-104,118, a novel, potent inhibitor of squalene synthase. <b>1995</b> , 5, 1989-1994		15
2302	Cholesterol in patients with coronary heart disease: how low should we go?. <b>1995</b> , 10, 464-71		7
2301	New targets for lipid lowering and atherosclerosis prevention. <b>1995</b> , 67, 433-47		6
2300	Economics of lipid lowering with HMG CoA reductase inhibitors. <b>1995</b> , 18, 295, 363		
2299	Chelation therapy for atherosclerosis: one man's view. <b>1995</b> , 18, 545		0
2298	Role of thrombosis in atherosclerosis and its complications. <b>1995</b> , 75, 3B-11B		82
2297	Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. <b>1995</b> , 15, 1829-38		105
2296	Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. <b>1995</b> , 15, 1938-44		107
2295	A Rational Policy for Measuring and Lowering Cholesterol. <b>1995</b> , vnr-6, 193-203		
2294	Nutritional disorders in the elderly. <i>Medical Journal of Australia</i> , <b>1995</b> , 163, 376-81	4	16
2293	Four Years Treatment Efficacy of Patients with Severe Hyperlipidemia. Lipid Lowering Drugs versus LDL-Apheresis. <b>1995</b> , 18, 786-793		6
2292	Niacin for lipid disorders. <b>1995</b> , 98, 185-193		13
2291	Comment: comparison of HMG-CoA reductase inhibitors. <b>1995</b> , 29, 1304		1
2290	overused in Angina patients?. <b>1995</b> , 98, 125-142		2
2289	Diet in The Prevention and Treatment of Atherosclerosis. <b>1995</b> , 11, 591-612		6
2288	The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. <b>1995</b> , 332, 488-93		968

2287	Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. <b>1995</b> , 74, 14-7	36
2286	Prospective study of patients aged 55 years or less with acute myocardial infarction between 1981 and 1985: outcome 7 years and beyond. <b>1995</b> , 74, 604-10	6
2285	Cholesterol lowering does have a role in secondary prevention. <b>1995</b> , 73, 4-5	4
2284	Insights into the pathogenesis and prevention of coronary artery disease. <b>1995</b> , 70, 69-79	32
2283	Lowering cholesterol with drugs and diet. <b>1995</b> , 333, 1350-1	38
2282	Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. <b>1995</b> , 333, 664-5	122
2281	Evaluating the Efficiency of Cholesterol Modification for Coronary Heart Disease with Decision Analytic Models: A Case Study. <b>1995</b> , 29, 1441-1457	3
2280	Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki Businessmen Study. <b>1995</b> , 74, 449-54	42
2279	Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach. <b>1995</b> , 71, 321-2	2
2278	Angiographic trials of lipid-lowering therapy: end of an era?. <b>1995</b> , 74, 343-7	13
2277	Statins: is there a need for alternative or adjunctive therapy?. <b>1995</b> , 74, 13	6
2276	Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: a common link between risk factors and coronary and peripheral vascular disease?. <b>1995</b> , 53, 385-96	42
2275	Occupational medicine for policing. <b>1995</b> , 2, 105-10	5
2274	Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. <b>1995</b> , 116, 1894-8	44
2273	Preventing and arresting coronary atherosclerosis. <b>1995</b> , 130, 580-600	46
2272	Comparison of the effects of simvastatin versus hormone replacement therapy in the treatment of postmenopausal women with primary hypercholesterolemia. <b>1995</b> , 56, 515-529	2
2271	Contemporary management of acute myocardial infarction. <b>1995</b> , 99, 195-206	14
2270	American Heart Association consensus panel statement on preventing heart attack and death in patients with coronary disease. <b>1995</b> , 26, 291	

2269	Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. <b>1995</b> , 26, 1133-9		353
2268	Cost-effectiveness analysis and clinical practice. <b>1995</b> , 26, 920-1		
2267	Risk factors of coronary heart disease and total mortality among elderly men with and without preexisting coronary heart disease. Finnish cohorts of the Seven Countries Study. <b>1995</b> , 26, 1623-9		35
2266	Physician use of beta-adrenergic blocking therapy: a changing perspective. <b>1995</b> , 26, 547-52		52
2265	Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. <b>1995</b> , 332, 512-21		571
2264	Screening for Cardiovascular Risks ¶n Whose Interest do we Act?. <b>1995</b> , 1, 101-102		5
2263	Acute cerebral infarction. Optimal management in older patients. <b>1995</b> , 6, 445-55		4
2262	Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). <i>Drugs</i> , <b>1995</b> , 50, 263-88	2.1	33
2261	Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. <i>Drugs</i> , <b>1995</b> , 50, 334-63	12.1	72
2260	Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia. <b>1995</b> , 10, 127-38		21
2259	Grundlagen und Stellenwert kontrollierter Interventionsstudien. <b>1995</b> , 84, 553-564		
2258	Secondary prevention of atherosclerosis: emphasizing risk factor management to patients. <b>1995</b> , 60, 1		6
2257	Risk factors for coronary heart disease in the prospective Dubbo Study of Australian elderly. <b>1995</b> , 117, 107-18		37
2256	Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. <b>1995</b> , 116, 153-62		14
2255	Coronary atherosclerosis stabilization: an achievable goal. <b>1995</b> , 118, S91-S101		12
2254	Does diet or alcohol explain the French paradox?. <i>Lancet, The</i> , <b>1995</b> , 345, 527-8	40	2
2253	A suitable case for treatment. <i>Lancet, The</i> , <b>1995</b> , 345, 1051	40	
2252	Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). <i>Lancet, The</i> , <b>1995</b> , 345, 1274-1275	40	253

2251	Implications of 4S evidence on baseline lipid levels. <i>Lancet, The</i> , <b>1995</b> , 346, 181-182	40	4
2250	Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston. <i>Lancet, The</i> , <b>1995</b> , 346, 750-3	40	5
2249	Statins prevent coronary heart disease. <i>Lancet, The</i> , <b>1995</b> , 346, 1378-9	40	22
2248	Evidence-based management of dyslipidaemia. <i>Lancet, The</i> , <b>1995</b> , 346, 1440-2	40	23
2247	Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. <i>Lancet, The</i> , <b>1995</b> , 346, 1467-71	40	103
2246	Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. <i>Lancet, The</i> , <b>1995</b> , 346, 1647-1653	40	73 <sup>2</sup>
2245	Angioplasty versus bypass surgery. <i>Lancet, The</i> , <b>1995</b> , 346, 1174-5	40	14
2244	Familial hypercholesterolaemia: mutations in the gene for the low-density-lipoprotein receptor. <b>1995</b> , 1, 90-7		3
2243	The genetic determinants of plasma cholesterol and response to diet. <b>1995</b> , 9, 797-823		7
2242	Currently available hypolipidaemic drugs and future therapeutic developments. <b>1995</b> , 9, 825-47		23
2241	Lipoproteins and the progression/regression of atherosclerosis. <b>1995</b> , 9, 849-66		8
2240	Review of new guidelines for management of dyslipidaemia. <b>1995</b> , 9, 867-90		4
2239	Adjunctive therapy in the management of patients with acute myocardial infarction. <b>1995</b> , 70, 464-8		5
2238	Insights Into the Pathogenesis and Prevention of Coronary Artery Disease. <b>1995</b> , 70, 69-79		33
2237	Pathophysiology of plaque rupture and the concept of plaque stabilization. <b>1996</b> , 14, 17-29		63
2236	The New Paradigm for Coronary Artery Disease: Altering Risk Factors, Atherosclerotic Plaques, and Clinical Prognosis. <b>1996</b> , 71, 957-965		4
2235	Intravascular and intracardiac ultrasound: a tool of the future. <b>1996</b> , 12, 451-70		6
2234	Lessons from coronary atherosclerosis "regression" trials. <b>1996</b> , 14, 31-50		9

2233	Barriers to lifestyle change, and the need to develop an integrated approach to prevention. <b>1996</b> , 14, 159-69	17
2232	Coronary revascularization: importance of observational data. <b>1996</b> , 71, 1016-7	8
2231	Pathophysiology and inflammatory aspects of plaque rupture. <b>1996</b> , 14, 211-20	28
2230	Lipid lowering: the case for identifying and treating the high-risk patient. <b>1996</b> , 14, 117-30	7
2229	Simvastatin increases plasma NO <sub>2</sub> - and NO <sub>3</sub> - levels in patients with hypercholesterolemia. <b>1996</b> , 127, 43-7	10
2228	Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. <b>1996</b> , 127, 113-22	19
2227	Spirals, paradigms, and the progression of heart failure. <b>1996</b> , 2, 1-4	8
2226	Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. <b>1996</b> , 27, 1119-27	203
2225	Silent ST-T changes in an epidemiologic cohort study--a marker of hypertension or coronary heart disease, or both: the Reykjavik study. <b>1996</b> , 27, 1140-7	64
2224	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. <b>1996</b> , 27, 964-76	150
2223	Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. <b>1996</b> , 28, 616-26	928
2222	Contemporary practice of coronary revascularization in U.S. hospitals and hospitals participating in the bypass angioplasty revascularization investigation (BARI). <b>1996</b> , 28, 609-15	22
2221	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. <b>1996</b> , 27, 978-90	80
2220	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. <b>1996</b> , 27, 991-1006	43
2219	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 7. Evaluation and management of risk factors for the individual patient (case management). <b>1996</b> , 27, 1030-9	12
2218	Cholesterol lowering and cerebrospinal fluid neurotransmitters: increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers. <b>1996</b> , 40, 302-4	10
2217	The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. <b>1996</b> , 335, 1001-9	6057
2216	Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. <b>1996</b> , 131, 872-8	16



2215	Uncoupling clinical outcomes and coronary angiography: a review and perspective of recent trials in coronary artery disease. <b>1996</b> , 132, 910-20	5
2214	Management of acute myocardial infarction: evaluating the past, practicing in the present, elaborating the future. <b>1996</b> , 132, 465-70; discussion 496-502	6
2213	Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. <b>1996</b> , 100, 605-10	149
2212	Risk stratification in coronary artery disease and special populations. <b>1996</b> , 101, 4A17S-22S; discussion 22S-24S	47
2211	Guest commentary. <b>1996</b> , 101, 3S-5S	
2210	The clinical and economic significance of atherosclerosis. <b>1996</b> , 101, 6S-9S	26
2209	Pathogenetic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. <b>1996</b> , 101, 10S-16S	21
2208	Review of cholesterol-lowering therapy: coronary angiographic and events trials. <b>1996</b> , 101, 4A34S-38S; discussion 39S	18
2207	Lipid management: current diet and drug treatment options. <b>1996</b> , 101, 4A40S-48S; discussion 48S-49S	44
2206	Pharmacologic therapies after myocardial infarction. <b>1996</b> , 101, 4A61S-69S; discussion 4A69S-70S	19
2205	Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. <b>1996</b> , 101, 627-34	218
2204	Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. <b>1996</b> , 119, 1269-75	48
2203	Drug therapy of severe hypercholesterolemia in patients with coronary artery disease. <b>1996</b> , 20, 286-91	1
2202	H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. <b>1996</b> , 20, 303-10	24
2201	Heparin-induced extracorporeal low-density lipoprotein precipitation and low-density lipoprotein chemoabsorption onto dextran sulfate: a comparison. <b>1996</b> , 20, 328-31	1
2200	Treatment of severe hyperlipidemia: six years' experience with low-density lipoprotein apheresis. <b>1996</b> , 20, 336-9	3
2199	Lipid apheresis: from a heroic treatment to routine clinical practice. <b>1996</b> , 20, 414-9	9
2198	Dietary fats and coronary heart disease. <b>1996</b> , 50, 261-8	32

2197	Women and Mexican Americans receive fewer cardiovascular drugs following myocardial infarction than men and non-Hispanic whites: the Corpus Christi Heart Project, 1988-1990. <b>1996</b> , 49, 279-87		35
2196	Prevalence of hypercholesterolemia in Saudi Arabia, epidemiological study. <b>1996</b> , 54, 41-9		30
2195	The pathogenesis of atherosclerosis. <b>1996</b> , 246, 21-38		89
2194	Inhibition of squalene synthase of rat liver by novel 3' substituted quinuclidines. <b>1996</b> , 51, 1477-87		39
2193	Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine. <b>1996</b> , 51, 1489-501		16
2192	Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. <b>1996</b> , 52, 433-9		73
2191	Clinical pharmacology and clinical trials in Japan. <b>1996</b> , 74, 479-86		8
2190	Beneficial effects of statins. GISSI-Prevenzione Investigators. <i>Lancet, The</i> , <b>1996</b> , 348, 1582	40	4
2189	West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. <i>Lancet, The</i> , <b>1996</b> , 348, 1339-1342	40	179
2188	Statins do more than just lower cholesterol. <i>Lancet, The</i> , <b>1996</b> , 348, 1079-82	40	602
2187	Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. <i>Lancet, The</i> , <b>1996</b> , 348, 387-8	40	121
2186	Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. <i>Lancet, The</i> , <b>1996</b> , 347, 466-469	40	5
2185	Statin therapy and CHD. <i>Lancet, The</i> , <b>1996</b> , 347, 128	40	3
2184	Is vascular smooth muscle cell proliferation beneficial?. <i>Lancet, The</i> , <b>1996</b> , 347, 305-7	40	108
2183	Spontaneously low LDL cholesterol and reaction to exercise-induced stress. <i>Lancet, The</i> , <b>1996</b> , 347, 405	40	3
2182	The governance of clinical trials. <i>Lancet, The</i> , <b>1996</b> , 347, 1387-8	40	7
2181	Statins and coronary heart disease. <i>Lancet, The</i> , <b>1996</b> , 347, 1389-90	40	12
2180	Statins, cholesterol, and mevalonate pathways?. <i>Lancet, The</i> , <b>1996</b> , 347, 551	40	4

2179	Detecting vulnerable coronary plaques. <i>Lancet, The</i> , <b>1996</b> , 347, 1422-3	40	30
2178	Atheroma: more than mush. <i>Lancet, The</i> , <b>1996</b> , 348 Suppl 1, s4-7	40	46
2177	CHD prevention in clinical practice. <i>Lancet, The</i> , <b>1996</b> , 348 Suppl 1, s26-8	40	10
2176	If I woke with central chest pain. <i>Lancet, The</i> , <b>1996</b> , 348 Suppl 1, s29-30	40	1
2175	ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). <b>1996</b> , 28, 1328-428		871
2174	Cardiovascular, pulmonary, and cancer rehabilitation. 1. Cardiac rehabilitation. <b>1996</b> , 77, S38-44		4
2173	Effects of growth hormone on serum lipids and lipoproteins: possible significance of increased peripheral conversion of thyroxine to triiodothyronine. <b>1996</b> , 45, 1016-20		9
2172	Effects of HMG-CoA reductase inhibition on erythrocyte membrane cholesterol and acyl chain composition. <b>1996</b> , 256, 53-63		22
2171	Decrease in plasma cholesteryl-ester transfer protein activity with simvastatin treatment in patients with type IIa hypercholesterolemia. <b>1996</b> , 57, 42-47		2
2170	A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. <b>1996</b> , 57, 62-71		
2169	Efficacy and safety of simvastatin in current clinical practice: the italian family physician simvastatin study. <b>1996</b> , 57, 418-429		3
2168	Low serum cholesterol and the risk of cerebral haemorrhage. <b>1996</b> , 119, 1-6		24
2167	The effects of the apolipoprotein B signal peptide (ins/del) and XbaI polymorphisms on plasma lipid responses to dietary change. <b>1996</b> , 122, 1-10		33
2166	Lipids and atherogenesis in diabetes mellitus. <b>1996</b> , 124 Suppl, S43-7		11
2165	Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol?. <b>1996</b> , 125, 267-9		23
2164	Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs. <b>1996</b> , 126, 43-51		2
2163	Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. <b>1996</b> , 18, 392-410; discussion 391		5
2162	Incidence and significance of cardiac arrhythmia in geriatric oral surgery patients. <b>1996</b> , 82, 42-6		15

2161	Recent trends in the consumption of lipid-lowering drugs in Finland. <b>1996</b> , 49, 1453-57		14
2160	Iron versus cholesterol--perspectives on the iron and heart disease debate. <b>1996</b> , 49, 1345-52		35
2159	Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate. <b>1996</b> , 49, 1353-8		7
2158	Cholesterol and coronary heart disease. <b>1996</b> , 5, 105-110		
2157	Heart attacks: gone with the century?. <b>1996</b> , 272, 629		97
2156	Bile acid transport systems as pharmaceutical targets. <b>1996</b> , 26, 715-32		63
2155	Coronary heart disease risk factors in older persons. <b>1996</b> , 8, 75-89		14
2154	HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease. <b>1996</b> , 14, 8-10		1
2153	Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. <b>1996</b> , 14, 11-24		74
2152	Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention. <b>1996</b> , 8, 275-98		8
2151	Optimal treatment of angina in older patients. <b>1996</b> , 8, 349-57		5
2150	Diabetes mellitus in older patients. Is tight blood glucose control warranted?. <b>1996</b> , 8, 401-7		5
2149	Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. <b>1996</b> , 31, 348-71		134
2148	Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. <i>Drugs</i> , <b>1996</b> , 51, 433-59	12.1	95
2147	The 4S study. Implications for prescribing. <i>Drugs</i> , <b>1996</b> , 51, 507-14	12.1	7
2146	Recognition and treatment of unstable angina. <i>Drugs</i> , <b>1996</b> , 52, 196-208	12.1	12
2145	Choosing the right lipid-regulating agent. A guide to selection. <i>Drugs</i> , <b>1996</b> , 52, 649-61	12.1	34
2144	The 4S study and its pharmacoeconomic implications. <b>1996</b> , 9, 101-5		13

2143	Apparent discontinuation rates in patients prescribed lipid-lowering drugs. <i>Medical Journal of Australia</i> , <b>1996</b> , 164, 208-11	4	168
2142	Dyslipidemia and Coronary Artery Disease in the Elderly. <b>1996</b> , 12, 33-40		10
2141	Pathophysiology of Coronary Artery Disease. <b>1996</b> , 12, 1-21		6
2140	Management of Postmyocardial Infarction in the Elderly Patient. <b>1996</b> , 12, 169-180		3
2139	Section Review: Cardiovascular & Renal: Treatment of severe and/or drug-resistant hyperlipidaemia. <b>1996</b> , 5, 513-520		
2138	Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine. <b>1996</b> , 16, 137-43		18
2137	Multiple risk intervention in high-risk hypertensive patients. A 3-year ultrasound study of intima-media thickness and plaques in the carotid artery. Risk Intervention Study (RIS) Group. <b>1996</b> , 16, 462-70		22
2136	Cardiovascular Disease in Peritoneal Dialysis. <b>1996</b> , 16, 19-22		12
2135	Coronary disease prevention: A study. <b>1996</b> , 7, 36-38		1
2134	The American College of Physicians versus the National Cholesterol Education Program: should endocrinologists listen?. <b>1996</b> , 2, 348-50		
2133	The New Paradigm for Coronary Artery Disease: Altering Risk Factors, Atherosclerotic Plaques, and Clinical Prognosis. <b>1996</b> , 71, 957-965		25
2132	What are outcomes?. <b>1996</b> , NS36, 39-49		10
2131	Lipid management: an opportunity for pharmacy service. <b>1996</b> , NS36, 609-19; quiz 619-21		
2130	Effectiveness and safety of low-dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia. <b>1996</b> , 36, 422-7		61
2129	Treating elevated cholesterol levels: the great Satan in perspective. <b>1996</b> , 36, 189-97		3
2128	Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors. <b>1996</b> , 100, 61-5, 70-2		
2127	Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol. <b>1996</b> , 1, 117-122		21
2126	Hyperlipidemia. When does treatment make a difference?. <b>1996</b> , 100, 138-49		

2125	The statin trials: closing arguments in the case against cholesterol?. <b>1996</b> , 41, 99-100	
2124	More on comparison of HMG-CoA reductase inhibitors. <b>1996</b> , 30, 414-5	1
2123	Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors. <b>1996</b> , 30, 1304-15	4
2122	Editorial Cardiovascular & Renal: Anti-atherosclerotic patents following the success of HMG-CoA reductase inhibitors. <b>1996</b> , 6, 427-430	1
2121	Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. <b>1996</b> , 93, 4114-9	76
2120	Cholesterol-lowering therapy: is there really a controversy?. <b>1996</b> , 30, 539-42	5
2119	Is there an association among low untreated serum lipid levels, anger, and hazardous driving?. <b>1996</b> , 3, 321-36	2
2118	Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. <b>1996</b> , 19, 683-9	23
2117	A review of the use of risk factor modification in the management of atherosclerotic arterial disease. <b>1996</b> , 5, 226-232	
2116	Physician extenders for cost-effective management of hypercholesterolemia. <b>1996</b> , 11, 277-86	42
2115	Lowering cholesterol for primary prevention of coronary heart disease: Extrapolation beyond the facts?. <b>1996</b> , 5, 9-11	
2114	Relevance of dyslipidemia in the elderly. <b>1996</b> , 5, 14-15	0
2113	Primary prevention □Have we gone too far?. <b>1996</b> , 5, 15-18	
2112	Ergebnisorientierte Evaluation kardiologischer Rehabilitation. <b>1996</b> , 4, 335-348	1
2111	New insights into the pathogenesis, prevention and management of acute coronary syndromes. <b>1996</b> , 26, 344-8	3
2110	Predictive value of lipid profile for salutary coronary angiographic changes in patients on a low-fat diet and physical exercise program. <b>1996</b> , 78, 163-7	15
2109	Cost of lipid-lowering statin drugs. <b>1996</b> , 77, 225-6	2
2108	The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. <b>1996</b> , 77, 851-4	145

2107	Verapamil following uncomplicated myocardial infarction: promising, but not proven. <b>1996</b> , 77, 421-2	16
2106	Relative survival benefits of risk factor modifications. <b>1996</b> , 77, 298-9	8
2105	Direct measurement of serum low-density lipoprotein cholesterol in patients with acute myocardial infarction on admission to the emergency room. <b>1996</b> , 77, 1232-4	6
2104	Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. <b>1996</b> , 78, 532-5	16
2103	The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. <b>1996</b> , 78, 572-5	54
2102	Effects of cardiac rehabilitation and exercise training programs in patients > or = 75 years of age. <b>1996</b> , 78, 675-7	75
2101	Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study. <b>1996</b> , 78, 1036-8	9
2100	Results of intensive long-term treatment of familial hypercholesterolemia. <b>1996</b> , 78, 1369-74	27
2099	Prognostic role of cardiovascular risk factors for men with cardiomegaly (the Reykjavik Study). <b>1996</b> , 78, 1355-61	9
2098	Rationale for effective treatment of hypercholesterolemia. <b>1996</b> , 78, 4-12	23
2097	Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction. <b>1996</b> , 78, 13-9	19
2096	Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention. <b>1996</b> , 78, 26-31	34
2095	Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. <b>1996</b> , 78, 32-41	19
2094	Modern management of acute myocardial infarction. <b>1996</b> , 21, 585-667	6
2093	Unstable angina: new insights into pathophysiologic characteristics, prognosis, and management strategies. <b>1996</b> , 21, 669-731	6
2092	The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. <b>1996</b> , 17, 550-83	28
2091	Nutrition and coronary heart disease in the elderly: low fat or laissez-faire?. <b>1996</b> , 12, 376-7	
2090	Genetic diagnosis of familial hypercholesterolemia in affected relatives using pedigree tracing. <b>1996</b> , 29, 371-7	4

2089	Stereoselective synthesis of J-104,118 and J-104,123, novel, potent inhibitors of squalene synthase. <b>1996</b> , 52, 13881-13894	12
2088	J-104,123, a novel and orally-active inhibitor of squalene synthase: Stereoselective synthesis and cholesterol lowering effects in dogs. <b>1996</b> , 6, 463-466	13
2087	Effective lovastatin therapy in elderly hypercholesterolemic patients - an antioxidative impact?. <b>1996</b> , 22, 207-21	12
2086	Jejunal permeability and hepatic extraction of fluvastatin in humans. <b>1996</b> , 60, 493-503	75
2085	Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. <b>1996</b> , 60, 54-61	218
2084	Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. <b>1996</b> , 10, 171-4	42
2083	Effect of ACE inhibitors on endothelial dysfunction: unanswered questions and implications for further investigation and therapy. <b>1996</b> , 10, 469-73	9
2082	Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study). <b>1996</b> , 10, 475-83	12
2081	Acute Myocardial Infarction in Canada: New Epidemiologic Insights on Incidence, Therapy, and Risk. <b>1996</b> , 3, 101-105	4
2080	The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing evidence-based treatment. <b>1996</b> , 72, 744-8	2
2079	Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid lowering intervention in patients receiving thrombolysis. <b>1996</b> , 75, 213-4	
2078	Squatting revisited: comparison of haemodynamic responses in normal individuals and heart transplant recipients. <b>1996</b> , 75, 213	
2077	Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study. <b>1996</b> , 47, 533-41	10
2076	Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. <b>1996</b> , 72, 739-43	7
2075	Nutrition and health: what is new?. <b>1996</b> , 6, 147-168	3
2074	Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsj�Sweden. <b>1996</b> , 50, 190-5	27
2073	Prevention of coronary heart disease with pravastatin. <b>1996</b> , 334, 1333; author reply 1334-5	7
2072	Association of serum cholesterol and triglyceride levels with agitation and cognitive function in a geropsychiatry unit. <b>1996</b> , 9, 53-6	10



2071	A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). <b>1996</b> , 75, 334-42	191
2070	A prospective cardiovascular population study used in genetic epidemiology. The Copenhagen City Heart Study. <b>1996</b> , 56, 65-71	5
2069	Current and future therapeutic approaches to hyperlipidemia. <b>1996</b> , 35, 79-114	9
2068	The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. <b>1996</b> , 28, 323-33	83
2067	Primary and secondary prevention of myocardial infarction. <b>1996</b> , 18, 547-58	2
2066	Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence. <b>1996</b> , 28, 357-62	10
2065	The cholesterol controversy. <b>1996</b> , 30, 495-500	9
2064	Beyond cholesterol reduction in coronary heart disease: is vitamin E the answer?. <b>1996</b> , 76, 293-4	2
2063	Lipid screening in an elderly population: difficulty in interpretation and in detection of occult metabolic disease. <b>1996</b> , 49, 278-83	8
2062	Delayed progression or regression of coronary atherosclerosis with intensive risk factor modification. Effects of diet, drugs, and exercise. <b>1996</b> , 22, 306-20	33
2061	A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin. <b>1996</b> , 1, 23-30	27
2060	Cardiovascular risk factors in the older adult. <b>1996</b> , 31, 135-8, 143-4, 147-8, passim	6
2059	Aspirin and coronary disease. <b>1996</b> , 335, 1161-2	2
2058	More on pravastatin and coronary disease. <b>1996</b> , 335, 1239-40	1
2057	Advances in coronary angioplasty. <b>1996</b> , 335, 1290-302	206
2056	Squalene synthase inhibitors: their potential as hypocholesterolaemic agents. <b>1996</b> , 33, 331-78	26
2055	Anti-atherosclerotics - Bile acid sequestrants, cholesterol absorption and fibrates. <b>1997</b> , 451-459	
2054	Use of coronary angiography and revascularization after acute myocardial infarction. <b>1997</b> , 336, 1024-5; author reply 1025	

2053	Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. <b>1997</b> , 336, 1276-82	1327
2052	Adjunctive drug therapy for acute myocardial infarction. <b>1997</b> , 336, 1455; author reply 1455-6	0
2051	Recent developments in the treatment of dyslipidaemia. <b>1997</b> , 7, 441-455	3
2050	Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. <b>1997</b> , 337, 595-601	164
2049	Post-transplant hyperlipidaemia. <b>1997</b> , 73, 785-93	16
2048	Health promotion and primary care. The Society's Annual Lecture for 1997. <b>1997</b> , 117, 250-9	
2047	The case for aggressive lipid regulation. <b>1997</b> , 32, 145-9, 155-6	3
2046	Discrepancies between meta-analyses and subsequent large randomized, controlled trials. <b>1997</b> , 337, 536-42	1038
2045	Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. <b>1997</b> , 2, 7-16	43
2044	The composition of coronary-artery plaques. <b>1997</b> , 336, 1312-4	171
2043	The iterative use of economic evaluation as part of the process of health technology assessment. <b>1997</b> , 2, 26-30	123
2042	Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. <b>1997</b> , 337, 1360-9	1070
2041	"Isolated" low high-density lipoprotein cholesterol. <b>1997</b> , 31, 89-97	4
2040	Lipoprotein disorders in women: which women are the best candidates for hormone replacement therapy?. <b>1997</b> , 31, 98-107	5
2039	Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. <b>1997</b> , 45, 8-14	75
2038	Mortality over four years in SHEP participants with a low ankle-arm index. <b>1997</b> , 45, 1472-8	121
2037	The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. <b>1997</b> , 2, 243-51	83
2036	The impact of thiazide diuretics on the initiation of lipid-reducing agents in older people: a population-based analysis. <b>1997</b> , 45, 71-5	7

2035	Squalene synthase inhibitors. <b>1997</b> , 2, 93-108	7
2034	Psychological distress in HIV-1 disease in relationship to hypocholesterolemia. <b>1997</b> , 27, 159-71	5
2033	Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity. <b>1997</b> , 34 ( Pt 3), 269-75	25
2032	Preventive medicine and screening in older adults. <b>1997</b> , 45, 344-54	68
2031	Evidence-based medicine holds the key to the future for geriatric medicine. <b>1997</b> , 45, 1268-72	6
2030	Impact of combined hormone replacement therapy on serum lipid metabolism: new aspects. <b>1997</b> , 11, 281-8	5
2029	Lipids, thrombosis and cardiovascular disease in diabetes. <b>1997</b> , 56, 273-80	1
2028	Triacylglycerol and coronary heart disease. <b>1997</b> , 56, 667-70	33
2027	Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. <b>1997</b> , 37, 496-501	10
2026	Design of cost-effective packages of care for non-insulin-dependent diabetes mellitus. Defining the information needs. <b>1997</b> , 13, 395-410	5
2025	Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. <b>1997</b> , 31, 859-63	50
2024	Preventing Heart Disease. <b>1997</b> , 8, 28-30	
2023	Chapter 29 Mode of action of lipid-lowering drugs. <b>1997</b> , 561-575	
2022	Chapter 10. Emerging Opportunities in the Treatment of Atherosclerosis. <b>1997</b> , 32, 101-110	2
2021	Fifteen years with clinical guidelines in the treatment of hypertension--still discrepancies between intentions and practice. <b>1997</b> , 15, 134-40	21
2020	Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. <b>1997</b> , 11, 89-110	11
2019	A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. <b>1997</b> , 12, 384-408	4
2018	Lipids and lipoproteins in women. <b>1997</b> , 72, 235-44	40

2017	Cardiovascular new drug discovery of the future: Molecules, genes, and machines. <b>1997</b> , 461-476		
2016	Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. <b>1997</b> , 32, 403-25		379
2015	Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. <i>Drugs</i> , <b>1997</b> , 53, 299-336	12.1	59
2014	Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. <i>Drugs</i> , <b>1997</b> , 53, 828-47	12.1	211
2013	Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? West Of Scotland Coronary Prevention Study. <i>Drugs</i> , <b>1997</b> , 54, 1-8	12.1	155
2012	Antiarrhythmic therapies for the prevention of sudden cardiac death. <i>Drugs</i> , <b>1997</b> , 54, 235-52	12.1	21
2011	Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. <i>Drugs</i> , <b>1997</b> , 54, 615-33	12.1	103
2010	A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits. <b>1997</b> , 16, 330-41		16
2009	Cholesterol and prevention of coronary heart disease. <i>Lancet, The</i> , <b>1997</b> , 349, 210	40	
2008	Cholesterol and prevention of coronary heart disease. <i>Lancet, The</i> , <b>1997</b> , 349, 210-1	40	1
2007	CAPRIE trial. <i>Lancet, The</i> , <b>1997</b> , 349, 354; author reply 356	40	3
2006	Indicators of Quality in Health Care. <b>1997</b> , 3, 103-108		144
2005	The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. <b>1997</b> , 3, 249-54		290
2004	Plasma homocysteine levels and mortality in patients with coronary artery disease. <b>1997</b> , 337, 230-6		1432
2003	Endothelial dysfunction and atherothrombotic occlusive disease. <i>Drugs</i> , <b>1997</b> , 54 Suppl 3, 41-9; discussion 49-50	12.1	11
2002	Management of lipid disorders in the elderly. <b>1997</b> , 10, 444-62		11
2001	Planned, ongoing and recently completed clinical trials for atherosclerosis prevention and regression: an update. <b>1997</b> , 6, 31-50		4
2000	Angiographic deterioration of target coronary artery narrowing as a result of percutaneous balloon angioplasty. <b>1997</b> , 133, 575-9		

1999	The secondary prevention of coronary artery disease. <b>1997</b> , 102, 572-81	33
1998	The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. <b>1997</b> , 102, 387-91	10
1997	Hypercholesterolemia in the United States: how far have we come?. <b>1997</b> , 102, 3-6	622
1996	Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease. <b>1997</b> , 102, 15-22	34
1995	Cholesterol screening should be targeted. <b>1997</b> , 102, 26-30	8
1994	Adults aged 20 and older should have their cholesterol measured. <b>1997</b> , 102, 31-6	9
1993	Current status of cholesterol treatment in the community: the Minnesota Heart Survey. <b>1997</b> , 102, 37-42	24
1992	Healthcare decisions and product labeling: results of a consumer comprehension study of prototype labeling for proposed over-the-counter cholestyramine. <b>1997</b> , 102, 50-6	19
1991	Aortic atherosclerosis and stroke. <b>1997</b> , 6, 125-9	1
1990	Cardiovascular complications following renal transplantation. <b>1997</b> , 11, 111-126	11
1989	Mild myocardial infarction--a classification problem in epidemiologic studies. WHO MONICA Project. <b>1997</b> , 50, 3-13	30
1988	Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond. <b>1997</b> , 1, 34-5	
1987	From journal to bedside: quantifying the benefits of treatment. <b>1997</b> , 1, 57-8	2
1986	A model practice. <b>1997</b> , 1, 158-160	
1985	Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. <b>1997</b> , 18 Suppl, S137-44	150
1984	Women at cardiac risk: is HRT the route to maintaining cardiovascular health?. <b>1997</b> , 59 Suppl 1, S19-27	11
1983	Comparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia. <b>1997</b> , 58, 154-162	7
1982	Increased thrombin generation and complement activation in patients with type IIA hyperlipoproteinemia: effects of simvastatin treatment. <b>1997</b> , 58, 706-723	10

1981	Revascularization of patients with coronary artery disease: the interventional cardiologist's perspective. <b>1997</b> , 63, S23-7		2
1980	Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. <b>1997</b> , 46, 625-33		29
1979	An audit of secondary prevention of ischaemic heart disease using aspirin and cholesterol-lowering. <b>1997</b> , 1, 27-29		
1978	Cholesterol-lowering drugs for primary prevention? The WOSCOP Study. <b>1997</b> , 35, 169-70		3
1977	Cholesterol and coronary heart disease: new data from the WOSCOP Study. <b>1997</b> , 35, 171-2		1
1976	The 4S study: a critical review. <b>1997</b> , 35, 165-6		0
1975	Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. <i>Lancet, The</i> , <b>1997</b> , 350, 1222	40	50
1974	Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines. <i>Lancet, The</i> , <b>1997</b> , 350, 1174-5	40	11
1973	Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial. <i>Lancet, The</i> , <b>1997</b> , 350, 442	40	3
1972	Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. <i>Lancet, The</i> , <b>1997</b> , 350, 461-468	40	407
1971	Coronary heart disease. Women's hearts are hard to break. <i>Lancet, The</i> , <b>1997</b> , 349 Suppl 1, s13-6	40	10
1970	Variations in cholesterol management practices of U.S. physicians. <b>1997</b> , 29, 139-46		108
1969	Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. <b>1997</b> , 30, 569-75		178
1968	Endothelial dysfunction: does it matter? Is it reversible?. <b>1997</b> , 30, 325-33		535
1967	Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. <b>1997</b> , 30, 863-9		115
1966	HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. <b>1997</b> , 30, 1212-7		358
1965	Predictors of graft patency 3 years after coronary artery bypass graft surgery. Department of Veterans Affairs Cooperative Study Group No. 297. <b>1997</b> , 29, 1563-8		37
1964	Plant-derived anticancer agents. <b>1997</b> , 53, 121-33		402

1963	Calcium antagonists and atherosclerosis. <b>1997</b> , 62 Suppl 2, S9-15	25
1962	Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on the haemostatic balance of familial hypercholesterolaemic subjects. <b>1997</b> , 11, 91-96	3
1961	[Tobacco smoking and cardiovascular risk]. <b>1997</b> , 18, 702-8	4
1960	Aggressive cholesterol management: role of the lipid nurse specialist. <b>1997</b> , 26, 337-44	15
1959	Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials. <b>1997</b> , 19, 778-97	23
1958	Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group. <b>1997</b> , 19, 487-97	11
1957	Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. <b>1997</b> , 19, 582-602; discussion 538-9	17
1956	The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. <b>1997</b> , 27, 261-74	106
1955	Cardiovascular disease prevention in postmenopausal women: a clinician's perspective. <b>1997</b> , 27, 1-3	3
1954	Renovascular disease: the fifth frontier. <b>1997</b> , 90, 315-8	1
1953	Dyslipidemia as a risk factor for coronary disease in patients with diabetes. <b>1997</b> , 3, 244-7	2
1952	[Life style and risk factors in patients with a first episode of acute myocardial infarct]. <b>1997</b> , 5, 69-82	4
1951	Prevention of Primary Event. <b>1997</b> , 8, 165-178	3
1950	Coronary Revascularization in Women. <b>1997</b> , 9, 497-509	4
1949	Pharmaceutical Companies and Managed Care in the UK. <b>1997</b> , 1, 100-102	1
1948	Guidelines for managing patients with unstable angina. Rating the evidence and rationale for treatment. <i>Medical Journal of Australia</i> , <b>1997</b> , 166, 644-7	4 7
1947	Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature. <b>1997</b> , 2, 231-50	14
1946	Cost-effective strategies for the management of vascular disease. <b>1997</b> , 2, 25-9	13

1945	Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. <b>1997</b> , 102, 81-4, 87-90	7
1944	In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. <b>1997</b> , 17, 3230-5	320
1943	Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. <b>1997</b> , 17, 2309-15	404
1942	The unstable atheroma. <b>1997</b> , 17, 1859-67	432
1941	Effect of phenotype on the transcription of the genes for platelet-derived growth factor (PDGF) isoforms in human smooth muscle cells, monocyte-derived macrophages, and endothelial cells in vitro. <b>1997</b> , 17, 2897-903	15
1940	Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. <b>1997</b> , 17, 1793-9	61
1939	Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. <b>1997</b> , 17, 1910-7	54
1938	Cholesterol reduction and clinical benefit. Are there limits to our expectations?. <b>1997</b> , 17, 3527-33	41
1937	Hyperlipidemias: National Cholesterol Education Program Recommendations, Treatment Regimens, and Pharmacoeconomic Implications. <b>1997</b> , 10, 185-187	
1936	Rhabdomyolysis after lung transplantation. <b>1997</b> , 27, 186	2
1935	Chronic renal disease and cardiovascular complications: inevitable or preventable? Now is the time for some intervention studies. <b>1997</b> , 27, 273-4	
1934	The effect of treating people with reversible ischaemic attacks of the brain and eye on the incidence of stroke in Australia. <b>1997</b> , 27, 420-30	9
1933	Do codeine and caffeine enhance the analgesic effect of aspirin?--A systematic overview. <b>1997</b> , 22, 79-97	44
1932	Non-pharmacological modification of cardiac risk factors: Part 2. The role of diet. <b>1997</b> , 22, 99-108	2
1931	Prescription of statins: cost implications of evidence-based treatment applied to a health authority population. <b>1997</b> , 22, 379-89	2
1930	Prehospital Thrombolysis in Acute Myocardial Infarction Salvages Myocardium. <b>1997</b> , 10, 315-325	
1929	Molecular determinants of atherosclerotic plaque vulnerability. <b>1997</b> , 811, 134-42; discussion 142-5	74
1928	LDL apheresis in clinical practice: long-term treatment of severe hyperlipidemia. <b>1997</b> , 1, 49-54	2



1927	Apheresis technology for prevention and regression of atherosclerosis: an overview. <b>1997</b> , 1, 233-41	15
1926	Clinical experience and future directions for low-density lipoprotein apheresis in the United States. <b>1997</b> , 1, 249-52	5
1925	Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. <b>1997</b> , 81, 57-64	34
1924	Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia?. <b>1997</b> , 4, 555-68	6
1923	Risk-sensitive therapeutic strategies for coronary artery disease: toward testing-driven therapy in stable angina patients with low-to-intermediate risk cardiac imaging results. <b>1997</b> , 4, 409-17	3
1922	Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies. <b>1997</b> , 122, 1209-15	15
1921	Cardiac complications in non-insulin-dependent diabetes mellitus. <b>1997</b> , 11, 123-30	25
1920	Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. <b>1997</b> , 11, 137-41	23
1919	Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. <b>1997</b> , 79, 756-62	95
1918	Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. <b>1997</b> , 79, 867-72	20
1917	Effects of intensive diet and exercise intervention in patients taking cholesterol-lowering drugs. <b>1997</b> , 79, 1112-4	35
1916	Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. <b>1997</b> , 79, 1298-301	17
1915	Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. <b>1997</b> , 79, 17-23	38
1914	The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. <b>1997</b> , 79, 24-8	21
1913	The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study. <b>1997</b> , 79, 1387-8	4
1912	Results of recent large cholesterol-lowering trials and implications for clinical management. <b>1997</b> , 79, 1663-6	21
1911	A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. <b>1997</b> , 80, 39-44	178
1910	Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <b>1997</b> , 80, 287-93	63

1909	New insights into the pathogenesis and prevention of acute coronary syndromes. <b>1997</b> , 79, 17-23	98
1908	Management of patients with chronic stable angina at low risk for serious cardiac events. <b>1997</b> , 79, 24-30	13
1907	Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. <b>1997</b> , 80, 426-33	106
1906	Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. <b>1997</b> , 80, 608-13	132
1905	The way ahead in the management of unstable coronary artery disease. <b>1997</b> , 80, 64E-67E	2
1904	Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. <b>1997</b> , 80, 799-802	11
1903	Treatment of hyperlipidemia by specialists versus generalists as secondary prevention of coronary artery disease. <b>1997</b> , 80, 1345-7	12
1902	Effects of lovastatin on the immune system. <b>1997</b> , 80, 1391-4	29
1901	Role of endothelial dysfunction in coronary artery disease and implications for therapy. <b>1997</b> , 80, 111-161	102
1900	Pathophysiology and treatment of single-vessel coronary artery disease. <b>1997</b> , 80, 21-101	1
1899	Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. <b>1997</b> , 80, 39H-44H	33
1898	Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction. <b>1997</b> , 80, 53H-56H	13
1897	Implementing quality assurance programs in multigroup practices for treating hypercholesterolemia in patients with coronary artery disease. <b>1997</b> , 80, 57H-61H	16
1896	Symposium summary remarks. <b>1997</b> , 80, 89H-90H	
1895	The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. <b>1997</b> , 79, 38-42	177
1894	A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lipid Coronary Angiography Trial. <b>1997</b> , 18, 93-119	21
1893	Clinical perspectives on the use of composite endpoints. <b>1997</b> , 18, 517-29; discussion 546-9	45
1892	Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. <b>1997</b> , 18, 530-45; discussion 546-9	131

1891	Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. <b>1997</b> , 20, 433-40	23
1890	Immune system differences in men with hypo- or hypercholesterolemia. <b>1997</b> , 84, 145-9	60
1889	Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors. <b>1997</b> , 4, 167-175	3
1888	[Rationale for lipid therapy. Prevention or treatment of coronary heart disease?]. <b>1997</b> , 22, 125-33	0
1887	[Goals and practical implementation of lipid therapy in coronary heart disease]. <b>1997</b> , 22, 134-40	1
1886	[Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients]. <b>1997</b> , 92, 363-9	5
1885	[Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany]. <b>1997</b> , 92, 686-94	6
1884	The genetic basis of atherosclerosis. <b>1997</b> , 27, 2-13	35
1883	Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. <b>1997</b> , 19, 230-8	15
1882	Compliance with cardiovascular disease prevention strategies: a review of the research. <b>1997</b> , 19, 239-63	227
1881	Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies. <b>1997</b> , 32, 255-62	34
1880	Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. <b>1997</b> , 5, 437-44	143
1879	Cardiac ischaemia: possibilities for future drug therapy. <b>1997</b> , 32, 687-707	6
1878	The risk and cost-effective individual patient management: the challenge of a new generation of clinical trials. <b>1997</b> , 10, 751-8	0
1877	Alternatives to mega-trials in cardiovascular disease. <b>1997</b> , 10, 759-65	2
1876	Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice. <b>1997</b> , 12, 567-80	69
1875	The interaction of diltiazem with lovastatin and pravastatin. <b>1998</b> , 64, 369-77	144
1874	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. <b>1998</b> , 63, 332-41	343

1873	Hyperlipidaemia: differences in management practices and attitudes in two regions in Europe--Sicily and the Stockholm area. <b>1998</b> , 14, 477-82	3
1872	The importance of lowering cholesterol in patients with coronary heart disease. <b>1998</b> , 21, 81-4	8
1871	The need for a prognosis trial of revascularization and aggressive medical therapy in patients with asymptomatic cardiac ischemia. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot. <b>1998</b> , 21, 154-6	1
1870	Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. <b>1998</b> , 21, 161-8	11
1869	Hormones and the cardiologist. <b>1998</b> , 21, 218-22	2
1868	Management strategies for a better outcome in unstable coronary artery disease. <b>1998</b> , 21, 314-22	31
1867	Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study). <b>1998</b> , 28, 327-33	16
1866	Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits. <b>1998</b> , 124, 277-82	3
1865	Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits. <b>1998</b> , 2, 25-30	7
1864	LDL-Therasorb immunoabsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. <b>1998</b> , 2, 142-6	10
1863	Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. <b>1998</b> , 19, 61-109	2064
1862	Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). <b>1998</b> , 81, 333-5	376
1861	Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. <b>1998</b> , 81, 578-81	65
1860	Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction. <b>1998</b> , 81, 531-7	34
1859	Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). <b>1998</b> , 81, 632-6	10
1858	Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. <b>1998</b> , 81, 18B-25B	378
1857	Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. <b>1998</b> , 81, 36B-42B	41
1856	Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. <b>1998</b> , 81, 43B-46B	12

1855	Treatment of diabetic dyslipidemia. <b>1998</b> , 81, 47B-51B	41
1854	Serum triglycerides and clinical benefit in lipid-lowering trials. <b>1998</b> , 81, 70B-73B	8
1853	Serum cholesterol levels are underevaluated and undertreated. <b>1998</b> , 81, 1353-6	21
1852	Lipid-lowering therapy after coronary revascularization: the interventional cardiologist's perspective. <b>1998</b> , 81, 55E-62E	4
1851	Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. <b>1998</b> , 82, 61-5	150
1850	Early efficacy and safety studies. <b>1998</b> , 81, 13F-16F	
1849	Results of percutaneous coronary angioplasty in patients . <b>1998</b> , 82, 135-9	11
1848	Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl. <b>1998</b> , 82, 668-9, A6, A8	42
1847	Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. <b>1998</b> , 82, 311-6	62
1846	Current and future treatment of hyperlipidemia: the role of statins. <b>1998</b> , 82, 3J-10J	123
1845	Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. <b>1998</b> , 82, 40J-46J	28
1844	Review of trials in the treatment of coronary artery disease: theoretical expectations versus lack of practical success--how can we explain the differences?. <b>1998</b> , 82, 15H-20H	4
1843	Assessing the benefits of lipid-lowering therapy. <b>1998</b> , 82, 2M-4M	10
1842	Clinical trial endpoints: angiograms, events, and plaque instability. <b>1998</b> , 82, 5M-11M	48
1841	Coronary arteriography and lipid lowering: limitations, new concepts, and new paradigms in cardiovascular medicine. <b>1998</b> , 82, 12M-21M	4
1840	Economic implications of lipid-lowering trials: current considerations in selecting a statin. <b>1998</b> , 82, 26M-31M	11
1839	Future of lipid-lowering trials: what else do we need to know?. <b>1998</b> , 82, 32M-38M	1
1838	Cost-effectiveness of statins. <b>1998</b> , 82, 1357-63	53

1837	Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. <b>1998</b> , 82, 1489-95	235
1836	Changing the treatment paradigm for coronary artery disease. <b>1998</b> , 82, 2T-4T	663
1835	Need for a paradigm shift: the importance of risk factor reduction therapy in treating patients with cardiovascular disease. <b>1998</b> , 82, 10T-13T	50
1834	Why cholesterol as a central theme in coronary artery disease?. <b>1998</b> , 82, 14T-17T	40
1833	Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial. <b>1998</b> , 82, 45T-48T	14
1832	Importance of endothelial function in mediating the benefits of lipid-lowering therapy. <b>1998</b> , 82, 49T-52T	79
1831	Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. <b>1998</b> , 82, 53T-56T	31
1830	Preventing coronary artery disease in the West of Scotland: implications for primary prevention. <b>1998</b> , 82, 57T-59T	114
1829	From heart surgery to prevention. <b>1998</b> , 82, 66T-71T	32
1828	A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. <b>1998</b> , 82, 29U-34U; discussion 39U-41U	114
1827	Introduction. <b>1998</b> , 82, 1-2	11
1826	Low-density lipoproteins and risk for coronary artery disease. <b>1998</b> , 82, 3Q-12Q	270
1825	Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. <b>1998</b> , 82, 28S-30S	7
1824	The antiatherogenic role of high-density lipoprotein cholesterol. <b>1998</b> , 82, 13Q-21Q	160
1823	Treatment of hyperlipidemia with combined niacin-statin regimens. <b>1998</b> , 82, 82U-84U; discussion 85-86U	74
1822	State-of-the-art update and review: clinical trials of lipid-lowering agents. <b>1998</b> , 82, 3U-17U; discussion 39U-41U	38
1821	Primary and secondary prevention of coronary artery disease: Trials of lipid lowering with statins. <b>1998</b> , 82, S28-S30	7
1820	The role of myocardial revascularization preceding noncardiac surgery. <b>1998</b> , 40, 383-404	10

1819	Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. <b>1998</b> , 80, 1-34	185
1818	Vascular morbidity and mortality during long-term follow-up in claudicants selected for peripheral bypass surgery. <b>1998</b> , 16, 292-300	10
1817	The management of hypercholesterolemia in patients with coronary artery disease: guidelines for primary care. <b>1998</b> , 1, 51-64	3
1816	Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. <b>1998</b> , 44, 249-56	16
1815	Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. <b>1998</b> , 28, 192-5	37
1814	[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]. <b>1998</b> , 23, 319-29	13
1813	[Coronary heart disease as inflammatory disease of the vascular bed? Etiology, sequela or misconception?]. <b>1998</b> , 23, 147-52	
1812	[Arteriosclerosis and coronary heart disease--strengths and weaknesses in the classical risk factor concept]. <b>1998</b> , 23, 153-62	1
1811	The benefit of lowering cholesterol: relative risk can be absolutely misleading!. <b>1998</b> , 167, 92-3	
1810	Prognostic characterization of patients with mild coronary artery disease with myocardial perfusion single photon emission computed tomography: validation of an outcomes-based strategy. <b>1998</b> , 5, 90-5	3
1809	Landmark trials in lipid reduction. <b>1998</b> , 1, 110-4	1
1808	Prevention of heart disease: is LDL reduction the outcome of choice? Absolutely yes. <b>1998</b> , 1, 115-9	1
1807	Cardiovascular disease and lipoproteins: available evidence and remaining questions. Reactor panel and open forum. <b>1998</b> , 1, 125-30	2
1806	The economics of hypercholesterolemia and lipid-lowering therapy: a brief historical tour. <b>1998</b> , 1, 159-65	2
1805	Lipid-lowering pharmacoeconomic studies. Reactor panel and open forum. <b>1998</b> , 1, 167-70	
1804	Compliance in the real world. <b>1998</b> , 1, 171-3	10
1803	Use of surrogate measures in cost-effectiveness analyses of lipid-lowering therapies. <b>1998</b> , 1, 175-80	4
1802	Clinical trials and external validity. <b>1998</b> , 1, 181-5	2

1801	Methodology issues in lipid pharmaco-economic investigations. Reactor panel and open forum. <b>1998</b> , 1, 195-200		
1800	What is happening in the real world in lipid therapy and is it appropriate? The need for a paradigm shift. <b>1998</b> , 1, 204-7		1
1799	Commentary on Langley and McKenney Papers. <b>1998</b> , 1, 216-7		
1798	A Canadian perspective. <b>1998</b> , 1, 218-23		
1797	A UK Perspective. <b>1998</b> , 1, 224-7		
1796	From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forum. <b>1998</b> , 1, 243-50		
1795	Lipoprotein(a) apheresis in severe coronary heart disease: an immunoabsorption method. <b>1998</b> , 22, 135-9		13
1794	Does cholesterol lowering prevent stroke?. <b>1998</b> , 23, 337-44		5
1793	An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. <b>1998</b> , 23, 385-9		78
1792	Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. <b>1998</b> , 243, 163-70		85
1791	Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. <b>1998</b> , 244, 143-7		15
1790	Lipid disorders in NIDDM: implications for treatment. <b>1998</b> , 244, 361-70		18
1789	DALI-the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. <b>1998</b> , 28, 994-1002		62
1788	Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. <b>1998</b> , 28, 971-9		39
1787	Influence of bilateral oophorectomy upon lipid metabolism. <b>1998</b> , 29, 147-54		15
1786	Statins for prevention of stroke. <i>Lancet, The</i> , <b>1998</b> , 352, 909-10	40	2
1785	Statins for prevention of stroke. <i>Lancet, The</i> , <b>1998</b> , 351, 1002-3	40	13
1784	Fatal lupus-like syndrome and ARDS induced by fluvastatin. <i>Lancet, The</i> , <b>1998</b> , 352, 114	40	28



1783	Prevention of stroke. <i>Lancet, The</i> , <b>1998</b> , 352 Suppl 3, SIII15-8	40	25
1782	Overview of atherosclerosis. <b>1998</b> , 20 Suppl B, B2-17		41
1781	Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia. <b>1998</b> , 20, 477-85		5
1780	A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia. <b>1998</b> , 20, 539-48		5
1779	Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost. <b>1998</b> , 20, 340-6		9
1778	[Cholesterolemia and pathology: update]. <b>1998</b> , 19, 180-4		
1777	Prediction of coronary heart disease using risk factor categories. <b>1998</b> , 97, 1837-47		6815
1776	Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. <b>1998</b> , 97, 2433-44		481
1775	Cardiovascular gene therapy. <b>1998</b> , 7, 114-120		
1774	An elderly woman with hypercholesterolaemia but no symptoms. <b>1998</b> , 2, 39-44		
1773	The implementation of multiprofessional guidelines for cardiac rehabilitation: a pilot study. <b>1998</b> , 2, 60-71		5
1772	Prevalence of cardiovascular risk factors in South Korean adults: results from the Korea Medical Insurance Corporation (KMIC) Study. <b>1998</b> , 8, 14-21		58
1771	Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. <b>1998</b> , 47, 863-8		41
1770	Synthesis of 4 alpha-(2-propenyl)-5,6-secocholestan-3 alpha-ol, a novel B-ring seco analog of the hypocholesterolemic agent 4 alpha-(2-propenyl)-5 alpha-cholestan-3 alpha-ol. <b>1998</b> , 63, 202-7		1
1769	Treatment of early onset atherosclerosis. <b>1998</b> , 123, 720-2		
1768	Iatrogenic problems caused by immunosuppressive drugs in transplant recipients. <b>1998</b> , 30, 14S-19S		5
1767	Open-label study of the efficacy, safety, and tolerability of policosanol in patients with high global coronary risk. <b>1998</b> , 59, 737-745		8
1766	Aggressive medical therapy for the prevention and treatment of coronary artery disease. <b>1998</b> , 44, 1-40		1

1765	Critical analysis of coronary artery bypass graft surgery: a 30-year journey. <b>1998</b> , 31, 1B-63B		82
1764	Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. <b>1998</b> , 31, 1490-2		5
1763	Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. <b>1998</b> , 32, 711-6		97
1762	Specialty differences in cardiovascular disease prevention practices. <b>1998</b> , 32, 1238-43		24
1761	The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. <b>1998</b> , 32, 1244-50		40
1760	HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. <b>1998</b> , 32, 2057-64		349
1759	Decreased blood oxygen diffusion in hypercholesterolemia. <b>1998</b> , 124, 692-8		14
1758	Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins. <b>1998</b> , 62, 406-19		64
1757	Dyslipoproteinemia and diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1998</b> , 27, 613-25, ix-x	5.5	22
1756	Role of inflammation and metalloproteinases in plaque disruption and thrombosis. <b>1998</b> , 3, 199-206		86
1755	Clinical trials of reducing low-density lipoprotein concentrations. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1998</b> , 27, 585-95, viii-ix	5.5	8
1754	Cardiovascular diseases in women. <b>1998</b> , 82, 1-19		8
1753	Control of lipid disorders in patients with atherosclerotic vascular disease. <i>Surgical Clinics of North America</i> , <b>1998</b> , 78, 431-46	4	1
1752	Gender differences in cardiac rehabilitation. <b>1998</b> , 16, 37-43		38
1751	New prospects for lipid-lowering drugs. <b>1998</b> , 7, 715-27		3
1750	Do lipid lowering drugs reduce the risk of coronary heart disease?. <b>1998</b> , 35, 603-21		15
1749	Serum cholesterol, lifestyle, working capacity and quality of life in patients with coronary artery disease. Experiences from a hospital-based secondary prevention programme. <b>1998</b> , 50, 1-20		26
1748	Risk indicators for recurrence among patients with coronary artery disease. Problems associated with their modification. <b>1998</b> , 32, 9-16		1

1747	Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain. <b>1998</b> , 13, 623-43	17
1746	Impact of dyslipidaemia. Lessons from clinical trials. <b>1998</b> , 14 Suppl 3, 1-9	1
1745	Resource utilisation in the management of dyslipidaemia. <b>1998</b> , 14 Suppl 3, 11-8	6
1744	The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. <b>1998</b> , 14 Suppl 3, 19-28	13
1743	Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols. <b>1998</b> , 14 Suppl 3, 29-38	5
1742	The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. <b>1998</b> , 14, 59-70	38
1741	Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease. <b>1998</b> , 14, 217-36	8
1740	Secondary Prevention after Myocardial Infarction. <b>1998</b> , 4, 6-10	7
1739	An introduction to Markov modelling for economic evaluation. <b>1998</b> , 13, 397-409	578
1738	Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention. <b>1998</b> , 27, 775-80	28
1737	Visceral obesity and the risk of ischaemic heart disease: insights from the Qubec Cardiovascular Study. <b>1998</b> , 8 Suppl B, 1-8	39
1736	Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). <b>1998</b> , 136, 115-24	36
1735	Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. <b>1998</b> , 104, 2S-5S	71
1734	Risk factor modification: rationale for management of dyslipidemia. <b>1998</b> , 104, 6S-8S	17
1733	Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. <b>1998</b> , 104, 9S-13S	34
1732	New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease. <b>1998</b> , 104, 2S-17S	145
1731	The future: screening and effective intervention. <b>1998</b> , 104, 54S-59S	0
1730	Biologic markers as predictors of cardiovascular disease. <b>1998</b> , 104, 18S-27S	78

1729	Lessons from cholesterol-lowering trials. <b>1998</b> , 104, 28S-32S	13
1728	The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. <b>1998</b> , 104, 42S-49S	14
1727	The American College of Physicians guidelines for screening blood cholesterol levels: a commentary. <b>1998</b> , 105, 75S-76S	3
1726	Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials. <b>1998</b> , 105, 63S-68S	7
1725	A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease. <b>1998</b> , 105, 69S-74S	8
1724	Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. <b>1998</b> , 339, 229-34	517 <sup>o</sup>
1723	Drug administration in patients with diabetes mellitus. Safety considerations. <b>1998</b> , 18, 441-55	12
1722	Choosing the most appropriate treatment for stable angina. Safety considerations. <b>1998</b> , 19, 23-44	33
1721	Cerivastatin. <i>Drugs</i> , <b>1998</b> , 55, 415-20; discussion 421-2	12.1 34
1720	Are there potential non-lipid-lowering uses of statins?. <i>Drugs</i> , <b>1998</b> , 56, 517-22	12.1 42
1719	Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. <b>1998</b> , 16, 219-27	12
1718	Evidence based approach for the management of mixed hyperlipidaemia. <b>1998</b> , 137 Suppl, S97-100	9
1717	Direct vascular effects of HMG-CoA reductase inhibitors. <b>1998</b> , 137 Suppl, S101-9	172
1716	Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. <b>1998</b> , 137 Suppl, S111-6	29
1715	The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. <b>1998</b> , 138, 229-35	133
1714	HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. <b>1998</b> , 139, 21-30	53
1713	Metabolic modes of action of the statins in the hyperlipoproteinemias. <b>1998</b> , 141, 203-7	47
1712	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. <b>1998</b> , 140, 199-270	422

1711	Dietary treatment of people at high coronary risk. <b>1998</b> , 11, 273-280		
1710	Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. <b>1998</b> , 339, 12-20		438
1709	Detection and evaluation of dyslipoproteinemia. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1998</b> , 27, 597-611, ix	5.5	10
1708	Women, dyslipoproteinemia, and estrogens. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1998</b> , 27, 627-39, x	5.5	5
1707	Risk factors for coronary heart disease in women. <b>1998</b> , 16, 1-8		36
1706	The role of lipid-lowering therapy in multiple risk factor management. <i>Drugs</i> , <b>1998</b> , 56 Suppl 1, 1-7; discussion 33	12.1	5
1705	Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. <i>Drugs</i> , <b>1998</b> , 56 Suppl 1, 25-31; discussion 33	12.1	16
1704	Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. <b>1998</b> , 97, 1129-35		1558
1703	Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. <b>1998</b> , 338, 1577-84		150
1702	Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. <b>1998</b> , 18, 1322-9		29
1701	Implications of Serum Cholesterol Measurement for the Vascular Surgeon. <b>1998</b> , 32, 241-244		1
1700	Insulin and coronary artery disease: is syndrome X the unifying hypothesis?. <b>1998</b> , 32, 233-47		22
1699	Guidelines for carotid endarterectomy: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. <b>1998</b> , 29, 554-62		247
1698	Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. <b>1998</b> , 52, 586-94		9
1697	Cholesterol reduction yields clinical benefit: impact of statin trials. <b>1998</b> , 97, 946-52		351
1696	Medical Therapy for Coronary Artery Disease: Primary and Secondary Prevention. <b>1998</b> , 6, 245-249		
1695	Secondary prevention in coronary heart disease: baseline survey of provision in general practice. <b>1998</b> , 316, 1430-4		152
1694	Statin trials and goals of cholesterol-lowering therapy. <b>1998</b> , 97, 1436-9		156

1693	Use of Lipid Drugs With Acute Myocardial Infarction Patients: An Examination of Physician Prescribing Behaviors. <b>1998</b> , 3, 217-222	3
1692	Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. <b>1998</b> , 49, 339-48	8
1691	Suppressive effect of simvastatin on intramural small coronary arterial lesions in cholesterol-fed rabbits. <b>1998</b> , 49, 211-20	
1690	Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update. <b>1998</b> , 6, 3-10	0
1689	Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. <b>1998</b> , 97, 501-9	333
1688	Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. <b>1998</b> , 49, 743-8	12
1687	Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. <b>1998</b> , 273, 24266-71	802
1686	Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention. <b>1998</b> , 3, 77-84	0
1685	Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. <b>1998</b> , 97, 1095-102	205
1684	Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reserve. <b>1998</b> , 98, 1291-6	116
1683	Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. <b>1998</b> , 98, 1993-9	64
1682	Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. <b>1998</b> , 83, 1015-26	124
1681	Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. <b>1998</b> , 339, 1349-57	454 <sup>0</sup>
1680	3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. <b>1998</b> , 83, 490-500	35 <sup>0</sup>
1679	Reversal of abnormal coronary vasomotion by calcium antagonists in patients with hypercholesterolemia. <b>1998</b> , 97, 1348-54	25
1678	The potential role of soluble fibre in the treatment of hypercholesterolaemia. <b>1998</b> , 74, 391-4	8
1677	Recognition and management of hypercholesterolaemia in patients awaiting elective coronary artery bypass grafting. <b>1998</b> , 74, 157-60	1
1676	New targeted AHA research program: Cardiovascular Care and Outcomes. <b>1998</b> , 97, 1221-2	5

1675	Cholesterol and coronary heart disease: screening and treatment. <b>1998</b> , 7, 232-9	14
1674	Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. <b>1998</b> , 97, 1876-87	432
1673	Atherothrombosis: mechanisms and clinical therapeutic approaches. <b>1998</b> , 3, 231-9	46
1672	The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice. <b>1998</b> , 74, 600-1	8
1671	Controlling blood lipids part 2: when and how to use medication. <b>1998</b> , 26, 56-65	
1670	Polymorphism of the cholesteryl ester transfer protein gene. <b>1998</b> , 338, 1624-5; author reply 1625-6	4
1669	Management of NonQ-Wave Myocardial Infarction. <b>1998</b> , 339, 1395-1398	1
1668	Recent advances. Cardiology. <b>1998</b> , 316, 911-5	2
1667	The atherogenic significance of an elevated plasma triglyceride level. <b>1998</b> , 35, 489-516	29
1666	Endothelial dysfunction: implications for therapy of cardiovascular diseases. <b>1998</b> , 32, 459-70	27
1665	Preventing coronary disease in women: brief observations from the clinical data. <b>1998</b> , 7, 195-7	1
1664	Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. <b>1998</b> , 339, 861-7	579
1663	Chronic heart failure in the United States: a manifestation of coronary artery disease. <b>1998</b> , 97, 282-9	640
1662	Cardiovascular disease prevention: a challenge for Latin America. <b>1998</b> , 98, 2103-4	9
1661	Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. <b>1998</b> , 97, 1446-52	311
1660	Animal model that mimics atherosclerotic plaque rupture. <b>1998</b> , 83, 705-13	71
1659	Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. <b>1998</b> , 97, 34-40	170
1658	Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. <b>1998</b> , 97, 1784-90	214

1657	Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). <b>1998</b> , 316, 823-8	1367
1656	Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. <b>1998</b> , 32, 1030-43	36
1655	IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy. <b>1998</b> , 18, 577-83	11
1654	Clinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia: Is molecular diagnosis superior to clinical diagnosis?. <b>1998</b> , 18, 331-2	9
1653	Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland. <b>1998</b> , 97, 1087-94	73
1652	Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). <b>1998</b> , 97, 1453-60	516
1651	Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. <b>1998</b> , 98, 851-5	146
1650	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. <b>1998</b> , 83, 683-90	287
1649	HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. <b>1998</b> , 18, 1671-8	430
1648	Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. <b>1998</b> , 18, 738-46	56
1647	Present status of HMG reductase inhibitors in treatment of dyslipidemia. <b>1998</b> , 49, 801-5	1
1646	Invited Review. <b>1998</b> , 32, 245-247	1
1645	Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. <b>1998</b> , 97, 535-43	960
1644	Coronary heart disease epidemiology: a look towards the south. <b>1998</b> , 52, 706	1
1643	Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). <b>1998</b> , 97, 1440-5	659
1642	Performance indicators for primary care groups: an evidence based approach. <b>1998</b> , 317, 1354-60	82
1641	Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. <b>1998</b> , 95, 8880-5	839
1640	Time trend analysis and variations in prescribing lipid lowering drugs in general practice. <b>1998</b> , 317, 1134-5	38



- 1639 Detecting and correcting hyperlipidemia. **1998**, 33, 83-90, 95-9; discussion 99-100, 102
- 1638 Underutilization of measurement of serum low-density lipoprotein cholesterol levels and of lipid-lowering therapy in older patients with manifest atherosclerotic disease. **1998**, 46, 1128-31 28
- 1637 Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. **1998**, 77, 378-83 25
- 1636 Contemporary Practice: Treatment Gap in Lipid-Lowering Therapy. **1998**, 11, 318-322
- 1635 Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. **1998**, 316, 1127-30 180
- 1634 Interim report from project ImPACT: hyperlipidemia. **1998**, 38, 529-34 16
- 1633 From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. **1998**, 317, 1130-4 97
- 1632 Cardiac rehabilitation: structure, effectiveness and the future. **1998**, 7, 1033-40 9
- 1631 Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. **1998**, 316, 1471-3 20
- 1630 Management of hyperlipidaemia after coronary revascularisation: follow up study. **1998**, 316, 1499 9
- 1629 Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. **1998**, 317, 1125-30 33
- 1628 Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. **1998**, 128, 444S-448S 154
- 1627 Secondary prevention in acute myocardial infarction. **1998**, 316, 838-42 27
- 1626 Communicating the risk reduction achieved by cholesterol reducing drugs. **1998**, 316, 1956-8 72
- 1625 Management of older persons after myocardial infarction. **1998**, 46, 1459-68 10
- 1624 Fighting heart disease and stroke. Recommendations of the AHA Stroke Positioning Task Force. **1998**, 29, 1272-3 5
- 1623 Prevalence of coronary artery disease, atherothrombotic brain infarction, and peripheral arterial disease: associated risk factors in older Hispanics in an academic hospital-based geriatrics practice. **1998**, 46, 481-3 17
- 1622 Guidelines for coronary heart disease in general practice. Practice-based audit: results from a dissemination and implementation programme. **1998**, 3, 161-165 1

1621	Cost-effectiveness of cardiovascular prevention programs in Spain. <b>1998</b> , 14, 320-30	30
1620	Phyto-oestrogens: where are we now?. <b>1998</b> , 79, 393-406	324
1619	Survival in treated hypertension: follow up study after two decades. <b>1998</b> , 317, 167-71	146
1618	The search for novel antiarrhythmic strategies. Sicilian Gambit. <b>1998</b> , 62, 633-48	6
1617	Cholesterol in Childhood. <b>1998</b> , 101, 141-147	221
1616	Modulators of dyslipidaemia. <b>1998</b> , 3, 147-172	20
1615	Management of lipids in the elderly. <b>1998</b> , 91, 189-91	3
1614	Effects of probiotics and prebiotics on blood lipids. <b>1998</b> , 80, S225-S230	75
1613	Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group. <b>1998</b> , 44, 134-140	23
1612	Plasma lipoprotein profiles change significantly during cardiac catheterization. <b>1998</b> , 44, 517-521	10
1611	Endothelium and acute coronary syndromes. <b>1998</b> , 44, 1799-1808	76
1610	Coronary risk factors 6-12 months after coronary arter bypass surgery. <i>Medical Journal of Australia</i> , <b>1998</b> , 169, 174-175	4
1609	Coronary atherosclerosis and its effect on cardiac structure and function: evaluation by electron beam computed tomography. <b>1998</b> , 44, 1871-1881	7
1608	Effects of Continuous and Cyclic Hormone Replacement Therapy on the Lipoprotein Profile in Postmenopausal Women. <b>1998</b> , 14, 12-17	
1607	Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?. <b>1998</b> , 104, 117-20, 123-4, 129	4
1606	Does 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor Therapy Exert a Direct Anti-Ischemic Effect?. <b>1998</b> , 97, 937-937	3
1605	Revisiting the effectiveness of the National Cholesterol Education Program's Step I and Step II diets: cholesterol-lowering diets in a pharmaceutically driven world. <b>1999</b> , 69, 581-2	9
1604	Switching to statins: a challenge for primary care. <b>1999</b> , 92, 522-4	1

1603	Is there a Place for LDL-apheresis in Non-Homozygous Patients?. <b>1999</b> , 22, 723-725	3
1602	Cholesterol reduction using manufactured foods high in monounsaturated fatty acids: a randomized crossover study. <b>1999</b> , 81, 439-446	34
1601	Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study. <b>1999</b> , 27, 115-29	13
1600	Outcomes Improvement Following Minimally Invasive Direct Coronary Artery Bypass Surgery. <b>1999</b> , 11, 177-188	4
1599	Abstracts from the Evidence Supported Medicine Union/NHS Executive West Midlands Conference, 17-18 March 1999, Birmingham. <b>1999</b> , 3, 11-64	
1598	The Role of Chlamydia Pneumoniae in the Pathogenesis of Coronary Heart Disease. <b>1999</b> , 15, 157-161	
1597	2. Cholesterol in perspective. <i>Medical Journal of Australia</i> , <b>1999</b> , 170, 385-390	4 1
1596	Recommendations for the Treatment of Lipid Disorders in Patients on Peritoneal Dialysis. <b>1999</b> , 19, 8-17	12
1595	Long-term clinical outcome after stent implantation in coronary arteries. <b>1999</b> , 2, 27-34	2
1594	Multiple risk factor interventions for primary prevention of coronary heart disease. <b>2000</b> , CD001561	19
1593	Explaining risk factors to patients during a general practice consultation. Conveying group-based epidemiological knowledge to individual patients. <b>1999</b> , 17, 3-5	14
1592	Anti-oxidant therapy for the treatment of coronary artery disease. <b>1999</b> , 8, 1763-1784	7
1591	Therapeutic controversy: Hormone replacement therapy--where are we going?. <b>1999</b> , 84, 1798-812	20
1590	Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. <b>1999</b> , 341, 70-6	711
1589	Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. <b>1999</b> , 84, 1043-9	275
1588	State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. <b>1999</b> , 34, 987-96	113
1587	Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. <b>1999</b> , 318, 1548-51	203
1586	Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. <b>1999</b> , 19, 1819-24	108

1585	A review of recent dietary intervention trials in the United Kingdom to reduce blood cholesterol levels. <b>1999</b> , 26, 427-42	
1584	Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. <b>1999</b> , 34, 1281-6	248
1583	Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. <b>1999</b> , 99, 475-81	129
1582	Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. <b>1999</b> , 4, 67-75	35
1581	Statins and cerebrovascular disease: plaque attack to prevent brain attack. <b>1999</b> , 4, 269-72	8
1580	Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. <b>1999</b> , 341, 410-8	2809
1579	Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. <b>1999</b> , 100, 1215-22	124
1578	Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. <b>1999</b> , 19, 2894-900	199
1577	Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. <b>1999</b> , 99, 2003-10	121
1576	Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. <b>1999</b> , 81, 380-6	191
1575	Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial Data Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. <b>1999</b> , 99, E1-7	64
1574	Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. <b>1999</b> , 100, 230-5	1259
1573	Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. <b>1999</b> , 15, 394-9; discussion 399-400	91
1572	Systematic review on the risk and benefit of different cholesterol-lowering interventions. <b>1999</b> , 19, 187-95	167
1571	Clinical utility of lipid and lipoprotein levels during hospitalization for acute myocardial infarction. <b>1999</b> , 4, 227-31	13
1570	Primary prevention of coronary heart disease: integrating risk assessment with intervention. <b>1999</b> , 100, 988-98	164
1569	Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. <b>1999</b> , 99, 1959-64	230
1568	Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. <b>1999</b> , 99, 216-23	357

1567	Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. <b>1999</b> , 99, 1165-72	577
1566	Factors associated with the use of various medications amongst patients with severe coronary artery disease. SECOR/SBU Project Group. <b>1999</b> , 245, 143-53	8
1565	Urinary albumin excretion. An independent predictor of ischemic heart disease. <b>1999</b> , 19, 1992-7	321
1564	Concurrent use of simvastatin and estrogen--progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. <b>1999</b> , 2, 181-8	12
1563	Genetic prediction of coronary heart disease: Lessons from Canada. <b>1999</b> , 59, 153-167	1
1562	Estimating the population impact of an intervention: a decision-analytic approach. <b>1999</b> , 8, 311-30	13
1561	Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <b>1999</b> , 100, 1481-92	815
1560	MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. <b>1999</b> , 19, 1956-9	81
1559	Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. <b>1999</b> , 13, 679-85	154
1558	Inhibition of arterial thrombus formation by ApoA1 Milano. <b>1999</b> , 19, 378-83	126
1557	Lipides et risque cardiovasculaire au cours de l'insuffisance rñale chronique. <b>1999</b> , 13, 187-190	0
1556	A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. <b>1999</b> , 13, 520-5	19
1555	Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. <b>1999</b> , 48, 610-5	13
1554	A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). <b>1999</b> , 47, 99-104	16
1553	LDL particle size: an important drug target?. <b>1999</b> , 48, 125-33	41
1552	Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. <b>1999</b> , 29, 404-12	15
1551	Developing risk stratification charts for diabetic and nondiabetic subjects. <b>1999</b> , 16, 219-27	38
1550	Intensive lipid-lowering strategy in patients with diabetes mellitus. <b>1999</b> , 16, 500-8	17

1549	Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study. <b>1999</b> , 16, 749-54	20
1548	Non-lipid properties of statins. <b>1999</b> , 24, 3-5	8
1547	Angina and its treatment. <b>1999</b> , 24, 171-9	
1546	Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. <b>1999</b> , 24, 397-408	43
1545	Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. <b>1999</b> , 245, 315-27	75
1544	Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. <b>1999</b> , 246, 75-80	11
1543	Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. <b>1999</b> , 246, 25-33	33
1542	Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. <b>1999</b> , 71, S113-6	37
1541	Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. <b>1999</b> , 14, 763-74	26
1540	Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. <b>1999</b> , 14, 711-7	97
1539	Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. <b>1999</b> , 3, 203-8	31
1538	Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis. <b>1999</b> , 3, 219-26	31
1537	Type 2 diabetes towards the new millennium--the relative importance of glycaemic versus lipid control. <b>1999</b> , 29, 249-53	
1536	Endothelial dysfunction, insulin resistance and diabetes: exploring the web of causality. <b>1999</b> , 29, 523-34	12
1535	Lipoproteins, atherogenicity, age and risk of myocardial infarction. <b>1999</b> , 23, 441-2	
1534	Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. <b>1999</b> , 13, 232-6	17
1533	Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. <b>1999</b> , 126, 961-8	44
1532	Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca <sup>2+</sup> signalling and insulin secretion due to blockade of L-type Ca <sup>2+</sup> channels in rat islet beta-cells. <b>1999</b> , 126, 1205-13	176

1531	Advances in the medical management of acute coronary syndromes. <b>1999</b> , 7, 171-89	7
1530	Platelet PIA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics. <b>1999</b> , 8, 89-103	12
1529	Pathogenesis and pathology of coronary heart disease syndromes. <b>1999</b> , 8, 167-89	12
1528	The importance of randomized clinical trials and evidence-based medicine: a clinician's perspective. <b>1999</b> , 22, 6-12	16
1527	Electron beam computed tomography: screening for coronary artery disease. <b>1999</b> , 22, 554-8	27
1526	[Ambulatory cardiac phase II rehabilitation--"the Cologne model"--including 3-year-outcome after termination of rehabilitation]. <b>1999</b> , 24 Suppl 1, 9-23	7
1525	[Outcome of a four-week ambulatory cardiac rehabilitation (phase II) on cardiovascular risk factors, physical fitness and occupational reintegration in patients after myocardial infarct, dilatation treatment and heart operation]. <b>1999</b> , 24 Suppl 1, 44-56	3
1524	[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]. <b>1999</b> , 24, 3-12	2
1523	[Therapy with CSE inhibitors--more than lipid lowering?]. <b>1999</b> , 24, 42-50	1
1522	Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. <b>1999</b> , 24, 51-6	18
1521	[Plaque stabilization by LDL apheresis?]. <b>1999</b> , 24, 57-61	5
1520	[Endothelial dysfunction--assessment of current status and approaches to therapy]. <b>1999</b> , 24, 62-71	17
1519	[Drug therapy for prognostic improvement after acute myocardial infarct]. <b>1999</b> , 24, 389-97	2
1518	[Group therapy for heart patients--an assessment of current status]. <b>1999</b> , 24, 242-9	0
1517	Effect of cholesterol-lowering diets on indices of depression and hostility. <b>1999</b> , 21, 98-101	2
1516	Hyperlipidemia under treatment with proteinase inhibitors. <b>1999</b> , 27, 77-81	62
1515	Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. <b>1999</b> , 29, 22-5	42
1514	Prevention of cardiovascular events in elderly hypercholesterolemic patients. <i>Current Atherosclerosis Reports</i> , <b>1999</b> , 1, 9-15	6 2

1513	New developments in the treatment of low high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , <b>1999</b> , 1, 24-30	6	2
1512	Recent developments in the treatment of hypertriglyceridemia. <i>Current Atherosclerosis Reports</i> , <b>1999</b> , 1, 31-7	6	6
1511	The Air Force/Texas Coronary Atherosclerosis Prevention Study: implications for preventive cardiology in the general adult US population. <i>Current Atherosclerosis Reports</i> , <b>1999</b> , 1, 38-43	6	3
1510	Effect of lipid-lowering therapy on vasomotion and endothelial function. <b>1999</b> , 1, 238-43		11
1509	Combination drug therapy for combined hyperlipidemia. <b>1999</b> , 1, 244-50		16
1508	The Hypertension Optimal Treatment Study: what did it give us?. <b>1999</b> , 1, 337-41		3
1507	New insights into the pharmacodynamic and pharmacokinetic properties of statins. <b>1999</b> , 84, 413-28		592
1506	Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design. <b>1999</b> , 83, 104D-111D		21
1505	Simvastatin decreases aldehyde production derived from lipoprotein oxidation. <b>1999</b> , 83, 846-51		93
1504	Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. <b>1999</b> , 83, 852-6		122
1503	Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. <b>1999</b> , 83, 1330-3		44
1502	Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. <b>1999</b> , 83, 1303-7		221
1501	Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. <b>1999</b> , 83, 1476-7, A7		106
1500	Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). <b>1999</b> , 84, 7-13		34
1499	Frequency of lipid-lowering therapy after a coronary event in Helsinki, Finland. <b>1999</b> , 84, 95, A8		1
1498	Diabetes, hyperlipidemia, and coronary artery disease. <b>1999</b> , 83, 17F-21F		73
1497	Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). <b>1999</b> , 84, 540-8		24
1496	Relation between low-density lipoprotein cholesterol and thoracic aortic atherosclerosis. <b>1999</b> , 84, 603-5, A9		22



1495	Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. <b>1999</b> , 84, 639-43	26
1494	Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. <b>1999</b> , 84, 811-5	111
1493	Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias. <b>1999</b> , 84, 63R-68R	13
1492	Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. <b>1999</b> , 180, 283-9	42
1491	Current status of calcium channel blockers in patients with cardiovascular disease. <b>1999</b> , 24, 236-340	11
1490	Sudden cardiac death. <b>1999</b> , 24, 461-538	10
1489	Diagnosis and management of patients with unstable angina. <b>1999</b> , 24, 681-744	8
1488	Baseline diene conjugation in LDL lipids: an indicator of circulating oxidized LDL. <b>1999</b> , 27, 1141-50	54
1487	Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. <b>1999</b> , 18, 191-221	68
1486	Pathophysiological events during pregnancy influence the development of atherosclerosis in humans. <b>1999</b> , 9, 205-14	47
1485	Late survival after abdominal aortic aneurysm repair. <b>1999</b> , 17, 338-42	40
1484	Lipid levels and emotional distress among healthy male college students. <b>1999</b> , 15, 159-165	3
1483	United Kingdom prospective diabetes study (UKPDS): what now or so what?. <b>1999</b> , 15, 65-71	26
1482	Attending the diabetes center is associated with reduced cardiovascular mortality in type 2 diabetic patients: the Verona Diabetes Study. <b>1999</b> , 15, 170-4	13
1481	Cardiovascular pharmacology of hormone replacement therapy. <b>1999</b> , 15, 219-34	21
1480	Intermittent claudication in older patients. Practical treatment guidelines. <b>1999</b> , 14, 247-59	8
1479	Plaque disruption and thrombosis. Potential role of inflammation and infection. <b>1999</b> , 17, 271-81	59
1478	The health care burden of unstable angina. <b>1999</b> , 17, 247-61	7

1477	The treatment of hypertension and dyslipidemia in diabetes mellitus. <b>1999</b> , 26, 951-64	3
1476	Neuroprotective properties of statins in cerebral ischemia and stroke. <b>1999</b> , 30, 1969-73	312
1475	Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. <b>1999</b> , 33, 910-9	45
1474	Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. <b>1999</b> , 15, 47-74	60
1473	Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. <b>1999</b> , 15, 217-28	50
1472	Simvastatin after orthotopic heart transplantation. Costs and consequences. <b>1999</b> , 15, 279-89	2
1471	1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. <b>1999</b> , 21, 1009-60	410
1470	A series of hydrazone derivatives that elevate HDL-cholesterol. <b>1999</b> , 9, 1293-1298	
1469	Lipid management in ischaemic heart disease. <b>1999</b> , 3, 62-66	1
1468	Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia. <b>1999</b> , 10, 33-39	5
1467	Prevention of mortality from coronary heart disease with pravastatin. <b>1999</b> , 53, 405-8	
1466	Quality measurement issues in heart disease in women. <b>1999</b> , 9, 241-8; discussion 248-9	
1465	Cholesterol management: a review of literature and national cholesterol education program guidelines. <b>1999</b> , 6, 186-191	1
1464	Lipid-lowering medication and risk of cancer. <b>1999</b> , 52, 167-9	29
1463	Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. <b>1999</b> , 52, 589-94	42
1462	Lipid-lowering medication and risk of injury. <b>1999</b> , 52, 1197-200	1
1461	Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals. <b>1999</b> , 68, 309-16	7
1460	Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. <b>1999</b> , 69, 237-44	48

1459	A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. <b>1999</b> , 33, 694-701		241
1458	[Contraindicated medical references and vasoactive agents in arterial pathology of the lower limbs]. <b>1999</b> , 20, 68-73		
1457	[Opposable medical references of the ANDEM concerning hyperlipidemia and its treatment]. <b>1999</b> , 20, 341-6		
1456	Bilan d'extension de la maladie athromateuse au cours de la coronaropathie. Étude rétrospective chez 146 patients coronariens en centre de réadaptation. <b>1999</b> , 42, 76-81		0
1455	Coronary risk assessment methods and cholesterol lowering. <i>Lancet, The</i> , <b>1999</b> , 353, 1096-1097	40	
1454	Benefit of beta-blockers for heart failure. <i>Lancet, The</i> , <b>1999</b> , 354, 682	40	
1453	Better coronary risk assessment in women. <i>Lancet, The</i> , <b>1999</b> , 353, 1637-8	40	6
1452	Indications for cholesterol-lowering medication: comparison of risk-assessment methods. <i>Lancet, The</i> , <b>1999</b> , 353, 278-81	40	74
1451	Clinical trials, consensus conferences, and clinical practice. <i>Lancet, The</i> , <b>1999</b> , 354, 327-30	40	40
1450	Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. <i>Lancet, The</i> , <b>1999</b> , 354, 1234-41	40	474
1449	Acute coronary syndromes: drug treatments. <i>Lancet, The</i> , <b>1999</b> , 353 Suppl 2, SII20-3	40	8
1448	Changes in cholesterol levels in women after coronary artery bypass surgery. <b>1999</b> , 28, 270-5		3
1447	Effectiveness of antihyperlipidemic drug management in clinical practice. <b>1999</b> , 21, 1973-87		9
1446	Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. <b>1999</b> , 21, 2027-35		7
1445	Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy. <b>1999</b> , 21, 218-35		2
1444	Use of a tiered review for evaluation of appropriate use of hydroxymethylglutaryl coenzyme A reductase-inhibitor therapy. <b>1999</b> , 21, 422-9		1
1443	Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. International Quality of Life Multicenter Group. <b>1999</b> , 21, 1758-70		5
1442	A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. <b>1999</b> , 21, 1788-96		8

1441	Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. <b>1999</b> , 100, 1134-46	1470
1440	Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. <b>1999</b> , 33, 125-30	73
1439	Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects. <b>1999</b> , 33, 463-70	64
1438	The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged menAppendix. <b>1999</b> , 33, 909-915	9
1437	A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk. <b>1999</b> , 60, 379-391	26
1436	NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. <b>1999</b> , 60, 423-434	17
1435	Pharmacoepidemiologic study of policosanol. <b>1999</b> , 60, 458-467	23
1434	Role of the surgeon in managing hypercholesterolemia. <b>1999</b> , 125, 465-467	1
1433	The effects of lipids on graft outcome. <b>1999</b> , 31, 14S-15S	25
1432	Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. <b>1999</b> , 65, 1329-37	85
1431	Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects. <b>1999</b> , 48, 68-73	12
1430	Low-density lipoprotein particle size and coronary artery disease in a childhood-onset type 1 diabetes population. <b>1999</b> , 48, 531-4	20
1429	Implications of the United Kingdom prospective diabetes study. <b>1999</b> , 26, 809-27	10
1428	Evaluating the chest pain patient. Scope of the problem. <b>1999</b> , 17, 307-26	3
1427	Imaging of coronary artery calcification. Its importance in assessing atherosclerotic disease. <b>1999</b> , 37, 257-72, v	27
1426	Thrombosis and coagulation abnormalities in the acute coronary syndromes. <b>1999</b> , 17, 283-94, viii	13
1425	Angor estable e inestable: fisiopatología, diagnóstico y modalidades terapéuticas. <b>1999</b> , 1-3, 1-8	
1424	Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. <b>1999</b> , 74, 466-73	14

1423	Cost-effectiveness of stress-echocardiography. <b>1999</b> , 17, 583-95, x		1
1422	Heart failure. <b>1999</b> , 17, 123-35		27
1421	Cardiac rehabilitation and preventive cardiology in the elderly. <b>1999</b> , 17, 233-42		11
1420	Fluvastatin: a review of its use in lipid disorders. <i>Drugs</i> , <b>1999</b> , 57, 583-606	12.1	50
1419	How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. <i>Drugs</i> , <b>1999</b> , 58, 579-87	12.1	13
1418	The use of meta-analysis in cost-effectiveness analysis. Issues and recommendations. <b>1999</b> , 15, 1-8		14
1417	Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. <b>1999</b> , 33, 1294-304		164
1416	Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. <b>1999</b> , 33, 1286-93		112
1415	The Framingham Offspring Study: a commentary. 1980. <b>1999</b> , 33, 1136-40		6
1414	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). <b>1999</b> , 33, 2092-197		482
1413	Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. <b>1999</b> , 34, 62-9		29
1412	Cause of death in clinical research: time for a reassessment?. <b>1999</b> , 34, 618-20		493
1411	The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. <b>1999</b> , 34, 768-76		24
1410	Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. <b>1999</b> , 34, 2002-6		255
1409	Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. <b>1999</b> , 143, 415-25		32
1408	Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition. <b>1999</b> , 144, 335-42		16
1407	Heart rate variability and plasma lipids in men with and without ischaemic heart disease. <b>1999</b> , 145, 181-6		45
1406	Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. <b>1999</b> , 143, 229-43		80

1405	Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. <b>1999</b> , 145, 325-31	50
1404	Best practice--ongoing polemics. <b>1999</b> , 143 Suppl 1, S3-6	3
1403	Guidelines--a missed opportunity. <b>1999</b> , 143 Suppl 1, S7-12	4
1402	Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. <b>1999</b> , 146, 259-70	60
1401	Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. <b>1999</b> , 146, 337-44	35
1400	Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. <b>1999</b> , 147 Suppl 1, S3-10	41
1399	After 4S, CARE and LIPID--is evidence-based medicine being practised?. <b>1999</b> , 147 Suppl 1, S39-44	18
1398	Diabetic dyslipidaemia. <b>1999</b> , 13, 265-78	19
1397	Diabetes and myocardial infarction. <b>1999</b> , 13, 331-43	1
1396	Haemostatic function, arterial disease and the prevention of arterial thrombosis. <b>1999</b> , 12, 577-99	8
1395	The role of nuclear cardiology in clinical decision making. <b>1999</b> , 29, 280-97	38
1394	Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies. <b>1999</b> , 138, S406-12	2
1393	Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. <b>1999</b> , 138, 151-5	62
1392	Diet and atherosclerosis. <b>1999</b> , 138, S426-30	2
1391	Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues. <b>1999</b> , 138, S545-9	14
1390	Statin trials and goals of cholesterol-lowering therapy after AMI. <b>1999</b> , 138, S177-82	22
1389	Trends in clinical and economic outcomes of coronary angioplasty from 1992 to 1995: a population-based analysis. <b>1999</b> , 137, 1012-8	7
1388	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs. <b>1999</b> , 137, S97-104	5

1387	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective. <b>1999</b> , 137, S105-10	4
1386	Primary prevention of coronary heart disease: selection of patients for aggressive cholesterol management. <b>1999</b> , 107, 2S-6S	4
1385	Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <b>1999</b> , 107, 36S-39S	12
1384	Cholesterol lowering and endothelial function. <b>1999</b> , 107, 479-87	109
1383	Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. <b>1999</b> , 107, 588-94	203
1382	Retrobulbar and peripheral capillary blood flow in hypercholesterolemic subjects. <b>1999</b> , 128, 310-6	8
1381	Low density lipoprotein (LDL)-mediated suppression of Lewis lung carcinoma in hypercholesterolemic LDL receptor-deficient mice. <b>1999</b> , 255, 377-81	3
1380	Cardiovascular risk factors in Italy. <b>1999</b> , 29, S111-8	4
1379	Issues for cardiovascular disease risk factor development in Europe. <b>1999</b> , 29, S96-101	1
1378	Cancer and low levels of plasma cholesterol: the relevance of cholesterol precursors and products to incidence of cancer. <b>1999</b> , 29, 383-90	15
1377	How the health care system can influence cardiovascular disease risk factors. <b>1999</b> , 29, S66-71	1
1376	Periodic health examination and screening tests in adults. <b>1999</b> , 34, 117-8, 121-2, 124-6	3
1375	A simple computer program for guiding management of cardiovascular risk factors and prescribing. <b>1999</b> , 318, 101-5	76
1374	THE L-ARGININE - NITRIC OXIDE PATHWAY: ROLE AS AN ANTIOXIDANT MECHANISM IN ATHEROSCLEROSIS. <b>1999</b> , 46-51	
1373	Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. <b>1999</b> , 69, 231-6	376
1372	The Effect of the Menopause on Women at Risk of Heart Disease. <b>1999</b> , 5, 30-35	
1371	The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. <b>1999</b> , 39, 86-90	24
1370	Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. <b>1999</b> , 39, 402-9	53

1369	Individually randomized intervention trials for disease prevention and control. <b>1999</b> , 8, 287-309	12
1368	Achieving National Cholesterol Education Program Goals for Low-Density Lipoprotein Cholesterol in Cardiac Patients:Importance of Diet, Exercise, Weight Control, and Drug Therapy. <b>1999</b> , 74, 466-473	40
1367	Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. <b>1999</b> , 17, 1743-50	83
1366	Does the Intervention of Identifying Homeless Clients Who Should Receive Lipid Altering Therapy Decrease the Occurrence of Cardiovascular Events?. <b>1999</b> , 12, 166-169	
1365	Less heat, more light. <i>Current Opinion in Lipidology</i> , <b>1999</b> , 10, 219-23	4-4 2
1364	Underutilization of cardiac medications in the Pacemaker Selection in the Elderly study. <b>1999</b> , 47, 252-5	1
1363	1999 World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension. <b>1999</b> , 8, 9-43	42
1362	Association of low serum total cholesterol with major depression and suicide. <b>1999</b> , 175, 259-62	173
1361	Managing dyslipidemia in older adults. <b>1999</b> , 47, 1458-65	17
1360	The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators. <b>1999</b> , 47, 811-8	23
1359	Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management. <b>1999</b> , 17, 1641-6	1
1358	Nutrition. <i>Current Opinion in Lipidology</i> , <b>1999</b> , 10, 1-2	4-4
1357	Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. <b>1999</b> , 39, 111-8	35
1356	Use of unequal randomisation to aid the economic efficiency of clinical trials. <b>2000</b> , 321, 759	21
1355	Ten year audit of secondary prevention in coronary bypass patients. <b>2000</b> , 321, 22-3	11
1354	Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. <b>2000</b> , 132, 780-7	66
1353	Improving diabetes care in a large health care system: an enhanced primary care approach. <b>2000</b> , 26, 615-22	51
1352	Preventing ischemic stroke. Current approaches to primary and secondary prevention. <b>2000</b> , 107, 34-6, 39-42, 47-50	15



1351	Origin of atherosclerosis in childhood and adolescence. <b>2000</b> , 72, 1307S-1315S		346
1350	Treatment of stable angina. Use drugs before percutaneous transluminal coronary angioplasty. <b>2000</b> , 321, 62-3		3
1349	Statins: where are we now?. <b>2000</b> , 61, 789-92		1
1348	Cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary arteriograms. <b>2000</b> , 118, 756-60		21
1347	Use of statins in general practices, 1996-8: cross sectional study. <b>2000</b> , 320, 1583-4		27
1346	Treating dyslipidaemia in primary care. The gap between policy and reality is large in the UK. <b>2000</b> , 321, 1299-300		19
1345	Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. <b>2000</b> , 321, 548-50		37
1344	Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. <b>2000</b> , 321, 73-7		152
1343	Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. <b>2000</b> , 321, 1322-5		109
1342	Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines. <i>Current Opinion in Lipidology</i> , <b>2000</b> , 11, 345-9	4.4	1
1341	EPIDEMIOLOGIC DATA IN CLINICAL PRACTICE. <b>2000</b> , 48, 1157-1162		32
1340	Is hypercholesterolemia a risk factor and should it be treated in the elderly?. <b>2000</b> , 14, 347-56		11
1339	Incorporation of lean red meat into a National Cholesterol Education Program Step I diet: a long-term, randomized clinical trial in free-living persons with hypercholesterolemia. <b>2000</b> , 19, 351-60		29
1338	Pharmaceutical care services and results in project IMPACT: hyperlipidemia. <b>2000</b> , 40, 157-65		158
1337	Smoking cessation for the secondary prevention of coronary heart disease. <b>2003</b> , CD003041		22
1336	Cardiovascular Drugs. <b>2000</b> ,		
1335	Emerging concepts in metabolic abnormalities associated with coronary artery disease. <i>Current Opinion in Cardiology</i> , <b>2000</b> , 15, 416-21	2.1	44
1334	Quantification of the physiological relevance of a coronary stenosis using myocardial contrast echocardiography. <b>2000</b> , 11, 203-9		2

1333	At what level of coronary heart disease risk should a statin be prescribed?. <i>Current Opinion in Lipidology</i> , <b>2000</b> , 11, 363-7	4-4	7
1332	Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease. <i>Current Opinion in Lipidology</i> , <b>2000</b> , 11, 567-70	4-4	4
1331	Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia. <b>2000</b> , 40, 421-9		4
1330	Lipid-lowering drug therapies: the evidence. <b>2000</b> , 59, 423-4		
1329	The prescribing of lipid lowering drugs during a 1-year period: analysis of 7490 health insurance files. <b>2000</b> , 9, 119-26		4
1328	MANAGING DYSLIPIDAEMIA IN TYPE 2 DIABETES IN PRIMARY CARE. <b>2000</b> , 17, S1-S8		1
1327	Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market. <b>2000</b> , 3, 181-5		1
1326	Predictors of long-term persistence on statins in a subsidized clinical population. <b>2000</b> , 3, 417-26		92
1325	Health promotion practices of the older adult. <b>2000</b> , 17, 160-8		29
1324	Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies. <b>2000</b> , 4, 213-7		16
1323	Diabetes and vascular disease. <b>2000</b> , 2 Suppl 2, S1-5		5
1322	Vascular disease prevention in patients with diabetes. <b>2000</b> , 2 Suppl 2, S25-36		5
1321	Ethnicity and risk factors for coronary heart disease in diabetes mellitus. <b>2000</b> , 2, 91-7		26
1320	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. <b>2000</b> , 2, 263-70		2
1319	Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. <b>2000</b> , 2, 355-62		38
1318	Diabetes and lipids--a conundrum. <b>2000</b> , 17, 623-4		4
1317	Evidence-based patient information in diabetes. <b>2000</b> , 17, 823-9		36
1316	Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. <b>2000</b> , 49, 463-71		43

1315	Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. <b>2000</b> , 50, 255-62	57
1314	Drugs used in secondary prevention after myocardial infarction: case presentation. <b>2000</b> , 50, 405-17	3
1313	Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. <b>2000</b> , 30, 980-7	106
1312	Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. <b>2000</b> , 25, 445-51	105
1311	Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. <b>2000</b> , 247, 563-9	77
1310	Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. <b>2000</b> , 15, 871-9	27
1309	Are statins anti-inflammatory?. <b>2000</b> , 1, 161-165	69
1308	Reproducibility of volumetric quantification in intravascular ultrasound images. <b>2000</b> , 26, 367-74	25
1307	Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. <b>2000</b> , 20, 709-17	123
1306	The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. <b>2000</b> , 6, 1004-10	1230
1305	Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. <b>2000</b> , 129, 1748-54	242
1304	Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. <b>2000</b> , 131, 1179-87	49
1303	The influence of cholesterol on mortality after transplantation is age dependent. <b>2000</b> , 13, S117-S119	1
1302	Progress in Interventional Cardiology. <b>2000</b> , 13, 73-76	
1301	Plant Stanol/Sterol Ester-Containing Foods and Cardiovascular Disease Risk. <b>2000</b> , 3, 274-278	5
1300	Overall strategy and basic treatment for intermittent claudication. <b>2000</b> , 19, S66-S76	
1299	Optimising care of acute myocardial infarction: results of a regional quality improvement project. <b>2000</b> , 20, 12-9	19
1298	Food for prevention of coronary heart disease: Beyond the low fat, low cholesterol diet. <b>2000</b> , 9 Suppl 1, S86-90	1

1297	HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. <b>2000</b> , 52, 145-8		21
1296	Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. <b>2000</b> , 14, 154-74		100
1295	Modern management of acute myocardial infarction. <b>2000</b> , 25, 677-782		8
1294	Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 383-6	5.8	25
1293	Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 410-6	5.8	89
1292	The prevalence and prognostic significance of electrocardiographic abnormalities. <b>2000</b> , 25, 1-72		69
1291	Update in internal medicine. <b>2000</b> , 31, 329-52		
1290	Low cholesterol and violent crime. <b>2000</b> , 34, 301-9		89
1289	Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. <b>2000</b> , 119, 1008-13; discussion 1013-4		7
1288	A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol <b>2000</b> , 85, 305-8		35
1287	Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. <b>2000</b> , 85, 645-50, A10		46
1286	Cholesterol management in the era of managed care. <b>2000</b> , 85, 3A-9A		13
1285	Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. <b>2000</b> , 85, 10A-17A		58
1284	Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. <b>2000</b> , 85, 23A-29A		13
1283	Strategies for implementing lipid-lowering therapy: pharmacy-based approach. <b>2000</b> , 85, 30A-35A		21
1282	Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). <b>2000</b> , 85, 36A-42A		28
1281	Is it wise to restrict fat in the diets of children?. <b>2000</b> , 100, 28-32		28
1280	Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance. <b>2000</b> , 100, 218-24		38

1279	Post-hospitalization management of high-risk coronary patients. <b>2000</b> , 85, 13B-20B	116
1278	Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. The Economics of Noninvasive Diagnosis (END) Study Group. <b>2000</b> , 86, 1-7	61
1277	Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (a chest pain evaluation in the emergency room [CHEER] substudy). <b>2000</b> , 86, 133-8	46
1276	Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. <b>2000</b> , 86, 250-2	18
1275	Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. <b>2000</b> , 86, 257-62	227
1274	Effects of age, sex, race, diagnosis-related group, and hospital setting on lipid management in patients with coronary artery disease. <b>2000</b> , 86, 328-30	11
1273	Bridging the treatment gap. <b>2000</b> , 85, 3E-7E	74
1272	Population benefits of cholesterol reduction: epidemiology, economics, and ethics. <b>2000</b> , 85, 20E-3E	28
1271	Lipid-lowering therapy after coronary revascularization. <b>2000</b> , 86, 18H-28H	15
1270	Cholesterol lowering in atherosclerosis. <b>2000</b> , 86, 29H-32H	15
1269	Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. <b>2000</b> , 86, 1123-7	15
1268	Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. <b>2000</b> , 86, 1176-81	31
1267	Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. <b>2000</b> , 86, 1250-3, A6	24
1266	Exploring new strategies for the management of acute coronary syndromes. <b>2000</b> , 86, 44J-49J; discussion 49J-50J	12
1265	Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). <b>2000</b> , 86, 1293-8	122
1264	Matching cardiac rhythm management technology to patient needs: pacing/ablation/implantable cardioverter defibrillators. <b>2000</b> , 86, 58K-70K	1
1263	Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. <b>2000</b> , 86, 3J-8J; discussion 8J-9J	166
1262	Medical therapy of unstable angina and non-Q-wave myocardial infarction. <b>2000</b> , 86, 24J-33J; discussion 33J-34J	11

1261	Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. <b>2000</b> , 63, 225-34		43
1260	Other primary prevention trials-what is clinically and economically necessary?. <b>2000</b> , 4 Suppl 1, 109-15		3
1259	The effects of soy protein in women and men with elevated plasma lipids. <b>2000</b> , 12, 251-7		43
1258	Overview of the relationship between ischemia and congestive heart failure. <b>2000</b> , 23, IV4-8		25
1257	Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. <b>2000</b> , 23, 682-8		23
1256	Pathophysiology of atherosclerosis: development, regression, restenosis. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 251-8	6	7
1255	Percutaneous coronary intervention versus medical therapy for coronary heart disease. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 290-6	6	5
1254	Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 321-6	6	4
1253	Insulin resistance in human partial lipodystrophy. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 397-404	6	10
1252	Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 11-3	6	1
1251	Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 20-5	6	18
1250	Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 29-35	6	38
1249	Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 58-63	6	6
1248	Cholesterol, stroke risk, and stroke prevention. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 92-6	6	30
1247	Basic mechanisms of stroke prevention with lipid-lowering therapy. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 120-5	6	2
1246	Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 144-50	6	4
1245	Global risk assessment for lipid therapy to prevent coronary heart disease. <b>2000</b> , 2, 424-32		
1244	Implications of the atorvastatin versus revascularization treatment (AVERT) study for the clinician. <b>2000</b> , 2, 433-8		3

1243	Primary prevention of coronary heart disease: implications of the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). <b>2000</b> , 2, 439-44	4
1242	The role of fibric acid derivatives in the secondary prevention of coronary heart disease. <b>2000</b> , 2, 452-8	4
1241	Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. <b>2000</b> , 2, 269-73	15
1240	Hypercholesterolemia and Dyslipidemia. <b>2000</b> , 2, 173-187	7
1239	Ischemic Heart Disease. <b>2000</b> , 2, 27-36	
1238	Unstable Angina. <b>2000</b> , 2, 37-54	
1237	Current concepts in secondary prevention after acute myocardial infarction. <b>2000</b> , 25, 47-60	3
1236	Ökonomische Evaluation unterschiedlicher Therapieansätze bei Patienten mit stabiler Angina pectoris bzw. asymptomatischer Myokardischämie auf Basis der Resultate der Asymptomatic-Cardiac-Ischemia-Pilot-(ACIP-)Studie. <b>2000</b> , 95, 1-13	1
1235	Thrombolytic therapy in acute myocardial infarction: Third Irish Working Party Consensus. Irish Thrombolysis Concensus Group. <b>2000</b> , 169, 97-9	2
1234	The potential for drug interactions with statin therapy in Ireland. <b>2000</b> , 169, 176-9	30
1233	Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. <b>2000</b> , 30, 147-56	26
1232	Cholesterol and strokes. Cholesterol lowering is indicated for strokes due to carotid atheroma. <b>2000</b> , 320, 459-60	21
1231	Indications for Treatment of Asymptomatic Carotid Stenosis. <b>2000</b> , 11, 247-264	2
1230	Analytical and Clinical Evaluation of Two Homogeneous Assays for LDL-Cholesterol in Hyperlipidemic Patients. <b>2000</b> , 46, 1121-1131	53
1229	n-3 fatty acids and the prevention of coronary atherosclerosis. <b>2000</b> , 71, 224S-7S	110
1228	Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach. <b>2000</b> , 72, 1291S-1296S	65
1227	Hypertriglyceridemia and Coronary Heart Disease. <b>2000</b> , 85, 2098-2105	10
1226	Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. <b>2000</b> , 279, H2649-57	70

1225	Special Turku Coronary Risk Factor Intervention Project for Babies (STRIP). <b>2000</b> , 72, 1316S-1331S	43
1224	Regular review: treatment possibilities for unstable angina. <b>2000</b> , 321, 1269-75	3
1223	What is the optimal age for starting lipid lowering treatment? A mathematical model. <b>2000</b> , 320, 1134-40	26
1222	Evaluation of a Homogeneous Direct LDL-Cholesterol Assay in Diabetic Patients: Effect of Glycemic Control. <b>2000</b> , 46, 1848-1851	21
1221	Opportunistic Discovery of Occult Disease by Use of Test Panels in New, Symptomatic Primary Care Outpatients: Yield and Cost of Case Finding. <b>2000</b> , 46, 1091-1098	5
1220	Evaluation of Two Different Homogeneous Assays for LDL-Cholesterol in Lipoprotein-X-positive Serum. <b>2000</b> , 46, 1351-1356	32
1219	Cholesterol screening in children and adolescents. <b>2000</b> , 105, 637-8	31
1218	Indications for Treatment of Symptomatic Atherosclerotic Carotid Artery Disease. <b>2000</b> , 11, 235-246	
1217	Metabolic Changes in Persons After Spinal Cord Injury. <b>2000</b> , 11, 109-140	139
1216	Reply to EG Bliznakov. <b>2000</b> , 71, 153-154	
1215	Quality, Equity and Partnership—West Midlands Partnership for Developing Quality/NHS Executive Conference, 15-16 March 2000, Birmingham. <b>2000</b> , 4, 1-68	
1214	Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?. <b>2000</b> , 102, 722-7	58
1213	Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. <b>2000</b> , 84, 567-72	26
1212	Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. <b>2000</b> , 102, 846-51	111
1211	Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. <b>2000</b> , 28, 47-68	35
1210	Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation. <b>2000</b> , 20, 728-36	35
1209	Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). <b>2000</b> , 102, 1748-54	216
1208	How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. <b>2000</b> , 18, 232-6	8



1207	Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries. <b>2000</b> , 20, 737-43	46
1206	Evidence-based therapy for type 2 diabetes. The best and worst of times. <b>2000</b> , 107, 27-8, 31-4, 37-40, passim	5
1205	Standardization of lipoprotein reporting. <b>2000</b> , 114, 696-702	5
1204	Fluvastatin: effects beyond cholesterol lowering. <b>2000</b> , 5, 161-75	38
1203	Hyperlipidemia: diagnostic and therapeutic perspectives. <b>2000</b> , 85, 2089-112	37
1202	Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. <b>2000</b> , 101, 744-50	66
1201	Cerivastatin: the low-dose HMG-COA reductase inhibitor. <b>2000</b> , 9, 161-6	2
1200	The Management of Chronic Ischemic Heart Disease in the Elderly. <b>2000</b> , 9, 145-150	
1199	Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. <b>2000</b> , 31, 2442-9	310
1198	Non-lipid-related effects of statins. <b>2000</b> , 32, 164-76	269
1197	CME Paper: Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women: Promises, Controversies, and Clinical Trials. <b>2000</b> , 9, 81-88	4
1196	Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. <b>2000</b> , 101, 2777-82	201
1195	Lipoprotein (a) and stroke. <b>2000</b> , 53, 487-96	73
1194	Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. <b>2000</b> , 36, 923-8	43
1193	The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link. <b>2000</b> , 28, 247-57	31
1192	How accelerated atherosclerosis in SLE has changed our management of the disorder. <b>2000</b> , 9, 228-31	18
1191	Hypercholesterolemia causes mechanical weakening of rabbit atheroma : local collagen loss as a prerequisite of plaque rupture. <b>2000</b> , 86, 101-8	62
1190	Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. <b>2000</b> , 102, 1503-10	498

1189	Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. <b>2000</b> , 35, 329-36	103
1188	Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <b>2000</b> , 101, 477-84	462
1187	Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. <b>2000</b> , 102, 21-7	1079
1186	Aspirin use is low among United States outpatients with coronary artery disease. <b>2000</b> , 101, 1097-101	92
1185	Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. <b>2000</b> , 5, 275-9	29
1184	Oral L-arginine in patients with coronary artery disease on medical management. <b>2000</b> , 101, 2160-4	139
1183	Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. <b>2000</b> , 20, 1340-6	171
1182	Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol. <b>2000</b> , 34, 1432-9	45
1181	Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group. <b>2000</b> , 5, 33-9	13
1180	HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. <b>2000</b> , 20, 556-62	244
1179	Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. <b>2000</b> , 102, 1511-6	157
1178	Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. <b>2000</b> , 20, 2408-13	117
1177	Differential effect of National Cholesterol Education Program (NCEP) Step II diet on HDL cholesterol, its subfractions, and apoprotein A-I levels in hypercholesterolemic women and men after 1 year: the beFIT Study. <b>2000</b> , 20, 1580-7	55
1176	Cholesterol and arterial distensibility in the first decade of life: a population-based study. <b>2000</b> , 101, 1533-8	94
1175	Secondary prevention of coronary heart disease: the role of fibric acids. <b>2000</b> , 102, 2-4	34
1174	Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. <b>2000</b> , 102, 374-9	248
1173	High-density lipoprotein and coronary heart disease: lessons from recent intervention trials. <b>2000</b> , 3, 33-39	3
1172	Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the antiarrhythmics versus implantable defibrillators (AVID) study registry. <b>2000</b> , 139, 804-13	23

1171	Statins: effective antiatherosclerotic therapy. <b>2000</b> , 139, 577-83		131
1170	The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. <b>2000</b> , 139, S143-54		10
1169	Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum. <b>2000</b> , 139, 461-75		45
1168	Use of cholesterol-lowering medications in the United States from 1991 to 1997. <b>2000</b> , 108, 496-9		50
1167	Effects of lovastatin on cognitive function and psychological well-being. <b>2000</b> , 108, 538-46		238
1166	Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?. <b>2000</b> , 139, 734-8		33
1165	Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. <i>Lancet, The</i> , <b>2000</b> , 355, 688-700	40	379
1164	Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study. <b>2000</b> , 22, 949-60		9
1163	The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils. <b>2000</b> , 75, 85-90		4
1162	Effects of HMG-CoA reductase inhibitor on hemostasis. <b>2000</b> , 76, 23-32		42
1161	Lipid lowering improves endothelial functions. <b>2000</b> , 74 Suppl 1, S3-S10		28
1160	Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. <b>2000</b> , 72, 121-6		73
1159	Correlation between apolipoprotein B and endothelin-1-induced vasoconstriction in humans. <b>2000</b> , 21, 871-4		8
1158	Secondary prevention after myocardial infarction: reducing the risk of further cardiovascular events. <b>2000</b> , 4, 82-91		4
1157	A large proportion of dyslipidemic patients receiving lipid-lowering therapy did not reach NCEP LDL-C goals. <b>2000</b> , 4, 52		
1156	Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. <b>2000</b> , 139, 952-61		48
1155	Atorvastatin versus revascularization treatment (AVERT): fact or fancy?. <b>2000</b> , 140, 6-9		8
1154	Current perspectives on the management of hypertriglyceridemia. <b>2000</b> , 140, 232-40		37

1153	Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. <b>2000</b> , 140, 792-803	19
1152	Discrepancies among megatrials. <b>2000</b> , 53, 1193-9	33
1151	Computerised systematic secondary prevention in ischaemic heart disease: a study in one practice. <b>2000</b> , 114, 169-75	8
1150	Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. <b>2000</b> , 19, 529-37	79
1149	Statins after cardiac transplantation: which statin, what dose, and how low should we go?. <b>2000</b> , 19, 515-7	19
1148	Systematic, immediate in-hospital initiation of lipid-lowering drugs during acute coronary events improves lipid control. <b>2000</b> , 11, 309-316	6
1147	Clinical relevance of the oxidative stress concept. <b>2000</b> , 49, 30-4	35
1146	Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. <b>2000</b> , 49, 115-21	46
1145	Lipoprotein abnormalities in patients with asymptomatic acute porphyria. <b>2000</b> , 294, 37-43	10
1144	Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot study. <b>2000</b> , 61, 346-357	9
1143	Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. <b>2000</b> , 61, 137-146	26
1142	Dose-dependent cholesterol-lowering effects of d-003 on normocholesterolemic rabbits. <b>2000</b> , 61, 460-468	33
1141	Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: the Japan lipid intervention trial (J-LIT). <b>2000</b> , 61, 219-243	14
1140	Preventing, stopping, or reversing coronary artery disease—triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment. <b>2000</b> , 46, 421-503	5
1139	Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. <b>2000</b> , 56, 9-18	6
1138	Acute relief or future prevention: is urology ready for preventive health care?. <b>2000</b> , 56, 12-9	17
1137	Role of WHO-MONICA Project in unravelling of the cardiovascular puzzle. <i>Lancet, The</i> , <b>2000</b> , 355, 668-9	40 9
1136	Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. <i>Lancet, The</i> , <b>2000</b> , 356, 1871-5	40 55

1135	The current status of heart-mind relationships. <b>2000</b> , 48, 317-20	19
1134	Risk factor modification through nonpharmacological interventions in patients with coronary heart disease. <b>2000</b> , 48, 425-41	37
1133	Pravastatin therapy and the risk of stroke. <b>2000</b> , 343, 317-26	268
1132	Treatment of intermittent claudication. <b>2000</b> , 31, S77-S89	4
1131	Reduced or modified dietary fat for prevention of cardiovascular disease. <b>2000</b> , CD002137	56
1130	Lipid Clinics as Disease Management Programmes in the United States. <b>2000</b> , 8, 65-78	
1129	Differential pharmacokinetics of digoxin in elderly patients. <b>2000</b> , 17, 353-62	62
1128	The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients. <b>2000</b> , 17, 33-51	12
1127	Risks of coronary heart disease in women: current understanding and evolving concepts. <b>2000</b> , 75, 1289-303	29
1126	[Coronary risk and prescription in primary care patients with hypercholesterolemia]. <b>2000</b> , 25, 209-13	5
1125	Prevention of coronary artery disease with statin therapy is usually cost effective. <b>2000</b> , 15, 13-16	
1124	Role of lipid-lowering pharmacotherapy in children. <b>2000</b> , 2, 11-22	12
1123	Novel lipid-regulating drugs. <b>2000</b> , 9, 2619-28	17
1122	Current perspectives on statins. <b>2000</b> , 101, 207-13	958
1121	Modern adjunctive pharmacotherapy of myocardial infarction. <b>2000</b> , 1, 405-18	4
1120	Testing for endothelial dysfunction. <b>2000</b> , 32, 293-304	97
1119	High-density lipoprotein: gene-based approaches to the prevention of atherosclerosis. <b>2000</b> , 32, 642-51	13
1118	Potential of adenosine receptor agonists for the prevention and treatment of coronary artery disease and acute myocardial infarction. <b>2000</b> , 5, 89-108	4

1117	Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. <b>2000</b> , 9, 2663-71	41
1116	Angiotensin AT1 receptor over-expression in hypercholesterolaemia. <b>2000</b> , 32, 386-9	69
1115	Has interest in secondary prevention increased among physicians after the 4S study?. <b>2000</b> , 34, 164-7	5
1114	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. <b>2000</b> , 9, 194-201	31
1113	Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. <b>2000</b> , 1, 683-95	23
1112	Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. <b>2000</b> , 101, 948-54	1669
1111	[Control of cholesterolemia in Spain, 2000. A tool for cardiovascular prevention]. <b>2000</b> , 53, 815-37	51
1110	[How many patients need treatment for hypercholesterolemia?]. <b>2000</b> , 25, 395-9	3
1109	Cardiac rehabilitation and secondary prevention programs for elderly cardiac patients. <b>2000</b> , 16, 619-29	8
1108	Prevençã secundaria de la cardiopatã isquãmica en la provincia de Ciudad Real. Efectividad de la terapãutica hipolipemiente en atenciã primaria. <b>2000</b> , 115, 321-325	13
1107	[Failure of an educational intervention to change anticholesteremic drug prescription in primary care]. <b>2000</b> , 26, 245-8	0
1106	Stroke prevention: hypertension, diabetes, tobacco, and lipids. <b>2000</b> , 18, 309-19	36
1105	Hyperlipidemia. <b>2000</b> , 27, 541-87,v	23
1104	[The quality of the drug treatment in hyperlipemia patients from 4 health areas. The VICAF Group]. <b>2000</b> , 26, 368-73	7
1103	Prevençã de enfermedades cardiovasculares: ¿deben aplicarse los mismos criterios en Amfca Latina que en Europa y Norteamfca?. <b>2000</b> , 53, 889-895	
1102	Decreasing mortality with primary percutaneous coronary intervention in patients with acute myocardial infarction: the Mayo Clinic experience from 1991 through 1997. <b>2000</b> , 75, 994-1001	11
1101	Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group. <b>2000</b> , 75, 1124-32	16
1100	Management of hypercholesterolemia. <b>2000</b> , 84, 23-42	45

1099	Putting prevention into daily practice. <b>2000</b> , 84, 267-78		3
1098	[Which statin is more efficient? Concepts and applications in economic evaluation]. <b>2000</b> , 26, 333-8		1
1097	Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose. <b>2000</b> , 11, 89-106		
1096	Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). <b>2000</b> , 102, 42-7		1841
1095	Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca. <b>2000</b> , 53, 1095-1120		36
1094	Premature atherosclerosis in systemic lupus erythematosus. <b>2000</b> , 26, 257-78		101
1093	Helicobacter pylori is an aetiological factor for ischaemic heart disease: the case against. <b>2000</b> , 32, 65-8		14
1092	Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. <b>2000</b> , 32, 138-51		11
1091	Raising HDL-cholesterol [HIT or miss?]. <b>2000</b> , 4, 109-110		
1090	HMG-CoA reductase inhibitors and myotoxicity. <b>2000</b> , 22, 441-57		203
1089	Comparative tolerability of the HMG-CoA reductase inhibitors. <b>2000</b> , 23, 197-213		128
1088	Clinical pharmacokinetics of cerivastatin. <b>2000</b> , 39, 99-116		91
1087	HMG-CoA reductase inhibitors in the prevention of stroke. <i>Drugs</i> , <b>2000</b> , 59, 1-6	12.1	12
1086	Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?. <i>Drugs</i> , <b>2000</b> , 59, 1127-35	12.1	5
1085	Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. <i>Drugs</i> , <b>2000</b> , 60, 1179-206	12.1	20
1084	A Working-Day Evaluation of Dyslipidaemia in a Spanish Population (JADE Study). <b>2000</b> , 19, 131-142		6
1083	LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid Goals. <b>2000</b> , 19, 219-229		15
1082	Antihyperlipidaemic Drugs. <b>2000</b> , 19, 457-464		0

1081	Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia : The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study. <b>2000</b> , 20, 67-79	24
1080	Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy. <b>2000</b> , 20, 109-21	6
1079	Utilisation of Lipid-Lowering Drugs in Spain between 1986 and 1998. <b>2000</b> , 20, 197-201	3
1078	Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). <b>2000</b> , 150, 429-36	57
1077	The effects of lificrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway. <b>2000</b> , 153, 69-80	6
1076	Cardiovascular risk changes after lipid lowering medications: are they predictable?. <b>2000</b> , 152, 1-8	12
1075	Treating to target with statins. <b>2000</b> , 1, 21-5	6
1074	Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia. <b>2000</b> , 153, 525-6	1
1073	Inhibition of tissue-factor-mediated thrombin generation by simvastatin. <b>2000</b> , 149, 111-6	86
1072	Effects of reserpine on expression of the LDL receptor in liver and on plasma and tissue lipids, low density lipoprotein and fibrinogen in rabbits in vivo. <b>2000</b> , 149, 267-75	5
1071	Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. <b>2000</b> , 150, 331-41	44
1070	Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. <b>2000</b> , 150, 421-8	70
1069	Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. <b>2000</b> , 152, 217-27	86
1068	Risk stratification in unstable coronary artery disease--exercise test and troponin T from a gender perspective. FRISC-Study Group. Fragmin during InStability in Coronary artery disease. <b>2000</b> , 35, 1791-800	21
1067	Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making?. <b>2000</b> , 36, 13-21	123
1066	Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. <b>2000</b> , 36, 427-31	165
1065	Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. <b>2000</b> , 36, 766-72	103
1064	Prevention of recurrent life-threatening arrhythmias: will lipid-lowering therapy make a difference?. <b>2000</b> , 36, 773-5	5



1063	The aggressive low density lipoprotein lowering controversy. <b>2000</b> , 36, 1419-25		18
1062	How deadly is the "deadly quartet"? A post-CABG evaluation. <b>2000</b> , 36, 1159-65		36
1061	Prediction of coronary events with electron beam computed tomography. <b>2000</b> , 36, 1253-60		618
1060	HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. <b>2000</b> , 36, 1691-7		94
1059	Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. <b>2000</b> , 36, 1774-80		107
1058	Exercise performance-based outcomes of medically treated patients with coronary artery disease and profound ST segment depression. <b>2000</b> , 36, 2140-5		24
1057	The framingham offspring study: A commentary. <b>2000</b> , 35, 13B-17B		4
1056	The evolving role of statins in the management of atherosclerosis. <b>2000</b> , 35, 1-10		458
1055	Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. <b>2000</b> , 35, 214-21		116
1054	Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. <b>2000</b> , 35, 106-11		348
1053	Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. <b>2000</b> , 35, 640-6		19
1052	The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). <b>2000</b> , 35, 881-8		89
1051	Diabetes mellitus: the disease. <b>2000</b> , 1-24		
1050	Effect of computerized coronary heart disease risk assessment on the use of lipid-lowering therapy in general practice patients. <b>2001</b> , 5, 4-8		5
1049	Clinical pharmacokinetics of fluvastatin. <b>2001</b> , 40, 263-81		116
1048	Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. <i>Drugs</i> , <b>2001</b> , 61, 197-206	12.1	73
1047	Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. <i>Drugs</i> , <b>2001</b> , 61, 1835-81	12.1	111
1046	Comparison of the Efficacy, Safety and Tolerability of Policosanol versus Fluvastatin in Elderly Hypercholesterolaemic Women. <b>2001</b> , 21, 103-113		17

1045	Effects of Policosanol on Lipid Profile and Cardiac Events in Older Hypercholesterolaemic Patients with Coronary Disease. <b>2001</b> , 21, 485-497		23
1044	Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus. <b>2001</b> , 21, 671-678		5
1043	Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. <i>Pharmacotherapy</i> , <b>2001</b> , 21, 1130-9	5.8	20
1042	The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. <b>2001</b> , 154, 171-7		8
1041	Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. <b>2001</b> , 155, 61-70		35
1040	F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. <b>2001</b> , 155, 131-42		21
1039	Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. <b>2001</b> , 155, 403-12		90
1038	A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects—the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. <b>2001</b> , 155, 347-57		90
1037	Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. <b>2001</b> , 157, 423-9		56
1036	Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. <b>2001</b> , 159, 201-8		77
1035	Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. <b>2001</b> , 159, 513-9		36
1034	Intermittent claudication: an objective office-based assessment. <b>2001</b> , 37, 1381-5		49
1033	Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. <b>2001</b> , 37, 1284-8		320
1032	Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. <b>2001</b> , 37, 1558-64		67
1031	Plaque burden, arterial remodeling and plaque vulnerability: determined by systemic factors?. <b>2001</b> , 38, 718-23		61
1030	Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. <b>2001</b> , 38, 2006-12		102
1029	Use of statins in CNS disorders. <b>2001</b> , 187, 81-9		101
1028	Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. <b>2001</b> , 41, 347-66		373

1027	Lipids and atherosclerosis: clinical management of hypercholesterolaemia. <b>2001</b> , 2, 419-30	9
1026	Estudio observacional en el Eea 10: manejo de la hipercolesterolemia en ancianos diabéticos1. <b>2001</b> , 36, 221-227	
1025	Tratamiento hipolipemiante en ancianos. <b>2001</b> , 36, 195-209	
1024	Cartas al Editor. <b>2001</b> , 116, 398	
1023	How well tolerated are lipid-lowering drugs?. <b>2001</b> , 18, 665-83	21
1022	Contemporary management of chronic stable angina. <b>2001</b> , 18, 109-21	8
1021	Management of type 2 diabetes mellitus in the elderly: special considerations. <b>2001</b> , 18, 31-44	69
1020	Cardiac rehabilitation and secondary prevention of coronary heart disease. <b>2001</b> , 345, 892-902	551
1019	Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. <b>2001</b> , 104, 2746-53	1924
1018	Prognostic significance of endothelial dysfunction in hypertensive patients. <b>2001</b> , 104, 191-6	901
1017	A Comparison of NCEP and Absolute Risk Stratification Methods for Lipid-Lowering Therapy in Middle-Aged Adults: The ARIC Study. The ARIC Investigators. <b>2001</b> , 4, 148-157	2
1016	Direct measurement of low-density-lipoprotein cholesterol is more effective than total cholesterol for the purpose of lipoprotein screening. <b>2001</b> , 32, 224-9	11
1015	The last frontier in cardiovascular health: a landmark lecture for the XVII World Congress of the International Society for Heart Research. <b>2001</b> , 33, 2063-9	1
1014	Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. <b>2001</b> , 101, 79-84	75
1013	Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. <b>2001</b> , 110, 352-60	166
1012	Current utilization trends for beta-blockers in cardiovascular disease. <b>2001</b> , 110 Suppl 5A, 2S-6S	16
1011	Clinical context: current concepts of coronary heart disease management. <b>2001</b> , 110 Suppl 6A, 3S-11S	28
1010	A means to an end: an overview of a hyperlipidemia outcomes management program. <b>2001</b> , 110 Suppl 6A, 12S-16S	50

1009	A case-management program of medium intensity does not improve cardiovascular risk factor control in coronary artery disease patients: the Heartcare I trial. <b>2001</b> , 110, 543-50	17
1008	Do statins cause cancer? A meta-analysis of large randomized clinical trials. <b>2001</b> , 110, 716-23	164
1007	Quality of ambulatory care after myocardial infarction among Medicare patients by type of insurance and region. <b>2001</b> , 111, 24-32	19
1006	Statins and cancer: a case of meta-uncertainty. <b>2001</b> , 110, 738-40	12
1005	Medical therapy or coronary artery bypass graft surgery for chronic stable angina: an update using decision analysis. <b>2001</b> , 111, 89-95	18
1004	Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. <b>2001</b> , 111, 185-91	150
1003	Clinically relevant differences between the statins: implications for therapeutic selection. <b>2001</b> , 111, 390-400	154
1002	Prognosis determination in heart failure. <b>2001</b> , 110 Suppl 7A, 14S-36S	80
1001	Mechanisms of acute coronary syndromes and the potential role of statins. <b>2001</b> , 2, 9-14	13
1000	Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients. <b>2001</b> , 2, 15-9	11
999	Clinical relevance of statins: their role in secondary prevention. <b>2001</b> , 2, 21-5	9
998	Changing the practice of cardiovascular medicine. <b>2001</b> , 2, 27-30	3
997	PPARS, metabolic disease and atherosclerosis. <b>2001</b> , 44, 345-52	99
996	Atorvastatin prevented early recurrence of ischemic events and death in patients with unstable angina or non-Q-wave MI. <b>2001</b> , 5, 43-45	
995	Cholesterol: an important but relatively overemphasized risk factor for ischemic heart disease. <b>2001</b> , 57, 593-601	5
994	Drug therapy or coronary angioplasty for the treatment of coronary artery disease: new insights. <b>2001</b> , 141, S22-5	7
993	Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. <b>2001</b> , 141, 722-6	30
992	Noninvasive tests of vascular function and structure: why and how to perform them. <b>2001</b> , 141, 694-703	76

991	Randomized clinical trials and recent patterns in the use of statins. <b>2001</b> , 141, 957-63	30
990	Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. <b>2001</b> , 142, 119-26	108
989	The effect of pravastatin and atorvastatin on coenzyme Q10. <b>2001</b> , 142, E2	60
988	The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. <b>2001</b> , 142, 211-7	78
987	Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. <b>2001</b> , 142, 452-9	46
986	Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. <b>2001</b> , 142, 502-11	100
985	Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease. <b>2001</b> , 142, 975-81	14
984	Multifactorial cardiovascular disease prevention in patients aged 75 years and older: A randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. <b>2001</b> , 142, 945-51	49
983	Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. <b>2001</b> , 69, 1161-77	62
982	Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. <b>2001</b> , 23, 177-92	64
981	Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. <b>2001</b> , 23, 276-83; discussion 274-5	6
980	A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. <b>2001</b> , 23, 467-78	6
979	STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. <b>2001</b> , 23, 858-70	17
978	STATINS & NEWER HOPE FOR ATHEROSCLEROSIS ASSOCIATED DISEASES. <b>2001</b> , 57, 129-30	
977	The endothelium: a gynecological and obstetric point of view. <b>2001</b> , 94, 180-5	4
976	Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. <b>2001</b> , 1, 105-18	103
975	Cholesterol, A beta and Alzheimer's disease. <b>2001</b> , 24, S45-8	82
974	Cholesterol, A $\beta$ and Alzheimer's disease. <b>2001</b> , 24, 45-48	61

973	Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. <b>2001</b> , 77, 247-53		151
972	Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats. <b>2001</b> , 79, 215-21		15
971	Molecular genetics and gene expression in atherosclerosis. <b>2001</b> , 80, 161-72		38
970	"Natural history" clinical trials: an enduring contribution to modern medical practice. <b>2001</b> , 56, 1-12		1
969	HMG-CoA reductase inhibitors. <b>2001</b> , 56, 77-114		31
968	Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. <b>2001</b> , 37, 484-489		163
967	Coronary heart disease in the statin and aspirin era: are results of clinical trials being put into practice?. <b>2001</b> , 12, 490-5		2
966	If cardiac patients benefit from statins, why not commonly prescribe them and follow up their use?. <b>2001</b> , 12, 475-6		1
965	LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy. <b>2001</b> , 306, 43-9		3
964	A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. <b>2001</b> , 312, 41-7		20
963	Comparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: a randomized, double-blind, placebo-controlled study. <b>2001</b> , 62, 194-208		8
962	Comparison of the effects of D-003 and policosanol on lipid profile and endothelial cells in normocholesterolemic rabbits. <b>2001</b> , 62, 209-220		25
961	Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: two-year follow-up of the prevention of coronary sclerosis study. <b>2001</b> , 62, 473-485		4
960	Effects of atorvastatin on lipid profile and coagulation parameters. <b>2001</b> , 62, 691-698		9
959	Optimal medical management of patients with chronic ischemic heart disease. <b>2001</b> , 47, 154-96		
958	Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. <b>2001</b> , 33, 1194-5		21
957	Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. <i>Lancet, The</i> , <b>2001</b> , 357, 577-81	40	765
956	Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. <i>Lancet, The</i> , <b>2001</b> , 357, 995-1001	40	576

955	Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. <i>Lancet, The</i> , <b>2001</b> , 357, 1063-8	40	247
954	Measurement of atherosclerosis progression. <i>Lancet, The</i> , <b>2001</b> , 358, 328-9	40	0
953	Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. <i>Lancet, The</i> , <b>2001</b> , 358, 351-5	40	312
952	Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. <i>Lancet, The</i> , <b>2001</b> , 358, 1033-41	40	2580
951	Economics of drug treatment: for which patients is it costeffective to lower cholesterol?. <i>Lancet, The</i> , <b>2001</b> , 358, 1251-6	40	22
950	Learning from the cerivastatin experience. <i>Lancet, The</i> , <b>2001</b> , 358, 1383-5	40	86
949	[Chromatic computerized analysis is an early predictor of cardiovascular risk associated to hypercholesterolemia]. <b>2001</b> , 54, 1417-25		5
948	Los fitosteroles, el colesterol y la prevenci3n de las enfermedades cardiovasculares. <b>2001</b> , 13, 209-218		3
947	Eficacia y seguridad de la atorvastatina en la pr3ctica m3dica habitual en Espaã (estudio Zar). <b>2001</b> , 13, 19-25		
946	[Subclinical carotid atherosclerosis in patients with coronary disease]. <b>2001</b> , 116, 441-5		4
945	[Risk factor prevalence and drug treatment in coronary patients at hospital discharge. Results of a national multicenter registry (3C Program)]. <b>2001</b> , 54, 159-68		15
944	Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. <b>2001</b> , 76, 1039-46		26
943	Hiperhomocisteinemia. Diagn3stico y tratamiento. <b>2001</b> , 13, 36-42		
942	Estudio observacional del manejo de la hipercolesterolemia en ancianos en un 3rea de atenci3n primaria. <b>2001</b> , 13, 108-114		
941	Efectividad del tratamiento hipocolesterolemizante a largo plazo. <b>2001</b> , 13, 118-120		
940	Mejor3a de la disfunci3n endotelial en individuos con hipercolesterolemia moderada y enfermedad coronaria tratados con pravastatina. <b>2001</b> , 13, 1-8		
939	Smoking diminishes the beneficial effect of statins: observations from the landmark trials. <b>2001</b> , 52, 575-87		46
938	[Cellular and molecular biology of atherosclerotic lesions]. <b>2001</b> , 54, 218-31		13

937	Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia. <b>2001</b> , 76, 619-31	38
936	Developing guidance for budget impact analysis. <b>2001</b> , 19, 609-21	130
935	Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. <b>2001</b> , 21, 1165-71	161
934	Lipodistrofia y alteraciones metabólicas en pacientes infectados por el virus de la inmunodeficiencia humana tratados con inhibidores de la proteasa. <b>2001</b> , 13, 254-259	0
933	Evidence-based treatment of patients with ischemic cerebrovascular disease. <b>2001</b> , 19, 79-105	6
932	Complicaciones de la diabetes mellitus. Diagnóstico y tratamiento. <b>2001</b> , 27, 132-145	3
931	Mejoría de la función endotelial al reducir las concentraciones lipídicas en pacientes con hipercolesterolemia y arterias coronarias normales. <b>2001</b> , 54, 685-692	7
930	Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. <b>2001</b> , 76, 971-82	122
929	Evaluación farmacoeconómica de la reducción de colesterol con inhibidores de la HMG-CoA reductasa (estatinas) en la hipercolesterolemia. <b>2001</b> , 13, 241-253	3
928	[Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care]. <b>2001</b> , 27, 18-24	5
927	Adjunctive therapies in the treatment of acute coronary syndromes. <b>2001</b> , 76, 391-405	1
926	[Secondary prevention of ischemic heart disease in primary care (PRESENCIAP)]. <b>2001</b> , 27, 29-32	7
925	MANAGEMENT OF HYPERCHOLESTEROLEMIA. <b>2001</b> , 19, 295-310	1
924	Pharmacology and clinical experience with simvastatin. <b>2001</b> , 2, 153-63	20
923	The natural history of coronary heart disease is changing--why?. <b>2001</b> , 35, 4-6	
922	Novel agents for managing dyslipidaemia. <b>2001</b> , 10, 1901-11	6
921	Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. <b>2001</b> , 19, 411-20	39
920	Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?. <b>2001</b> , 15, 589-96	23



919	HMG-CoA reductase inhibitors: useful in stroke prevention?. <b>2001</b> , 17, 10-12		
918	The HMG-CoA reductase inhibitors [new safety concerns?. <b>2001</b> , 17, 11-15		
917	Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD. <b>2001</b> , 1, 353-61		25
916	The role of nicorandil in the treatment of myocardial ischaemia. <b>2001</b> , 2, 845-56		9
915	Dietary fat intake and prevention of cardiovascular disease: systematic review. <b>2001</b> , 322, 757-63		236
914	In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. <b>2001</b> , 21, 1327-32		182
913	HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. <b>2001</b> , 15, 1454-6		77
912	Hypolipidaemic and antiplatelet agents. <b>2001</b> , 11, 1301-1327		2
911	Statins in the 21st century: end of the simple story?. <b>2001</b> , 10, 1755-66		17
910	Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. <b>2001</b> , 6, 137-45		28
909	Rapid assessment of chest pain. <b>2001</b> , 323, 586-7		13
908	Simvastatin: building on success. <b>2001</b> , 62, 29-32		
907	Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. <b>2001</b> , 281, H655-60		17
906	Coronary Atherosclerosis and Restenosis. <b>2001</b> , 967-1009		
905	The Discovery of the Pathophysiological Aspects of Atherosclerosis [A Review. <b>2001</b> , 101, 162-169		31
904	Lipid-lowering therapy following major cardiac events: progress and deficits. <i>Medical Journal of Australia</i> , <b>2001</b> , 175, 138-40	4	4
903	Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. <b>2001</b> , 38, 69-77		48
902	Action of an HMG CoA reductase inhibitor, lovastatin, on apoptosis of untransformed and ts-SV40 transformed human smooth muscle cells derived from saphenous vein. <b>2001</b> , 38, 161-73		9

901	Endothelial function and cardiovascular prevention: role of blood lipids, exercise, and other risk factors. <b>2001</b> , 9, 282-6	18
900	Major trauma in elderly adults receiving lipid-lowering medications. <b>2001</b> , 50, 678-83	4
899	Adjunctive Therapies in the Treatment of Acute Coronary Syndromes. <b>2001</b> , 76, 391-405	8
898	. <b>2001</b> , 8, 63-71	54
897	. <b>2001</b> , 8, 291-297	92
896	Relatively low red cell folate levels and acute coronary syndromes. <b>2001</b> , 12, 665-8	10
895	Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. <b>2001</b> , 41, 70-8	14
894	The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1. <b>2001</b> , 41, 779-82	3
893	Colombian study to assess the use of noninvasive determination of endothelium-mediated vasodilatation (CANDEV). Normal values and factors associated. <b>2001</b> , 8, 157-66	41
892	Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. <b>2001</b> , 37, 502-11	34
891	Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment. <b>2001</b> , 110, 111-4, 117-8, 121-3	6
890	Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells. <b>2001</b> , 85, 147-54	15
889	Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages. <b>2001</b> , 86, 289-96	8
888	Angiotensin II antagonists in systolic blood pressure control. <b>2001</b> , 62, 773-7	4
887	[Lipid-lowering drugs]. <b>2001</b> , 118, 389-95	7
886	Ischaemic Heart Disease. <b>2001</b> ,	0
885	Myocardial infarction in men and women under 65 years of age: no evidence of gender bias. <b>2001</b> , 46, 73-8	4
884	Relationship of early carotid artery disease with lipoprotein (a), apolipoprotein B, and fibrinogen in asymptomatic essential hypertensive patients and normotensive subjects. <b>2001</b> , 49, 505-13	6

883	Perspectives on vascular biology and diabetes. <b>2001</b> , 49, 100-3		0
882	Analisi costi-efficacia del trattamento con n-3 PUFA nel post-infarto miocardico: i risultati dello studio GISSI-Prevenzione. <b>2001</b> , 3, 105-114		
881	Involvement of Oxidation-Sensitive Mechanisms in the Cardiovascular Effects of Hypercholesterolemia. <b>2001</b> , 76, 619-631		64
880	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. <b>2001</b> , 19, 1139-47		195
879	Prevention of Cardiovascular Disease in Women: Evidence for the Use of Hormone Replacement Therapy. <b>2001</b> , 7, 8-11		
878	Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. <b>2001</b> , 32, 280-99		341
877	Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. <b>2001</b> , 322, 832		113
876	Gender may affect the action of garlic oil on plasma cholesterol and glucose levels of normal subjects. <b>2001</b> , 131, 1471-8		48
875	Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. <b>2001</b> , 104, 2376-83		211
874	Antithrombotic Secondary Prevention After Stroke. <b>2001</b> , 3, 451-462		3
873	Statin trials in progress: unanswered questions. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 9-13	6	6
872	Diabetes: statins, fibrates, or both?. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 19-28	6	18
871	Statins, hormones, and women: benefits and drawbacks for atherosclerosis and osteoporosis. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 35-42	6	10
870	Herbs and atherosclerosis. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 93-6	6	31
869	Prevention of strokes. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 321-7	6	5
868	Diet and drug therapy: a dynamic duo for reducing coronary heart disease risk. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 507-13	6	5
867	Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 174-9	6	27
866	New developments in atherosclerosis imaging: electron beam tomography. <i>Current Atherosclerosis Reports</i> , <b>2001</b> , 3, 417-24	6	4

865	Potential use of Ca <sup>++</sup> scanning to determine the need for and intensity of lipid-lowering therapy in asymptomatic adults. <b>2001</b> , 3, 408-15	5
864	Actual practice in hypertension: implications for persistence with and effectiveness of therapy. <b>2001</b> , 3, 481-7	8
863	Statins and blood pressure regulation. <b>2001</b> , 3, 281-8	40
862	Choices in medical management for prevention of acute ischemic stroke. <b>2001</b> , 1, 33-8	3
861	Transplant Coronary Vasculopathy. <b>2001</b> , 3, 55-63	4
860	Dyslipidemia. <b>2001</b> , 3, 347-357	1
859	Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low". <b>2001</b> , 2, 8-11	6
858	Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl". <b>2001</b> , 2, 12-15	3
857	A review of clinical trials in dietary interventions to decrease the incidence of coronary artery disease. <b>2001</b> , 2, 123-128	10
856	Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421]. <b>2001</b> , 2, 195-204	26
855	Debate: Should statin be used in patients with heart failure?. <b>2001</b> , 2, 266-267	10
854	Debate: Statins should be used in patients with heart failure. <b>2001</b> , 2, 268-270	9
853	Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. <b>2001</b> , 173, 139-43	36
852	Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. <b>2001</b> , 51, 461-70	55
851	Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. <b>2001</b> , 60, 1990-7	77
850	Idiopathic membranous glomerulonephritis. <b>2001</b> , 59, 1983-94	98
849	Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. <b>2001</b> , 16, 531-7	45
848	Medicare prescription coverage and congressional gridlock. <b>2001</b> , 16, 864-866	17

847	Effects of low-density lipoprotein apheresis on coronary and carotid atherosclerosis and diabetic scleredema in patients with severe hypercholesterolemia. <b>2001</b> , 5, 244-51		11
846	Current topics on low-density lipoprotein apheresis. <b>2001</b> , 5, 293-300		17
845	Factors associated with healthy aging: the cardiovascular health study. <b>2001</b> , 49, 254-62		127
844	Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. <b>2001</b> , 3, 279-86		12
843	Therapeutic considerations for postprandial dyslipidaemia. <b>2001</b> , 3, 143-56		6
842	Vascular risk factors and erectile dysfunction. <b>2001</b> , 87, 838-45		145
841	Coronary heart disease risk assessment in diabetes mellitus--a comparison of PROCAM and Framingham risk assessment functions. <b>2001</b> , 18, 355-9		31
840	Statins can benefit patients with primary membranous nephropathy on venous thromboembolism. <b>2021</b> , 43, 302-306		1
839	Atorvastatin impairs liver mitochondrial function in obese C57BL/6J mice but heart and skeletal muscle are not affected. <b>2021</b> , 11, 2167		2
838	The association of echocardiographic parameters on renal outcomes in chronic kidney disease. <b>2021</b> , 43, 433-444		2
837	The Questions on Everyone's Mind: What is and Why Do We Need Preventive Cardiology?. <b>2021</b> , 17, 8-14		
836	Pravastatin Promotes Endothelial Colony-Forming Cell Function, Angiogenic Signaling and Protein Expression In Vitro. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
835	Recent Updates of Lipoprotein(a) and Cardiovascular Disease. <b>2021</b> , 57, 36-43		3
834	Association between Statin Therapy and Lower Incidence of Hyperglycemia in Patients Hospitalized with Acute Coronary Syndromes. <b>2021</b> , 116, 285-294		0
833	Coronary CT Angiography Guided Medical Therapy in Subclinical Atherosclerosis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
832	Effects of different statins application methods on plaques in patients with coronary atherosclerosis. <b>2021</b> , 9, 812-821		
831	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
830	Achieving Optimal Medical Therapy: Insights From the ORBITA Trial. <b>2021</b> , 10, e017381		4

829	Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. <b>2021</b> , 10, e018869	4
828	Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. <b>2021</b> , 12, 1325	60
827	Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. <b>2021</b> , 372, n48	2
826	Low levels of low-density lipoprotein cholesterol and cognitive decline. <b>2021</b> , 66, 1684-1684	8
825	Emerging views of statin pleiotropy and cholesterol lowering. <b>2021</b> ,	8
824	Inference of a causal relation between low-density lipoprotein cholesterol and hypertension using mendelian randomization analysis. <b>2021</b> , 27, 7	
823	Invasive therapy versus conservative therapy for patients with stable coronary artery disease: An updated meta-analysis. <b>2021</b> , 44, 675-682	7
822	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. <b>2021</b> , 16, 499-517	4
821	PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. <b>2021</b> , 17, 1365-1377	11
820	Physical activity and sedentary behaviour in secondary prevention of coronary artery disease: A review. <b>2021</b> , 5, 100146	4
819	Genetic Risk Stratification: A Paradigm Shift in Prevention of Coronary Artery Disease. <b>2021</b> , 6, 287-304	6
818	Treatment Candidacy for Pharmacologic Therapies for NASH. <b>2021</b> ,	6
817	Which LDL Value Should Clinicians Look at?. <b>2021</b> , 13, 129-133	0
816	A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. <b>2021</b> , 77, 1473-1484	5
815	The safety of JAK-1 inhibitors. <b>2021</b> , 60, ii24-ii30	14
814	Qualitative Exploration of Barriers to Statin Adherence and Lipid Control: A Secondary Analysis of a Randomized Clinical Trial. <b>2021</b> , 4, e219211	2
813	The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. <b>2021</b> , 11,	0
812	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment. <b>2021</b> , 16, e18	6

811	Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. <i>BMJ Open</i> , <b>2021</b> , 11, e043714	3	4
810	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. <b>2021</b> , 41, 2237-2251		2
809	Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist's Perspective. <b>2021</b> , 57,		1
808	A Less than Provocative Approach for the Primary Prevention of CAD. <b>2021</b> , 1		1
807	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
806	Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. <b>2021</b> , 26,		3
805	Low LAL (Lysosomal Acid Lipase) Expression by Smooth Muscle Cells Relative to Macrophages as a Mechanism for Arterial Foam Cell Formation. <b>2021</b> , 41, e354-e368		4
804	Is there more to a healthy-heart diet than cholesterol?. <b>2021</b> , 594, S12-S13		
803	Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
802	Statin therapy for patients with aortic stenosis who underwent transcatheter aortic valve implantation: a report from a Japanese multicentre registry. <i>BMJ Open</i> , <b>2021</b> , 11, e044319	3	1
801	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. <b>2021</b> , 26, 533-549		2
800	Immigrants, Ethnicity, and Adherence to Secondary Cardiac Prevention Therapy: A Substudy of the ISLAND Trial. <b>2021</b> , 3, 913-923		0
799	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. <b>2021</b> , 3, 936-949		0
798	Statins Protect against Thrombosis of Cannulated Radiocephalic Fistulas in Diabetic Patients. <b>2021</b> , 75, 280-286		
797	Cholesterol: the race to the bottom. <b>2021</b> , 42, 4612-4613		1
796	Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia. <b>2021</b> , 78, e631-e640		
795	A New Disease Concept in the Age of Processed Foods-Phosphorus-Burden Disease; including CKD-MBD Concrete Analysis and the Way to Solution. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	1
794	Three Technologies That Will Guide Revascularization of Chronic Coronary Syndrome Patients into the 21st Century: A Review. <b>2021</b> , 30, 212-220		

793	Preventive implantable cardioverter defibrillator therapy in contemporary clinical practice: need for more stringent selection criteria. <b>2021</b> , 8, 3656-3662		1
792	Pharmacoepidemiology Research-Real-World Evidence for Decision Making. <b>2021</b> , 12, 723427		2
791	Cyclosporine A and Tacrolimus Induce Functional Impairment and Inflammatory Reactions in Endothelial Progenitor Cells. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
790	Seaweeds and Their Natural Products for Preventing Cardiovascular Associated Dysfunction. <b>2021</b> , 19,		1
789	Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. <b>2021</b> , 37, 102439		1
788	CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. <b>2021</b> , 28, 1083-1094		3
787	Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. <b>2021</b> , 14, 20406223211014028		1
786	Do statins reduce the mortality rate in stroke patients treated with systemic thrombolysis in a 5-year. <b>2021</b> , 16, 1807-1812		2
785	Studies for labeling versus reimbursement. <b>2021</b> , 21-32		
784	Lipoproteins in chronic kidney disease: from bench to bedside. <b>2021</b> , 42, 2170-2185		7
783	A Checklist Approach for Enhanced Outpatient Guideline-Directed Management in the Secondary Prevention of Atherosclerotic Cardiovascular Disease. <b>2021</b> , 17, 79-86		0
782	Treatment With Cardiovascular Medications: Prognosis in Patients With Myocardial Injury. <b>2021</b> , 10, e017239		5
781	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. <b>2021</b> , 11,		8
780	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. <b>2018</b> , 11, CD012345		23
779	Application of Isogeometric Analysis to Simulate Local Nanoparticulate Drug Delivery in Patient-Specific Coronary Arteries. 149-167		1
778	Lipids, Atherogenic Dyslipidemia, and Therapy. 347-408		1
777	Cardiovascular Risk Factors. 657-683		1
776	Statins in Critical Illness. <b>2005</b> , 477-487		1



775	Protection of endothelial function. <b>2005</b> , 619-44	11
774	Modulation of macrophage function and metabolism. <b>2005</b> , 665-95	5
773	Dyslipidemias. <b>2003</b> , 1019-1029	1
772	Coronary Artery Disease. <b>2012</b> , 179-216	2
771	Lipid Metabolism in Pregnancy. <b>1998</b> , 221-258	9
770	Active Vaccine and Drug Surveillance. <b>2013</b> , 251-279	1
769	Soyfoods: Their Role in Disease Prevention and Treatment. <b>1997</b> , 442-477	18
768	Pathogenesis of Atherosclerosis. <b>1999</b> , 3-18	1
767	Managing menopausal problems. <b>2000</b> , 103, 1-23	0
766	Menopausal Hormone Therapy. <b>2004</b> , 321-348	0
765	Coronary Atherosclerosis. <b>1998</b> , 133-140	1
764	Critical Pathways for Acute Coronary Syndromes. <b>1999</b> , 611-627	4
763	Obesity and Chronic Disease. <b>2005</b> , 383-401	3
762	Lipid Metabolism and Coronary Artery Disease. <b>2006</b> , 130-137	4
761	Cardiovascular Disease in Women. <b>2007</b> , 349-368	2
760	Dietary Fat Intake: Promotion of Disease in Carotid Artery Disease: Lipid Lowering Versus Side Effects of Statins. <b>2010</b> , 151-184	1
759	Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids. <b>2010</b> , 660, 153-66	41
758	History and development of HMG-CoA reductase inhibitors. <b>2002</b> , 1-17	1

757	Kardiologie. <b>2008</b> , 343-387	2
756	High-density lipoprotein: structural and functional changes under uremic conditions and the therapeutic consequences. <b>2015</b> , 224, 423-53	5
755	Statins. <b>2015</b> , 123-147	1
754	Issues in Data Analysis. <b>2015</b> , 403-462	2
753	Arzneiverordnungen für ältere Patienten. <b>2008</b> , 923-960	1
752	Statins and demyelination. <b>2008</b> , 318, 313-24	14
751	Lipidsenkende Mittel. <b>2010</b> , 665-680	0
750	Gesundheitspolitische Aspekte und Ausblick. <b>2002</b> , 435-455	1
749	Arzneiverordnungen 2003 im Überblick. <b>2004</b> , 3-36	0
748	Lipidsenkende Mittel. <b>2011</b> , 683-698	1
747	Systemic Hypertension. <b>2002</b> , 1015-1064	2
746	Anatomie und Pathologie der Koronararterien. <b>2000</b> , 209-553	2
745	MED-PED: An Integrated Genetic Strategy for Preventing Early Deaths. <b>1996</b> , 35-45	18
744	Vaskuläre Erkrankungen. <b>1999</b> , 954-1093	1
743	Qualität der Arzneimittelversorgung. <b>2003</b> , 832-852	1
742	Akuter Myokardinfarkt. <b>2000</b> , 393-442	1
741	NHG-Standaard Cardiovasculair risicomanagement. <b>2011</b> , 361-408	1
740	Mortality Affected by Health Care and Public Health Policy Interventions. <b>2011</b> , 583-607	5

739	Atherogenic Dyslipidemia and the Metabolic Syndrome: Pathogenesis and Challenge of Therapy. <b>1996</b> , 237-247	3	
738	Noncholesterol Serum Sterols in Scandinavian Simvastatin Survival Study. <b>1996</b> , 473-476	5	
737	Prophylactic Implantation of Implantable Cardioverter/Defibrillators in Post-Myocardial Infarction Patients. <b>1998</b> , 305-310	2	
736	Introduction to Invasive Assessment of the Coronary Circulation. <b>2000</b> , 25-49	1	
735	Homocysteine as a Risk Factor for Coronary Artery Disease. <b>2000</b> , 173-202	2	
734	An Overview of the Homocysteine Lowering Clinical Trials. <b>2000</b> , 413-429	9	
733	Vascular Biology and Atherosclerosis of Cerebral Arteries. <b>2004</b> , 763-774	1	
732	Impact of Nontraditional Antiarrhythmic Drugs on Sudden Cardiac Death. <b>2004</b> , 950-958	2	
731	Carotid Occlusive Disease. <b>2011</b> , 3615-3620	1	
730	Epidemiology of Stroke. <b>2011</b> , 198-218	1	
729	Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk. <b>2010</b> , 81-86.e2	1	
728	Cardiac Rehabilitation. <b>2011</b> , 713-740	1	
727	High-Density Lipoprotein Metabolism. <b>2009</b> , 45-55	2	
726	Special Patient Populations: Diabetes and Metabolic Syndrome. <b>2009</b> , 443-462	1	
725	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. <b>2019</b> , 31, 271-277	6	
724	Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. <b>2020</b> , 32, 175-182	3	
723	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. <b>2020</b> , 164, 108197	2	
722	A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. <i>Journal of Cardiology</i> , <b>2017</b> , 70, 537-544	3	71

721	Aspects médico-économiques de la polyarthrite rhumatoïde. <b>2012</b> , 196, 1295-1306	2
720	Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. <b>2000</b> , 41, 1136-1144	49
719	Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. <b>1998</b> , 39, 1430-1437	39
718	Effects of legume consumption on serum cholesterol, biliary lipids, and sterol metabolism in humans. <b>1997</b> , 38, 1120-1128	66
717	Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. <b>1997</b> , 38, 1496-1500	59
716	Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. <b>1997</b> , 38, 373-390	121
715	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells.. <b>1996</b> , 37, 148-158	71
714	Determination of triglycerides in lipoproteins separated by agarose gel electrophoresis.. <b>1995</b> , 36, 1839-1847	12
713	Perioperative cardiovascular evaluation: heads or tails?. <b>2012</b> , 58, 505-512	1
712	Una historia resumida. Impacto de los avances en cardiopatía isquémica. <b>2017</b> , 17, 2-6	1
711	Avant-propos Ars longa iudicium difficile . L'exemple des recommandations dans les dyslipidémies du diabétique. <b>2018</b> , 12, 248-254	1
710	PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. <b>2018</b> , 47, 165-176	5
709	Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. <b>2000</b> , 224, 8-19	108
708	Begründung für die neuen LDL-Cholesterin-Zielwerte. <b>2020</b> , 9, 351-356	1
707	The new European guidelines for prevention of cardiovascular disease are misleading. <b>2020</b> , 13, 1289-1294	4
706	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. <b>2017</b> , 19, D3-D54	11
705	Traditional coronary risk factors in African Americans. <b>1999</b> , 317, 189-92	22
704	Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. <b>2000</b> , 14, 2790-2	37

703	Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. <b>1996</b> , 27, 563-70	48
702	Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. <b>1999</b> , 33, 473-8	42
701	Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. <b>2000</b> , 35, 256-62	42
700	Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. <b>2000</b> , 35, 361-5	23
699	Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. <b>2000</b> , 35, 549-55	122
698	Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. <b>1996</b> , 62, 1559-64	66
697	Hyperlipidemia in solid organ transplantation. <b>1997</b> , 63, 331-8	245
696	Cholesterol as an independent predictor of outcome after renal transplantation. <b>2000</b> , 69, 1704-10	67
695	Endothelial dysfunction and coronary risk reduction. <b>1998</b> , 18, 60-7	10
694	Comprehensive cardiac rehabilitation improves the control of dyslipidemia in secondary prevention. <b>1998</b> , 18, 408-15	18
693	Recent advances in stroke therapy. <b>1998</b> , 11, 57-64	8
692	Lipoprotein classes and coronary disease regression. <i>Current Opinion in Lipidology</i> , <b>1998</b> , 9, 329-36	4.4 12
691	Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. <b>2005</b> , 12, 530-534	10
690	Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. <b>2003</b> , 96, 318-20	14
689	Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications. <b>2003</b> , 96, 266-75	5
688	Medical prevention of stroke, 2003. <b>2003</b> , 96, 354-8	10
687	Statin therapy in rheumatoid arthritis. <b>2005</b> , 98, 534-40; quiz 541, 572	8
686	Simvastatin restores ischemic preconditioning in the presence of hyperglycemia through a nitric oxide-mediated mechanism. <b>2008</b> , 108, 634-42	26

685	The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. <b>2020</b> , 9, 143-152	1
684	Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering Capacity. <b>2000</b> , 224, 8-19	9
683	Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use. <b>2009</b> , 2009,	2
682	Having too much evidence (depression, suicide, and low serum cholesterol). <b>1996</b> , 313, 651-2	12
681	Secondary prevention clinics for coronary heart disease: randomised trial of effect on health. <b>1998</b> , 316, 1434-7	116
680	Cholesterol: how low is low enough?. <b>1998</b> , 317, 425-6	9
679	Simvastatin seems unlikely to cause impotence. <b>1999</b> , 318, 192	25
678	Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. <b>2000</b> , 320, 680-5	41
677	Statins as the new aspirin. Conclusions from the heart protection study were premature. <b>2002</b> , 324, 789	4
676	Might money spent on statins be better spent?. <b>2003</b> , 327, 933	4
675	Low atherosclerotic response of a strain of rabbits to diet-induced hypercholesterolemia. <b>1995</b> , 15, 1181-8	8
674	Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. <b>1996</b> , 16, 236-49	17
673	Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. <b>1997</b> , 17, 107-13	264
672	No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. <b>1997</b> , 17, 273-8	17
671	Impact of a combination of a calcium antagonist and a beta-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. <b>1997</b> , 17, 979-88	18
670	Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. <b>1997</b> , 17, 1011-7	99
669	Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). <b>1995</b> , 91, 2528-40	554
668	Molecular bases of the acute coronary syndromes. <b>1995</b> , 91, 2844-50	1289

667	Thrombolysis for acute myocardial infarction. Why is there no extra benefit after hospital discharge?. <b>1995</b> , 91, 2862-4	19
666	Cholesterol reduction yields clinical benefit. A new look at old data. <b>1995</b> , 91, 2274-82	132
665	Angiographic and clinical progression in unstable angina. From clinical observations to clinical trials. <b>1995</b> , 91, 2295-8	16
664	Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. <b>1995</b> , 92, 646-56	45
663	Coronary plaque disruption. <b>1995</b> , 92, 657-71	2317
662	Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. <b>1995</b> , 92, 2333-42	751
661	Late outcome after coronary artery bypass graft surgery in patients <b>1995</b> , 92, 1114-9	16
660	Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CAIT) substudy. <b>1995</b> , 92, 2404-10	38
659	Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. <b>1995</b> , 92, 2419-25	186
658	Compliance enhancement. A call for multidisciplinary team approaches. <b>1996</b> , 93, 4-6	32
657	Cost of prevention. The case of lipid lowering. <b>1996</b> , 93, 1774-6	34
656	Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. <b>1996</b> , 93, 1796-802	114
655	LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. <b>1996</b> , 93, 1826-35	200
654	Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. <b>1996</b> , 93, 1928-37	111
653	Risk-reduction therapy: the challenge to change. Presented at the 68th scientific sessions of the American Heart Association November 13, 1995 Anaheim, California. <b>1996</b> , 93, 2205-11	51
652	Cholesterol screening in asymptomatic adults. No cause to change. Task Force on Risk Reduction, American Heart Association. <b>1996</b> , 93, 1067-8	7
651	Levels of soluble cell adhesion molecules in patients with dyslipidemia. <b>1996</b> , 93, 1334-8	206
650	Cardiovascular disease epidemiology: a journey from the past into the future. <b>1996</b> , 93, 1755-64	51

649	Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. <b>1996</b> , 94, 26-34	45
648	Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). <b>1996</b> , 94, 2381-8	104
647	Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon. <b>1996</b> , 94, 2982-5	39
646	Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. <b>1996</b> , 94, 3026-49	617
645	Decline of coronary heart disease mortality in Finland during 1983 to 1992: roles of incidence, recurrence, and case-fatality. The FINMONICA MI Register Study. <b>1996</b> , 94, 3130-7	61
644	Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. <b>1996</b> , 94, 1175-92	727
643	Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. <b>1996</b> , 94, 1503-5	107
642	Estrogen therapy, atherosclerosis, and clinical cardiovascular events. <b>1996</b> , 94, 1809-11	8
641	Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. <b>1996</b> , 94, 2013-20	601
640	Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. <b>1997</b> , 95, 1-4	217
639	Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. <b>1997</b> , 95, 5-7	49
638	Clinical reality of lowering total and LDL cholesterol. <b>1997</b> , 95, 306-7	5
637	Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. <b>1997</b> , 95, 324-8	128
636	Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. <b>1997</b> , 95, 1062-71	534
635	The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. <b>1997</b> , 95, 1085-90	301
634	Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. <b>1997</b> , 95, 1126-31	674
633	Remarks about postinfarction prognosis in light of the experience with the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI) trials. <b>1997</b> , 95, 1341-5	21
632	Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. <b>1997</b> , 95, 1542-8	66



631	Cholesterol screening guidelines consensus, evidence, and the departure from common sense. <b>1997</b> , 95, 1651-3	6
630	When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. <b>1997</b> , 95, 1683-5	79
629	Silent myocardial ischemia: some good news. <b>1997</b> , 95, 1992-3	2
628	Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. <b>1997</b> , 95, 2037-43	289
627	Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. <b>1997</b> , 96, 37-43	160
626	Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. <b>1997</b> , 96, 4204-10	332
625	Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). <b>1997</b> , 96, 4211-8	339
624	Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. <b>1997</b> , 96, 4226-31	160
623	Cholesterol management in theory and practice. <b>1997</b> , 96, 4424-30	48
622	Lipid lowering versus revascularization: an idea whose time (for testing) has come. <b>1997</b> , 96, 1360-2	32
621	Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. <b>1997</b> , 96, 1398-402	329
620	The Mûster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. <b>1997</b> , 96, 2128-36	73
619	Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. <b>1997</b> , 96, 2137-43	280
618	Coronary risk estimation and treatment of hypercholesterolemia. <b>1997</b> , 96, 2449-52	30
617	Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. <b>1997</b> , 96, 2534-41	233
616	Heart rate adjustment of exercise-induced ST-segment depression identifies men who benefit from a risk factor reduction program. <b>1997</b> , 96, 2899-904	17
615	Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. <b>1996</b> , 28, 647-51	20
614	The intima. Soil for atherosclerosis and restenosis. <b>1995</b> , 77, 445-65	638

613	Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. <b>1996</b> , 27, 2166-72	43
612	Effect of short-term regression of atherosclerosis on reactivity of carotid and retinal arteries. <b>1996</b> , 27, 927-33	14
611	High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. <b>1997</b> , 28, 83-7	86
610	Vascular effects of statins in stroke. <b>1997</b> , 28, 2315-20	85
609	Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. <b>1997</b> , 28, 946-50	193
608	Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project. An ecological study of 18 populations. <b>1997</b> , 28, 1367-74	82
607	American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. <b>1997</b> , 28, 1507-17	377
606	Risk Reduction. <b>2000</b> , 102,	3
605	Eligibility for Lipid-Lowering Drug Therapy in Primary Prevention. <b>2002</b> , 105, 136-139	3
604	Smooth muscle glucose metabolism promotes monocyte recruitment and atherosclerosis in a mouse model of metabolic syndrome. <b>2018</b> , 3,	9
603	Isoprenoids as mediators of the biological effects of statins. <b>2002</b> , 110, 285-288	307
602	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. <b>2001</b> , 108, 1429-37	337
601	Isoprenoids as mediators of the biological effects of statins. <b>2002</b> , 110, 285-8	138
600	Effect of statins on insulin requirements during non-cardiac surgery. <b>2014</b> , 42, 350-5	0
599	2016 Chinese guidelines for the management of dyslipidemia in adults. <b>2018</b> , 15, 1-29	142
598	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. <b>2019</b> , 16, 182-241	205
597	Vitamin D and Cardiovascular Disease. <b>2012</b> , 363-384	2
596	Does Estrogen Have a Role in the Prevention of Cardiovascular Disease?. <b>1999</b> , 84, 1806-1812	1

595	Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. <b>2017</b> , 6, 134	37
594	The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. <b>2008</b> , 3, e2584	43
593	The relationships of markers of cholesterol homeostasis with carotid intima-media thickness. <b>2010</b> , 5, e13467	32
592	Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. <b>2011</b> , 6, e25320	19
591	Changes in clinical profile, treatment, and mortality in patients hospitalised for acute myocardial infarction between 1985 and 2008. <b>2011</b> , 6, e26917	32
590	LDL-induced impairment of human vascular smooth muscle cells repair function is reversed by HMG-CoA reductase inhibition. <b>2012</b> , 7, e38935	9
589	Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. <b>2013</b> , 8, e52828	40
588	Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). <b>2013</b> , 8, e54242	77
587	Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study. <b>2013</b> , 8, e67611	41
586	The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials. <b>2013</b> , 8, e82775	28
585	Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. <b>2014</b> , 9, e92388	25
584	Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis. <b>2014</b> , 9, e104922	24
583	If It's Not One Thing, It's Another: An Inverse Relationship of Malignancy and Atherosclerotic Disease. <b>2015</b> , 10, e0126855	5
582	Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative-Effectiveness Modeling Study. <b>2015</b> , 10, e0138092	24
581	Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. <b>2016</b> , 11, e0150785	16
580	High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. <b>2016</b> , 11, e0151587	39
579	Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. <b>2016</b> , 11, e0163644	60
578	Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. <b>2017</b> , 9, 638-649	12

577	Statins: Then and Now. <b>2019</b> , 15, 23-31	30
576	Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study. <b>2002</b> , 43, 319-31	8
575	The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. <b>2004</b> , 45, 977-87	11
574	Acceptability and Long-Term Compliance with Drug Treatment for Hypercholesterolemia in Japanese Male Workers: I. Acceptability of Drug Treatment. <b>2002</b> , 44, 166-175	2
573	[High doses statins administration causing rhabdomyolysis: case report]. <b>2005</b> , 49, 604-9	2
572	[Situation of lawsuits concerning the access to medical products by the Health Department of Santa Catarina State, Brazil, during the years 2003 and 2004]. <b>2010</b> , 15 Suppl 3, 3551-60	18
571	Management of Hypertension and Dyslipidemia for Primary Prevention of Cardiovascular Disease. <b>2017</b> , 389-404	6
570	Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. <b>2017</b> , 8, 75411-75417	9
569	Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19. <b>2020</b> ,	12
568	Management of hyperlipidemia with statins in the older patient. <b>2006</b> , 1, 433-8	5
567	A new paradigm of cardiovascular risk factor modification. <b>2005</b> , 1, 101-9	3
566	Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia. <b>2005</b> , 1, 155-61	6
565	Optimal lipid modification: the rationale for combination therapy. <b>2005</b> , 1, 317-31	18
564	Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study. <b>2005</b> , 1, 351-6	9
563	Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. <b>2006</b> , 2, 157-62	45
562	Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. <b>2006</b> , 2, 441-6	2
561	High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. <b>2008</b> , 4, 39-57	38
560	Perioperative use of statins in noncardiac surgery. <b>2008</b> , 4, 75-81	8

559	Cardiovascular risk reduction in African Americans: Current concepts and controversies. <b>2016</b> , 2016, e201602	4
558	Role of Lipid-Lowering Pharmacotherapy in Children. <b>2000</b> , 2, 11-22	5
557	Statins in Stroke. <b>2019</b> , 26, 6174-6185	9
556	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. <b>2019</b> , 20, 72-82	7
555	The many roles of statins in ischemic stroke. <b>2014</b> , 12, 564-74	32
554	The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. <b>2017</b> , 13, 209-216	73
553	Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: a Systematic Review. <b>2020</b> ,	10
552	Statin treatment, carotid atherosclerotic plaque macrophage infiltration and circulating inflammatory markers. <b>2008</b> , 2, 110-4	10
551	The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms. <b>2009</b> , 3, 48-50	5
550	Trends in the Use of Evidence-based Therapies Early in the Course of Acute Myocardial Infarction and its Influence on Short Term Patient Outcomes. <b>2011</b> , 5, 171-8	5
549	Telemedicine in Primary Care for Patients With Chronic Conditions: The ValCrŕic Quasi-Experimental Study. <b>2017</b> , 19, e400	30
548	Trends in cardiovascular risk factors among patients with coronary heart disease: results from the EUROASPIRE I, II, and III surveys in the Mŕster region. <b>2012</b> , 109, 303-10	14
547	The Treatment of Disorders of Lipid Metabolism. <b>2016</b> , 113, 261-8	40
546	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. <b>2015</b> , 19, 1-401, vii-viii	23
545	Association of carotid intraplaque hemorrhage and territorial acute infarction in patients with acute neurological symptoms using carotid magnetization-prepared rapid acquisition with gradient-echo. <b>2015</b> , 57, 94-9	8
544	Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 10,	5.1 3
543	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5 mg and Atorvastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). <b>2009</b> , 2, 159-73	4
542	First-line eradication of <i>Helicobacter pylori</i> : are the standard triple therapies obsolete? A different perspective. <b>2010</b> , 16, 3865-70	19

541	From blood to gut: direct secretion of cholesterol via transintestinal cholesterol efflux. <b>2010</b> , 16, 5953-7	28
540	Pleiotropic effects of statins in the diseases of the liver. <b>2016</b> , 22, 6201-13	33
539	Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. <b>2009</b> , 24, 330-6	1
538	Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. <b>2014</b> , 29, 754-63	9
537	Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage. <b>2012</b> , 4, 385-92	6
536	Nitric oxide and cardiovascular risk factors. <b>2007</b> , 3, 18	7
535	Martin's Equation as the Most Suitable Method for Estimation of Low-Density Lipoprotein Cholesterol Levels in Korean Adults. <b>2017</b> , 38, 263-269	15
534	Statins: past and present. <b>2011</b> , 12, 121-7	33
533	Correlation of Friedewald's calculated low-density lipoprotein cholesterol levels with direct low-density lipoprotein cholesterol levels in a tertiary care hospital. <b>2017</b> , 7, 57-62	8
532	Statins: Cholesterol guidelines and Indian perspective. <b>2015</b> , 19, 546-53	8
531	Pleiotropic effects of statins. <b>2015</b> , 19, 554-62	88
530	Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. <b>2014</b> , 3, 168	7
529	Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis. <b>2015</b> , 4, 167	10
528	An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT Group. <b>2011</b> , 6, 942-8	6
527	Evaluation of a pharmacist-managed diabetes medication therapy adherence clinic. <b>2010</b> , 8, 250-4	23
526	Endothelial progenitor cells: Exploring the pleiotropic effects of statins. <b>2017</b> , 9, 1-13	24
525	Prevention of coronary artery disease - time for action!. <b>1995</b> , 15, 309-10	4
524	Oxidative stress, NADPH oxidases, and arteries. <b>2016</b> , 36, 77-88	15

523	Economic Impact Associated with Pharmaceutical Interventions in Cardiovascular Disease. <b>2017</b> , 43, 680-690	2
522	Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. <b>2020</b> , 9,	3
521	Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. <b>2016</b> , 5, 212299	2
520	Psychological Stress as a Risk Factor for Cardiovascular Disease: A Case-Control Study. <i>Cureus</i> , <b>2020</b> , 12, e10757	1.2 2
519	The B-SMART Appropriate Medication-Use Process: A Guide for Clinicians to Help Patients- Part 1: Barriers, Solutions, and Motivation. <b>2009</b> , 13, 62-9	9
518	Collaborative cardiac care service: a multidisciplinary approach to caring for patients with coronary artery disease. <b>2008</b> , 12, 4-11	16
517	Association of eNOS (G894T, rs1799983) and KCNJ11 (E23K, rs5219) gene polymorphism with coronary artery disease in North Indian population.. <b>2021</b> , 21, 1163-1171	0
516	Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change: A Randomized Clinical Trial. <b>2021</b> , 4, e2121908	0
515	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. <b>2021</b> , 12, 713007	1
514	Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> ,	4.5 1
513	Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis. <b>2021</b> ,	
512	Anatomie und Pathologie des Koronargefäßsystems, Physiologie und Pathophysiologie der Koronardurchleitung, Pathogenese der Atherosklerose. <b>2000</b> , 295-326	
511	Klinik und Diagnostik der koronaren Herzkrankheit. <b>2000</b> , 327-353	
510	Insulin resistance: A pathogenic link between cardiovascular risk factors and atherosclerosis. <b>2000</b> , 171-178	
509	Koronare Herzkrankheit. <b>2000</b> , 503-510	
508	Role Of Lipid Concentrations and Apolipoproteins In Altering ApoB Metabolism and Promoting Coronary Events. <b>2000</b> , 12-18	
507	Lipidsenker und Reokklusionsprophylaxe. <b>2000</b> , 69-88	
506	Arterielle Hypertonie. <b>2000</b> , 259-268	

- 505 The BEST + ICD Trial: Is ICD Also Effective in the Presence of Optimized  $\beta$ -Blocking Therapy?. **2000**, 386-397
- 504 Sekundäre Fettstoffwechselstörungen: Welche Bedeutung | welche Therapie?. **2000**, 333-337
- 503 Coronary Heart Disease, Lipid Metabolism, and Steroid Hormones in Women. **2000**, 839-854
- 502 Gender Differences in Coronary Risk Factors and Risk Interventions. **2000**, 213-236
- 501 Does the Gene Encoding Apolipoprotein A-IMilano Protect the Heart?. **2000**, 67-81
- 500 Prevention of Heart Disease. **2000**, 176-191
- 499 Stoffwechsel und endokrine Erkrankungen. **2000**, 255-310
- 498 Lipid-Lowering Drugs. **2000**, 155-177
- 497 Weitere kardiovaskuläre Risikofaktoren. **2000**, 269-291
- 496 Therapie der stabilen und instabilen Angina pectoris. **2000**, 355-391
- 495 Durchblutungsfördernde Mittel. **2000**, 306-316
- 494 Lipidsenkende Mittel. **2000**, 382-391
- 493 Atherosclerosis Research after the Second World War. **2000**, 323-342
- 492 Circadian Variation in Myocardial Ischemia and Infarction. **2000**, 247-261
- 491 Ernährungsverhalten im mittleren und höheren Lebensalter. **2000**, 273-288
- 490 Lipid-Lowering Drugs. **2000**, 215-238
- 489 Ökonomische Aspekte in der Kardiologie. **2000**, 1389-1396
- 488 Überblick über die Arzneiverordnungen im Jahre 1998. **2000**, 1-22



487 Grundprinzipien medikamentöser Therapie und allgemeiner Lebensweise. **2000**, 331-338

486 Therapie von Fettstoffwechselstörungen, Harnsäuremetabolismus bzw. Gicht. **2000**, 504-522

485 Fettstoffwechsel, Übergewicht und Ernährung, Diabetes. **2000**, 239-257

484 Pharmacologic Treatment of Dyslipidemia. **2000**, 100, 55-60

483 A case for lipid-lowering?. **2000**, 17 Suppl 2, 4-5

482 The Aging Heart. **2001**, 401-410

481 Lipoproteins and Atherosclerosis. **2001**, 51-58

480 From the Heartland: Culture, Psychological Factors, and Coronary Heart Disease. **2001**, 141-162

479 Dietary Fat, Blood Lipids, and Coronary Heart Disease Risk. **2001**, 121-134

478 Epidemiologie zerebrovaskulärer Erkrankungen. **2001**, 123-149

477 Plötzlicher Tod: ACE-Hemmer und  $\beta$ -Blocker. **2001**, 60-66

476 How To Make A Mountain and A Mint Out of, At Most, A Molehill: Statin Drugs. **2001**, 95-116

475 Sekundärprävention zerebraler Durchblutungsstörungen. **2001**, 463-476

474 Überblick über die Arzneiverordnungen im Jahr 2000. **2001**, 1-22

1

473 Lipidsenkende Mittel. **2001**, 483-493

472 Genetic Influences on Blood Lipids and Cardiovascular Disease Risk. **2001**, 157-182

471 Praxis der Lipid senkenden Therapie in der kardiologischen Rehabilitation. **2001**, 125-131

470 New Approaches to Atherosclerosis Based on Endothelial Function. **2001**, 1-14

- 469 Q-Wave Myocardial Infarction. **2001**, 177-193
- 468 Risk Factors for Atherosclerosis in the Elderly. **2001**, 448-459
- 467 Obesity and Chronic Disease. **2001**, 205-221 3
- 466 Lipidstoffwechsel und Diabetes. **2001**, 271-286
- 465 Zerebrale Durchblutungsstörungen und Herzerkrankungen: Sitzen Neurologen und Kardiologen im gleichen Boot? **2001**, 75-79
- 464 Ursachen der koronaren Herzkrankheit [die Rolle von Hyperlipidämie, Bluthochdruck und Rauchen. **2001**, 86-98
- 463 Risk Factors for and Prevention of Atherosclerotic Cardiovascular Disease. **2001**, 97-106
- 462 Coronary artery disease: part 2. Treatment. **2001**, 174, 330-5 1
- 461 Clinical Assessment of Endothelial Function. **2002**, 691-700
- 460 Renal Vascular Diseases. **2002**, 1751-1786
- 459 Coronary Atherosclerosis: Chronic Coronary Syndromes. **2002**, 779-820
- 458 Hormone Replacement Therapy and Cardiovascular Disease in Women. **2002**, 1832-1836
- 457 Coronary Artery Disease and Endothelial Function. **2002**, 887-912
- 456 Koronarpharmaka. **2002**, 343-360
- 455 Indications and contra-indications for statin treatment (primary and secondary prevention of hypercholesterolemia). **2002**, 99-120
- 454 Clinical experience: studies with HMG-CoA reductase inhibitors. **2002**, 121-133
- 453 Women and CHD: The Case for Prevention. **2002**, 377-385
- 452 Reducing Cardiovascular Risk in Postmenopausal Women: Estrogen or Statins?. **2002**, 123-130

451 Primär- und Sekundärprävention der KHK. **2002**, 151-182

450 Statins.

449 Vascular Disease in Diabetes Mellitus. **2002**, 995-1008

448 PPAR $\alpha$ -Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis. **2002**, 63-79

447 Hyperlipidemia Pharmacy Practice. **2002**, 461-468

446 References. **2002**, 106, 3373-3421

1

445 Leukocyte-Endothelial Interactions Following Myocardial Ischemia. **2003**, 427-438

444 Hyperlipoproteinämien. **2003**, 397-402

443 Inflammation and Cardiovascular Disease. **2003**, 3-18

442 Cardiovascular Risk Factors and Peripheral Arterial Disease. **2003**, 113-120

441 The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. **2003**, 45-50

1

440 Koronarinsuffizienz und Herzinfarkt. **2003**, 3-29

439 Lipidsenkende Mittel. **2003**, 517-529

438 Primary and Secondary Prevention of Coronary Heart Disease. **2003**, 145-174

437 Therapie von Fettstoffwechselstörungen, Harnsäureidiathese bzw. Gicht. **2003**, 533-552

436 Lipid-Lowering Drugs. **2003**, 165-191

435 Fettstoffwechselstörungen. **2003**, 854-866

434 Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets. **2003**, 107-118

- 433 Acute Coronary Syndromes. **2003**, 391-411 1
- 432 Prevention of Stroke. **2003**, 349-362
- 431 Management of Acute Coronary Syndromes. **2003**, 15-36
- 430 Gender Differences in Coronary Risk Factors and Risk Interventions. **2003**, 235-258
- 429 Prevention of Heart Failure in Clinical Reality?. **2003**, 549-561
- 428 Clinical Features and Treatment of Coronary Heart Disease in Diabetes.
- 427 Treatment of diabetic nephropathy. **2003**, 135-141 1
- 426 Management of Unstable Angina and Non-ST Elevation Myocardial Infarction. **2003**, 109-125
- 425 Epidemiology of Atherosclerosis and Its Modification. **2003**,
- 424 Traditional chinese interventions for stable angina.
- 423 The discovery and development of the statins. **2003**, 31-43
- 422 Treatment Strategies for Women With Stable Angina. **2004**, 197-214
- 421 Cardiovascular Disease, Genes, and Nutrition: Gender Matters. **2004**, 737-751
- 420 Primary Prevention of Sudden Death in Post-Infarction Patients: When ICD Implantation is Really Cost-effective. **2004**, 497-504
- 419 Verordnungsprofil der Internisten. **2004**, 1013-1041
- 418 Risk Detection and Primary Prevention in Women. **2004**, 29-45
- 417 Immunosuppression in Pancreas Transplantation. **2004**, 267-347
- 416 Lipidsenkende Mittel. **2004**, 570-583

415 Prävention der koronaren Herzerkrankung. **2004**, 1119-1147

414 Expanding ICD Indications: Can We Afford It?. **2004**, 511-517

413 Molekulare Veränderungen beim ischämischen Schlaganfall. **2004**, 228-255

412 Kardiologie. **2004**, 313-356

411 Lipidsenkende Mittel. **2004**, 641-658

410 Hypolipidemic Agents and Their Role in the Therapy of Diabetes Mellitus.

409 The poorly controlled type 2 diabetic patient. **2004**, 197-231

1

408 Tutorials in Therapeutics Should Cholesterol Level be lowered below "Normal"? Insights from the Heart Protection Study. **2004**, 2004,

407 Bedside Platelet Monitoring. **2004**, 495-520

406 Treatment of Vulnerable Plaques. **2004**, 164-202

405 Clinical Evaluative Research: Which Patients Benefit, How and When? A Contribution to a European Discussion. **2005**, 105-115

404 Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. **2005**, 543-556

403 Nitrates for stable angina.

402 Advances in the Acute Treatment and Secondary Prevention of Stroke. **2005**, 21-33

401 Ischemic Heart Disease. **2005**, 567-578

400 Statin prescribing in primary care. **2005**, 2005,

399 Management of Hypertension in Carotid Stenosis. **2005**, 151-158

398 Stroke Prevention, Blood Cholesterol and Statins. **2005**, 123-150

397 Diet in the Management of Patients with Carotid Stenosis. **2005**, 175-180

396 Myocardial Infarction. **2005**, 367-383

395 Pharmacological Treatments of Lipid Abnormalities. **2005**, 183-212

394 Pharmacogenetics: Focus on the Liver. **2006**, 53-66

393 Is er nog plaats voor fibrinaten allh, of moet altijd een statine eerst worden gebruikt en bij slecht resultaat een fibraat toegevoegd?. **2006**, 2137-2137

392 Medical Treatment of Peripheral Arterial Disease. **2006**, 271-292

391 Epidemiology of Cerebrovascular Disease \* \*This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195.. **2006**, 411-432

390 Is het gerechtigd om bij diabetes mellitus II statines voor te schrijven onafhankelijk van de cholesterolwaarden?. **2006**, 2153-2154

389 Preventive Heart Disease: Dyslipidemia and Hypertension (Systemic). **2006**, 373-385

388 Antianginal drugs. **2006**, 260-263

387 Pharmacological interventions in reperfusion therapy for acute myocardial infarction. **2006**, 111-128

386 Statins and Toxicity. **2006**, 273-295

385 Secondary prevention of coronary heart disease in primary health care. **2006**, 6, 37-41

1

384 Pharmacogenetics and Metabolic Disease. **2006**, 243-272

383 The case for a generic statin. **2006**, 2006,

382 Sudden cardiac death: the size of the problem. **2006**, 25-36

381 Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. **2007**, 141-156

380 Frequently cited criticisms. **2007**, 205-213

- 379 Pharmacological Therapy for Cardiovascular Disease. **2007**, 121-148
- 378 Chronic Stable Angina. **2007**, 290-313
- 377 Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk. **2007**, 113-120
- 376 Management of Cholesterol Disorders. **2007**, 2667-2691
- 375 Management of Lipids in the Elderly. **2007**, 369-387
- 374 Management of Diabetic Dyslipidaemia. **2007**, 173-186
- 373 Familial Hypercholesterolemia and Lipid Apheresis. **2007**, 267-289 1
- 372 Statins, Oxidative Stress, and Polycystic Ovary Syndrome. **2007**, 263-278
- 371 Lipid-lowering agents. **2007**, 155-170
- 370 Common hyperlipidaemia. **2007**, 125-168
- 369 Genetic factors that contribute to interindividual variations in plasma low density lipoprotein-cholesterol levels. **1996**, 197, 194-206; discussion 206-10 0
- 368 Dyslipidemia and Diabetes. **2007**, 405-416
- 367 Preventie en behandeling van aandoeningen als gevolg van atherosclerose. **2008**, 57-69
- 366 Management of Associated Cardiovascular Risk in Essential Hypertension. **2008**, 635-643
- 365 Lipidsenkende Mittel. **2008**, 645-659
- 364 Overview of Evidence Supporting the Treatment of Hyperlipidemia. **2008**, 1-13
- 363 Traitement des dyslipidémies. **2008**, 443-462
- 362 Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. **2008**, 127-155

- 361 Cholesterol Management in Patients with Chronic Kidney Disease. **2008**, 715-724
- 360 Ereigniszeiten und konkurrierende Risiken für Planung und Auswertung der 4D -Studie. **2008**, 379-398
- 359 Evolving Targets of Therapy. **2009**, 387-395
- 358 CORONARY ARTERY DISEASE. **2009**, 321-365
- 357 Carotid Artery Stenosis Prevalence and Medical Therapy. **2009**, 3-19
- 356 Lipidsenkende Mittel. **2009**, 637-652
- 355 Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. **2009**, 410-419 1
- 354 Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. **2009**, 1-196
- 353 Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. **2009**, 279-317
- 352 Coronary Artery Disease Prevention. **2009**, 17-32
- 351 Lipid Disorders. **2009**, 65-75
- 350 Literatur. **2009**, 31-36
- 349 NHG-Standaard Cardiovasculair risicomanagement. **2009**, 106-152 2
- 348 Stratégies pédagogiques et outils pragmatiques pour réduire le risque cardiovasculaire. **2009**, 163-171
- 347 Intravascular Ultrasound. **2009**, 83-93
- 346 Special Patient Populations: Acute Coronary Syndromes. **2009**, 473-485
- 345 Cholesterol Metabolism and Vascular Disease.
- 344 Kidney Disease and Medications. **2010**, 208-217



- 343 Medical Management of Acute Coronary Syndromes. **2010**, 867-882
- 342 Lower Extremity Arterial Disease. **2010**, 1593-1612
- 341 The Coronary Circulation. **2010**, 903-917
- 340 Atherosclerosis. **2010**, 53-67
- 339 HDL Infusion Therapy. **2010**, 173-179
- 338 Atherosclerotic Risk Factors. **2010**, 435-449
- 337 Lower Limb Claudication Due to Iliac Artery Occlusive Disease. **2010**, 173-185
- 336 Childhood Obesity, Atherogenesis, and Adult Cardiovascular Disease. **2010**, 265-278
- 335 Ezetimibe in the Treatment of Patients with Metabolic Diseases. **2013**, 9, 55-60
- 334 Bewegungstherapie bei koronarer Herzkrankheit. **2010**, 115-142 1
- 333 Trattamento farmacologico. **2010**, 89-98
- 332 Cardiovascular Risk Factors in Infancy and Childhood. **2010**, 1219-1227
- 331 Lipoprotein Metabolism and the Treatment of Lipid Disorders. **2010**, 788-807
- 330 Pharmacoeconomics. **2010**, 999-1010
- 329 Coronary Artery Bypass Surgery. **2011**, 263-279 0
- 328 Unstable Angina and Non-ST Elevation Myocardial Infarction. **2011**, 195-225
- 327 Risk Reduction in the Diabetic Patient. **2011**, 281-315 1
- 326 Strategies for Treating Abnormal Lipid Profiles with Drugs. **2011**, 163-193

325 Gender Differences in Coronary Risk Factors and Risk Interventions. **2011**, 253-299

324 Diabetic Dyslipidemia. **2011**, 213-238

1

323 Low-Density Lipoprotein Cholesterol. **2011**, 215-229

322 Overweight, Obesity, and Cardiovascular Risk. **2011**, 317-330

321 NHG-Standaard Beleid na een doorgemaakt myocardinfarct. **2011**, 341-359

320 Stabilizing unstable plaque in acute coronary syndromes. **2011**, 338-345

319 Acute Coronary Syndromes. **2011**, 548-558

318 Plaque Passivation and Endothelial Therapy. **2011**, 289-298

317 Vaskuläre Erkrankungen. **2011**, 1055-1195

316 Disorders of Lipid Metabolism. **2011**, 1633-1674

315 Carotid Stenosis: Primary Prevention and Medical Treatment. 109-117

314 Acute Coronary Syndromes. **2012**, 19-50

313 Stable Angina. **2012**, 1-18

312 Secondary Prevention Strategies. **2012**, 169-182

311 Risk Factor Management of Atherosclerotic Peripheral Vascular Disease. **2012**, 175-192

310 Ezetimibe and Cholesterol Absorption.

309 Non-antiarrhythmic Therapies for Cardiac Arrhythmias. **2012**, 1167-1174

308 Lifestyle Interventions and Behavior Change. **2012**, 100-111

307 Lipid Lowering in Coronary Artery Disease. **2012**, 126-141

306 The Impact of Diabetes in Older Adults. **2012**, 453-475

305 Lipidsenkende Mittel. **2012**, 697-711

304 Cardiovascular Disease. **2012**, 478-549

303 Metabolic Disorders. **2012**, 727-766

302 Lipid-lowering therapy. **2012**, 68-77

301 References. 484-507

300 Clinical perspectives on the management of advanced stable coronary disease. **2012**, 377-384

299 Prevention of Cardiovascular Disease. 345-377

298 Introduction to Randomized Clinical Trials in Cardiovascular Disease. 1-43

297 Umsatzveränderungen in einzelnen Indikationsgruppen. **2013**, 43-376

296 Hormone Replacement Therapy and Cardiovascular Disease in Women. **2013**, 1-10

295 Lipidsenkende Mittel. **2013**, 687-702

294 Nitrates for stable angina.

293 PCSK9 - A New and Potent Approach to Lowering Cholesterol. **2013**, 28, 155-8

292 Prognosis following myocardial infarction. **2013**, 116-133

291 Secondary Prevention Within the Community. 205-225

290 Dyslipidemia. **2014**, 489-502

- 289 How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly. **2014**, 45-65
- 288 Statins: Practical Considerations - A Review. **2014**, 9, 71-75 3
- 287 Oxidative Stress in Diabetes Mellitus and Possible Interventions. **2014**, 237-261
- 286 Bibliografā. **2014**, 133-140
- 285 Effect of pitavastatin on vascular reactivity in hypercholesterolemic rabbits. **2014**, 103, 4-12
- 284 Medical Management of Coronary Artery Disease. **2014**, 1-17
- 283 Cardiovascular Disease in Renal Transplantation. **2014**, 472-490 1
- 282 Dyslipidemia and Its Management in Type 2 Diabetes. 165-184
- 281 Cholesterol-Lowering Coronary Angiography Trials: An Overview. **1995**, 321-333
- 280 Biologicals & Immunologicals: Methods and compositions relating to sterol regulatory element binding proteins. **1995**, 5, 569-570
- 279 Doctors, research funds and marketing. *Medical Journal of Australia*, **1995**, 162, 670, 672 4
- 278 Clinical efficacy and safety of pravastatin treatment in symptomatic patients [the REGRESS trial]. **1996**, 85-106
- 277 Simvastatin-Induced Reduction in Risk of Major Coronary Events is Related Mainly to Reduction in Ldl Cholesterol But also to Increase in Hdl Cholesterol. **1996**, 169-174
- 276 Treatment of Hyperlipidemia in Women. **1996**, 425-438
- 275 Impact upon angiographic disease progression following step drug therapy in normolipidaemic patients: results of the Harvard Atherosclerosis Reversibility Project (HARP). **1996**, 179-191
- 274 Epidemiologie und Prvention der koronaren Herzkrankheit. **1996**, 601-623
- 273 Koronare Herzkrankheit. **1996**, 241-255
- 272 Drug Treatment of Hyperlipidemia in the Elderly: Hmg-Coa Reductase Inhibitors and Fibric Acid Derivatives. **1996**, 459-464

271 Defining the Clinical Benefit of Cholesterol Lowering. **1996**, 145-149

270 Prevention of Osteoporosis. **1996**, 275-285

269 Effect of aggressive versus conventional lipid-lowering treatment on coronary and peripheral atherosclerosis: design and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression Study (LAARS). **1996**, 193-202

268 Assessment of the coronary arteries with electron beam computed tomography. **1996**, 545-558

267 Koronare Herzkrankheit und Herzinfarkt. **1996**, 421-554

266 Diabetes and Atherosclerosis: The Diabetes Atherosclerosis Intervention Study (Dais). **1996**, 405-411

265 Secondary prevention of myocardial infarction: the roles of  $\beta$ -adrenergic blockers, calcium-channel blockers, angiotensin converting enzyme inhibitors, and aspirin. **1996**, 367-394

6

264 The role of coronary vasomotor tone in coronary artery disease. **1996**, 219-236

263 Epilogue. **1996**, 215-217

262 Long-Term Effect of Ldl-Apheresis on Coronary Heart Disease. **1996**, 513-519

261 Medical Management of Postmyocardial Infarction Patients. **1996**, 477-482

260 Clinical Consequences of Lowering Cholesterol. **1996**, 137-143

259 Extending the Benefit of Lipid Lowering: A Look Ahead. **1996**, 151-155

258 Pharmakotherapie bei Dyslipoproteinämien. **1996**, 651-666

1

257 what are criteria for treatment of dyslipidemia in women?. **1996**, 413-423

256 Battling Heart Disease. **1996**, 273, 15-16

255 Spezielle Erkrankungen mit präventivem Potential. **1997**, 193-569

254 Primär- und Sekundärprävention des Schlaganfalls. **1997**, 73-84

- 253 Primary and Secondary Prevention of Cardiovascular Diseases in Menopausal Women: Alternative Treatment to Hormonal Replacement Therapy. **1997**, 327-338
- 252 Introduction to Invasive Assessment of the Coronary Circulation. **1997**, 25-47
- 251 Approaches for the design of novel anti-atherogenic compounds. **1997**, 28, 507-39
- 250 Rationale Therapie bei koronarer Herzkrankheit. **1997**, 49-55
- 249 Endothelial (dys)Function, Lipid Reduction and Balloon Angioplasty. **1997**, 55-82 1
- 248 Effects of Renovascular Disease and Autotransplantation on Blood Pressure and Renal Function. **1997**, 1-20
- 247 Koronarpharmaka. **1997**, 331-348
- 246 Serum total, fractionated cholesterol concentration distribution and prevalence of hypercholesterolemia in Saudi Arabia, regional variation. **1997**, 17, 179-84 1
- 245 Moderatormanual Koronare Herzkrankheit. **1998**, 129-165
- 244 Prophylaxe ischämischer Insulte. **1998**, 1328-1333
- 243 Atherosclerosis: Implications of Angiotensin II and the AT-1 Receptor. **1998**, 233-243
- 242 Perspectives on Lipid-Lowering Therapy: Past and Present. **1998**, 25-33
- 241 When and How to Treat Hypercholesterolemia in the Elderly?. **1998**, 219-225
- 240 Pathophysiology of Atherosclerosis. **1998**, 3-58
- 239 Effect of Statins Beyond Lowering Cholesterol: Where Do We Stand?. **1998**, 253-265
- 238 Dyslipidemias. **1998**, 1056-1065
- 237 Study Population. **1998**, 30-40 2
- 236 Spezielle Erkrankungen mit präventivem Potential. **1998**, 285-733

235 Lipoproteins and Cardiovascular Risk: From Genetics to Prevention of Coronary Heart Disease. **1998**, 217-228

234 European Action on Secondary Prevention. **1998**, 109-117

233 Lipid Lowering Drugs and the Arterial Wall. **1998**, 19-24

232 Improving the Cost Effectiveness of Lipid Lowering Therapy in Coronary Heart Disease Prevention. **1998**, 275-284

231 Diabetes and Atherosclerosis: Risk Factors and Clinical Trials. **1998**, 165-170

230 Coronary Heart Disease in Women, a Decade of Changing Concepts: Approaches to Diagnostic Evaluation and Preventive Therapy. **1998**, 137-150

229 Therapie von Dyslipoproteinämien. **1998**, 957-972

228 Das metabolische Syndrom bei Frauen. **1998**, 9-16

227 Medical Treatment in the Case of Severe Coronary Artery Disease. **1998**, 67-77

226 Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators. **1998**, 227, 314-6

1

225 Cholestanol and survival with simvastatin. More data are needed. **1998**, 317, 1252-3

224 Hyperlipidaemia and cardiovascular disease. *Current Opinion in Lipidology*, **1998**, 9, 507-10

4.4

223 Therapy and clinical trials. *Current Opinion in Lipidology*, **1998**, 9, 519-20

4.4

222 The management of lipids Are we being effective?. **1998**, 8, 21-26

221 Secondary prevention in coronary heart disease. Cost effectiveness of treatment must be borne in mind. **1998**, 317, 1592

1

220 Zerebrale Durchblutungsstörungen. **1999**, 1151-1166

219 Fettstoffwechselstörungen. **1999**, 770-782

218 Is Selective Reporting of Well-Designed Clinical Research Unethical as Well as Unscientific?. **1999**, 90-98

- 217 Human Diseases as Models of Accelerated Aging. **1999**, 51-58
- 216 Risk Factor Modification. **1999**, 107-126
- 215 Cholesterol Lowering. **1999**, 571-592
- 214 Secondary Prevention of Myocardial Infarction. **1999**, 593-600
- 213 Lipid Lowering Therapy. **1999**, 69-101
- 212 Der Blutdruck im Alter [Hypertonie und Hypotonie. **1999**, 36-66
- 211 Das Herz des alternden Menschen. **1999**, 67-125
- 210 Koronarinsuffizienz und Herzinfarkt. **1999**, 3-31
- 209 Management of Stable Angina Pectoris. **1999**, 19-39
- 208 Koronarpharmaka. **1999**, 331-348
- 207 Durchblutungsffördernde Mittel. **1999**, 281-290
- 206 Lipidsenkende Mittel. **1999**, 356-365
- 205 Coronary Intervention. **1999**, 225-237
- 204 Glukosetoleranz und Diabetes mellitus im Alter. **1999**, 203-243
- 203 Frauen und Herzerkrankung. **1999**, 137-146
- 202 Überblick über die Arzneiverordnungen im Jahre 1997. **1999**, 1-19
- 201 Secondary prevention in coronary heart disease. Effects of statins have been in addition to those of aspirin and beta blockers. **1999**, 318, 1419-20
- 200 Maybe the time has come for the primacy of the patient in the NHS. **1999**, 318, 1700



- 199 Introduction to Pharmionics: The Vagaries in Ambulatory Patients' Adherence to Prescribed Drug Dosing Regimens, and Some of Their Clinical and Economic Consequences. 751-767
- 198 Nuclear Cardiology 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging. **2015**, 463-528
- 197 When 4.5 million people become patients. **2014**, 52, 85
- 196 Metabolic Syndrome. **2014**, 69-114
- 195 Medical Management of Coronary Artery Disease. **2015**, 2369-2382
- 194 Hormone Replacement Therapy and Cardiovascular Disease in Women. **2015**, 4671-4679
- 193 Epidemiology of Cardiovascular Disease. **2015**, 1-20
- 192 Evidence for Preventing Cardiovascular Disease. **2015**, 301-308
- 191 Impact of Preventive Therapies on Clinical Management and Outcomes. 479-493
- 190 Cholesterol Metabolism and Vascular Disease. 1-12
- 189 Of statins and low-density lipoprotein cholesterol, "fats" and fiction. **2016**, 20, 151-3
- 188 Acute toxicity and antihyperlipidemic activity of rhizome of *Alpinia officinarum*: A folklore herb. **2016**, 37, 238-243 1
- 187 Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe. **2016**, 106, 279-88 4
- 186 Measurement of Lipoproteins: Upping the Game in Characterizing the Lipid Phenotype. **2016**, 1, 243-246
- 185 Lipertance - jeden krok v likardiovaskulárním riziku, aneb nikdy to nebylo jednoduší **2016**, 58, 648-652
- 184 Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer's disease. 1
- 183 Coronary atherosclerosis regression - theory, facts and clinical relevance. **2016**, 15, 179-182
- 182 Paradigm Shift of the Treatment of Dyslipidemia for Prevention of Atherosclerotic Cardiovascular Diseases. **2017**, 13, 199-204

- 181 Cardiovascular Comorbidities. **2017**, 114, 560
- 180 Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. **2018**, 320-342
- 179 Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. **2018**, 99-122.e3
- 178 Primärprävention und Sekundärprävention des Hirninfarkts. **2018**, 1-31
- 177 Coronary Intervention in the Chronic Kidney Disease, Diabetic and Elderly Populations. **2018**, 291-303
- 176 Optimal Strategies for Mitigating Sudden Cardiac Death Risk in At-risk Patients with Structural Heart Disease. **2018**, 9, 3025-3032
- 175 OBSOLETE: Epidemiology of Atherosclerotic Cardiovascular Disease. **2018**,
- 174 Ischaemic Heart Disease. **2019**, 355-363
- 173 Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. **2019**, 218-240
- 172 Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. **2019**, 593-615
- 171 Primärprävention und Sekundärprävention des Hirninfarkts. **2019**, 1-31
- 170 Role of Rare and Low Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels.
- 169 The Use of Statins in Respiratory Diseases. **2019**, 15, 2-3
- 168 Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. **2020**, 35, 367-376 1
- 167 Coronary artery bypass surgery versus medical therapy alone for ischaemic heart disease. 78
- 166 On Mendelian Randomisation Mixed-Scale Treatment Effect Robust Identification (MR MiSTERI) and Estimation for Causal Inference. 1
- 165 Discontinuity in care: Practice closures among primary care providers and patient health care utilization. **2021**, 80, 102551 1
- 164 Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). **2021**, 295-306

163 Preventive Cardiology as Specialized Medical Art. **2021**, 733-743

162 Personalised Medicine: Problems of Translation into the Human Domain. **2020**, 19-48

161 Cardiovascular Health. **2020**, 163-177

160 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82

159 Comparison of Formulas for Low-Density Lipoprotein (LDL) Calculation for Predicting the Risk of Metabolic Syndrome. **2020**, 9, e1607

0

158 Primärprävention und Sekundärprävention des Hirninfarkts. **2020**, 883-913

157 Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol® +Centellicum® . **2020**, 68, 15-21

0

156 Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. **2021**, 1

1

155 A practical approach to lipid management in the elderly.

154 Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. **2006**, 21, 171-6

8

153 Koronarinsuffizienz und Herzinfarkt. **2005**, 3-33

152 Fettstoffwechselstörungen. **2005**, 898-911

151 Störungen des Lipidstoffwechsels. **2005**, 418-423

150 Koronare Herzkrankheit und Herzinfarkt. **2006**, 27-142

149 Begutachtung und ökonomische Aspekte in der Kardiolog. **2006**, 871-886

2

148 Therapie von Fettstoffwechselstörungen, Harnsäureidiathese bzw. Gicht. 539-560

147 Lipidsenkende Mittel. 698-715

146 Vaskuläre Erkrankungen. **2006**, 941-1073

- 145 Spezielle therapeutische Probleme im hheren Alter. **2005**, 98-122
- 144 Arterielle Verschlusskrankheit (AVK). **2005**, 146-149
- 143 Lipide. **2005**, 362-377
- 142 Kardiovaskulre Pharmakologie. **2006**, 1-30
- 141 Pathogenesis of the Acute Coronary Syndromes: Hypotheses Generated from Clinical Experience. **1997**, 183-205
- 140 Coronary Atherothrombosis: Pathophysiology and Clinical Implications. **1999**, 57-75
- 139 Atherosclerotic Coronary Disease. **2006**, 121-129
- 138 Women and Coronary Artery Disease. **2006**, 217-235
- 137 Insulin Resistance and Cardiovascular Disease. **2008**, 207-228
- 136 Omega-3 Fatty Acids and Cardiovascular Disease: The Epidemiological Evidence.. **2002**, 6, 203-209 2
- 135 Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death. **2008**, 733-759
- 134 Basis of Cardiac Imaging 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging in Coronary Artery Disease and Congestive Heart Failure. **2006**, 352-394
- 133 Cardiovascular Medications: Pharmacokinetics and Pharmacodynamics. **2009**, 425-452
- 132 Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors. **2021**, 46, 415-423 1
- 131 Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. **1998**, 316, 894-8 141
- 130 Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. **1998**, 316, 1065-70 37
- 129 Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. **2000**, 163, 1263-9 6
- 128 Did the major clinical trials of statins affect prescribing behaviour?. **2001**, 164, 1695-6 10

127	A qualitative study of evidence in primary care: what the practitioners are saying. <b>2002</b> , 166, 1525-30	23
126	Risks and benefits of hormone replacement therapy: the evidence speaks. <b>2003</b> , 168, 1001-10	17
125	The use of cholesterol-lowering medications after coronary revascularization. <b>2003</b> , 169, 1153-7	1
124	Communicating risk reductions. Data were selectively used. <b>1999</b> , 318, 602; author reply 603-4	
123	Statins for stroke should be considered in biologically fit people over 75. <b>2000</b> , 320, 1278	
122	Long standing heart disease should be better screened. <b>2000</b> , 321, 1083-4	
121	Familial hypercholesterolaemia is underdiagnosed after AMI. <b>2001</b> , 322, 111	5
120	Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. <b>2005</b> , 2, A05	3
119	Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. <b>2005</b> , 55, 369-75	14
118	Diagnosis and treatment of non-hemodynamically significant coronary heart disease: where to start?. <b>2005</b> , 116, 273-80; discussion 281	
117	Medicare prescription coverage and congressional gridlock. <b>2001</b> , 16, 864-6	
116	Management strategies of dyslipidemia in the elderly: 2005. <b>2005</b> , 7, 8	
115	A glimpse at HDL-based therapy for atherosclerosis. <b>2004</b> , 25, 3-5	
114	Radiology rounds. Cerebellar astrocytoma. <b>1995</b> , 41, 1298, 1305-9	
113	Family practice patients' adherence to statin medications. <b>2007</b> , 53, 2144-5	20
112	Implementing NCEP guidelines in a Web-based disease-management system. <b>1997</b> , 764-8	2
111	Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events. <b>2007</b> , 53, 1502-7	
110	Cholesterol lowering for secondary prevention: what statin dose should we use?. <b>2007</b> , 3, 615-27	8

109	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. <b>2007</b> , 3, 711-9	2
108	Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction. <b>2007</b> , 3, 1045-51	3
107	Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. <b>2007</b> , 12, 91-6	3
106	Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. <b>2007</b> , 12, 17-28	58
105	Common and rare gene variants affecting plasma LDL cholesterol. <b>2008</b> , 29, 11-26	38
104	Reaching target lipid levels and the natural history of diabetes mellitus in patients surviving acute coronary syndrome: A retrospective cohort study from a tertiary care outpatient clinic. <b>2008</b> , 13, 25-8	2
103	Statins improve human coronary atherosclerotic plaque morphology. <b>2008</b> , 35, 99-103	11
102	Recommendations for management of dyslipidemia in high cardiovascular risk patients. <b>2008</b> , 13, 71-4	2
101	Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?. <b>2005</b> , 10, 9-16	2
100	Stroke Best Practices: a team approach to evidence-based care. <b>2004</b> , 96, 5S-20S	2
99	Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients. <b>2010</b> , 54, 43-51	3
98	Statins do not decrease small, dense low-density lipoprotein. <b>2010</b> , 37, 421-8	17
97	Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?. <b>2011</b> , 122, 256-89	33
96	The effect of statin therapy in stroke outcome: a double blind clinical trial. <b>2012</b> , 3, 68-72	5
95	Fish oil in cardiovascular prevention. <b>2002</b> , 4, 83-91	4
94	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5 mg and Pravastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1). <b>2009</b> , 2, 148-58	
93	Statins as first-line therapy for acute coronary syndrome?. <b>2012</b> , 17, 227-36	9
92	Cholesterol and cardiovascular disease in the elderly. Facts and gaps. <b>2013</b> , 4, 154-69	33

91	Heart rate variability as an indicator of left ventricular systolic dysfunction. <b>2009</b> , 20, 278-83	7
90	High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention. <b>2013</b> , 10, 355-60	3
89	Statins: emerging role in chemoprevention for hepatocellular carcinoma?. <b>2013</b> , 2, 117-20	1
88	An overview of lipid abnormalities in patients with inflammatory bowel disease. <b>2011</b> , 24, 181-187	57
87	A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. <b>2007</b> , 18, 325-9	1
86	Gender Differences in the Association between Lipid Profile and Sexual Function among Patients with Coronary Artery Disease. <b>2014</b> , 8, 9-14	10
85	Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. <b>2010</b> , 58, 945-9	9
84	Recurrent stroke: what have we learnt?. <b>2007</b> , 2, 70-3	
83	Sex-specific association of the SPTY2D1 rs7934205 polymorphism and serum lipid levels. <b>2015</b> , 8, 665-81	9
82	The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. <b>2014</b> , 10, 298-304	5
81	ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/reperfusion injury. <b>2015</b> , 29, 191	1
80	Statin therapy for heart failure: to prescribe or not?. <b>2015</b> , 7, 1702-3	
79	Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death. <b>2015</b> , 8, 148-51	20
78	Lack of Association between High-Density Lipoprotein Cholesterol and Angiographic Coronary Lesion Severity in Chinese Patients with Low Background Low-Density Lipoprotein Cholesterol. <b>2015</b> , 31, 528-35	4
77	Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. <b>2016</b> , 9, 123-6	7
76	The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. <b>2017</b> , 76, 99-102	2
75	Risk factor control five years after coronary bypass grafting. <b>1996</b> , 30, 136-41	2
74	Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association. <b>1996</b> , 30, 115-8	9

- 73 ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. **2017**, 19, D163-D189
- 72 Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients. **2017**, 14, 383-391
- 71 Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. **2017**, 63, e495-e503 16
- 70 Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. **2018**, 34, 371-378 5
- 69 Diabetes Mellitus and Cardiovascular Disease. **2003**, 14, 74-77
- 68 Red yeast rice for dyslipidemia. **2013**, 110, 349-54 3
- 67 Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. **2020**, 12, 463-477 6
- 66 PREVENTIVE CARDIOLOGY AS NEW SUBSPECIALTY OF CARDIOVASCULAR MEDICINE. **2020**, 131, 33-41 2
- 65 The Effectiveness of Target Low-Density Lipoprotein Cholesterol Achieved with Strict Management in Secondary Prevention of Long-Term Coronary Events in Japanese Patients. **2021**, 37, 65-73
- 64 Fish Oil Supplements for Prevention of Cardiovascular Disease: The Jury Is Still Out: CON: Fish Oil is Useful to Prevent or Treat Cardiovascular Disease. **2021**, 118, 219-225 1
- 63 Vulnerable atherosclerotic plaque features: findings from coronary imaging. **2021**, 18, 577-584 1
- 62 Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction. **2021**, 18, 609-622
- 61 Statins for Patients Undergoing Thoracic Aortic Aneurysm Repair Surgery: What to Do?. **2021**, 9, 169-170
- 60 The Magnitude of the Survival Benefit of Internal Thoracic Artery Grafting: Absolute Risk Reduction. **2021**,
- 59 Gas Chromatography and Flame-Ionization Detection of Non-Cholesterol Sterols as Indicators of Cholesterol Absorption and Synthesis in 158 Chinese Individuals with Normolipidemia, Hyperlipidemia, and Familial Hypercholesterolemia.. **2022**, 28, e934471
- 58 Nutrients, Cognitive Function, and Brain Aging: What We Have Learned from Dogs. **2021**, 9, 1
- 57 Assessing the Overall Validity of Randomised Controlled Trials. 1-24
- 56 Statin Therapy in Very Old Patients: Lights and Shadows.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 779044 5.4 2



55	Characteristics associated with early- vs. later-onset adult diabetes: The CARDIA study. <b>2021</b> , 182, 109144		0
54	Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review.. <b>2022</b> , 79, 66-82		2
53	PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?. <b>2022</b> ,		2
52	Prevalence of statin intolerance: a meta-analysis.. <b>2022</b> ,		8
51	Rosuvastatin Alleviates Coronary Microembolization-Induced Cardiac Injury by Suppressing Nox2-Induced ROS Overproduction and Myocardial Apoptosis.. <b>2022</b> , 22, 341		2
50	Cholesterol in the Cell Membrane-An Emerging Player in Atherogenesis.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	1
49	The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study.. <b>2021</b> , 12, 804000		
48	Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics.. <b>2022</b> , 74, 103304		2
47	Prognostic Value of Serial Coronary CT Angiography in Atherosclerotic Plaque Modification: What have we learnt?. <b>2022</b> , 15, 1		
46	Hyperlipidemia and hypertension have synergistic interaction on ischemic stroke: insights from a general population survey in China.. <i>BMC Cardiovascular Disorders</i> , <b>2022</b> , 22, 47	2.3	0
45	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. <i>Molecular and Cellular Biochemistry</i> , <b>2003</b> , 246, 45-50	4.2	11
44	Cholesterol lowering with simvastatin in people with diabetes. <i>Current Atherosclerosis Reports</i> , <b>2004</b> , 6, 85-6	6	
43	Intensive versus moderate lipid lowering with statins in acute coronary syndromes. <i>Current Atherosclerosis Reports</i> , <b>2005</b> , 7, 85-6	6	1
42	Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease. <i>Current Atherosclerosis Reports</i> , <b>2006</b> , 8, 7-8	6	
41	Clinical significance of single nucleotide polymorphisms in PCSK9. <i>Current Atherosclerosis Reports</i> , <b>2007</b> , 9, 175-6	6	
40	HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. <i>Current Atherosclerosis Reports</i> , <b>2008</b> , 10, 281	6	3
39	Dyslipidemia. <b>2022</b> , 461-472		
38	A Propensity Score Matched Analysis of Statin Effects on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients Over 75 Years Old.. <i>Internal Medicine</i> , <b>2022</b> ,	1.1	0

37	Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis.. <i>BMJ Open</i> , <b>2022</b> , 12, e048893	3	1
36	Association between Adipose Tissue Depots and Dyslipidemia: The KORA-MRI Population-Based Study.. <i>Nutrients</i> , <b>2022</b> , 14,	6.7	0
35	Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.. <i>JAMA Internal Medicine</i> , <b>2022</b> ,	11.5	4
34	Contemporary Management of Dyslipidemia.. <i>Drugs</i> , <b>2022</b> , 1	12.1	1
33	The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review.. <i>Global Heart</i> , <b>2022</b> , 17, 18	2.9	0
32	Simultaneous evaluation of fatty acid and triglycerides after percutaneous coronary intervention.. <i>Journal of Cardiology</i> , <b>2022</b> ,	3	0
31	Team-based strategies to prevent heart failure.. <i>Current Opinion in Cardiology</i> , <b>2022</b> ,	2.1	
30	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review.. <i>Geriatrics (Switzerland)</i> , <b>2022</b> , 7,	2.2	
29	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	0
28	What characterizes event-free elderly FH patients? A comprehensive lipoprotein profiling.. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2022</b> ,	4.5	0
27	Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia.. <i>Parkinsonism and Related Disorders</i> , <b>2022</b> , 97, 15-24	3.6	2
26	Statin-Associated Muscle Symptoms - A review: Individualizing the approach to optimize care.. <i>Pharmacotherapy</i> , <b>2022</b> ,	5.8	0
25	Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial.. <i>Cureus</i> , <b>2021</b> , 13, e20710	1.2	
24	COPD - do the right thing.. <i>BMC Family Practice</i> , <b>2021</b> , 22, 244	2.6	5
23	Poor achievement of lipid targets after acute coronary syndrome: what can we improve?. <i>Medical Journal of Australia</i> , <b>2022</b> ,	4	
22	Statins, the mass media and side effects. <i>British Journal of Cardiac Nursing</i> , 1-3	0.2	
21	Blood lipids and molecular pathways of atherogenesis. <b>2022</b> , 623-637		
20	Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia.. <i>Disease Markers</i> , <b>2022</b> , 2022, 2008556	3.2	

19	Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement.. <i>Cardiology Research and Practice</i> , <b>2022</b> , 2022, 7537510	1.9	0
18	New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. <i>Biomedicines</i> , <b>2022</b> , 10, 970	4.8	1
17	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 808712	5.4	1
16	Hypertension and dyslipidemia treatment in stroke. <i>Vnitřní Lekarství</i> , <b>2022</b> , 68, 172-177	0.3	
15	Availability of bioactive flax lignan from foods and supplements.. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2022</b> , 1-16	11.5	2
14	Current status of low-density lipoprotein cholesterol for primary prevention of coronary artery disease in late-stage elderly persons with type 2 diabetes mellitus: A retrospective, single-center study.. <i>Journal of Diabetes Investigation</i> , <b>2022</b> ,	3.9	1
13	Assessment of the appropriateness of cardiovascular preventive medication in older people: using the RAND/UCLA Appropriateness Method.. <i>BMC Geriatrics</i> , <b>2022</b> , 22, 394	4.1	
12	Lipid-modifying and antiatherosclerotic drugs. <b>2013</b> , 398-435		3
11	A Comparison of Rehospitalization Risks on Diabetic and Non-Diabetic Patients after Recovery from Acute Coronary Syndrome. <i>Healthcare (Switzerland)</i> , <b>2022</b> , 10, 1003	3.4	
10	Colchicina en prevención del ictus. ¿Es hora de cambiar nuestra práctica clínica?. <i>Neurología</i> , <b>2022</b> ,	1.4	
9	Semaglutide is precipitating a revolution in obesity care. <i>Translational Metabolic Syndrome Research</i> , <b>2022</b> , 5, 24-24	0.3	
8	Epidemiology of Coronary Artery Disease. <i>Surgical Clinics of North America</i> , <b>2022</b> , 102, 499-516	4	1
7	Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 3331	5.1	1
6	Chasing LDL cholesterol to the bottom [PCSK9 in perspective. <b>2022</b> , 1, 554-561		2
5	Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. <i>Current Opinion in Lipidology</i> , <b>2022</b> , 33, 147-159	4.4	0
4	Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. <i>Clinical Trials</i> , 174077452211055	2.2	
3	Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up. <i>Journal of Thoracic Imaging</i> , Publish Ahead of Print,	5.6	
2	LDL Cholesterol: How Low Can We Go?. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2022</b> ,	5.5	0

- 1 A New Appraisal of Reducing Cholesterol in the Prevention of Coronary Heart Disease. *Journal of the Royal College of Physicians of Edinburgh, The*, **1998**, 28, 126-126 0.9